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Chapter 1 
1 General introduction 
1.1 The ABC protein superfamily 
The ATP-binding cassette (ABC) protein superfamily is one of the largest transporter gene families in 
living organisms. So far, 48 genes encoding ABC proteins have been identified in humans. 
The Transporter Classification (TC) Database, a classification system for membrane transport 
proteins, approved by the International Union of Biochemistry and Molecular Biology (IUBMB), 
divides the ABC family (TC# 3.A.1) into importers and exporters and subdivides the exporters into 
three evolutionarily independent distinct superfamilies [Wang et al., 2009]. These have been 
designated ABC1, ABC2 and ABC3 as they evolved along three different pathways of origin, arising 
from triplication of a primordial 2 transmembrane α-helical segment (TMS), duplication of a three-
TMS-encoding genetic element or from a 4 TMS precursor yielding either eight- or ten-TMS proteins, 
respectively. Within the ABC superfamily there are dozens of subfamilies corresponding to their 
substrate specificities. 
According to a standard nomenclature recommended by to the Human Genome Organization 
(HUGO), the ABC proteins are divided into seven subfamilies (ABCA-ABCG) based on their sequence 
homology and domain organization [Dean et al., 2001], in particular the monophyletic ATP 
hydrolyzing constituents. A comprehensive list is available at 
http://www.genenames.org/genefamilies/ABC.  
ABCB1 (P-glycoprotein, P-gp; MDR1), ABCC1 (multidrug resistance-associated protein 1, MRP1) and 
ABCG2 (Breast Cancer Resistance Protein, BCRP; mitoxantrone resistance protein, MXR) are the most 
intensely studied representatives of all ABC transporters and play a major role in the transport of 
drugs across biological barriers and the development of multidrug resistance (MDR) in cancer cells 
[Borst and Elferink, 2002]. 
 
2 Chapter 1 
 
1.2 Physiological and pharmacological functions of ABC 
transporters 
The ABC efflux pumps use the energy of ATP hydrolysis to transport a huge variety of molecules 
against the concentration gradient across biological membranes [Deeley et al., 2006]. In our cellular 
defense system, the location of ABC transporters in the gastrointestinal tract represents the first 
defense mechanism against numerous ingested xenobiotics. As this also includes numerous orally 
administered drugs, ABC proteins, especially P-gp, play a major role in limiting the uptake and, thus, 
the bioavailability of drugs [Sarkadi et al., 2006]. ABC transporters are furthermore involved in 
limiting the access of various compounds to sensitive compartments like the testes, the placenta or 
the brain, thereby protecting these organs from toxic agents. Classically exemplified by ABCB1, 
ABCC1 and ABCG2, respectively, it became clear that these plasma membrane proteins are key 
players in protecting the organism from xenobiotics and toxines by preventing their uptake and 
procuring their elimination.  
Mutations of ABC proteins are responsible for the appearance of diseases such as Dubin-Johnson 
syndrome (DJS; ABCC2), mucoviscidosis (ABCC7) or pseudoxanthoma elasticum (PXE; ABCC6) 
[Chassaing et al., 2005; Deeley et al., 2006; Gadsby et al., 2006; Burke et al., 2008]. Furthermore, the 
cholesterol efflux regulatory protein (CERP; ABCA1) mediates the transport of cholesterol and 
phospholipids from cells to HDL apolipoproteins, such as apoA-I [Oram et al., 2008]. Mutations of the 
ABCA1 protein led to hypoalphalipoproteinemia (Tangier disease), an inherited disorder 
characterized by a reduced circulation of HDL and a risk factor for cardiovascular disease 
[Negi et al., 2013]. 
1.2.1 Structures and cellular mechanisms of ABC transporters 
In eukaryotes, the ABC full-transporter is supposed to encode four domains consisting of two 
cytosolic ATP-binding segments, also known as nucleotide-binding domains (NBDs) and two 
transmembrane domains (TMDs). Half-size transporters contain only one NBD and one TMD forming 
either homodimers or heterodimers to create a functional transporter and are found in both 
prokaryotes and eukaryotes. The TMDs contain 6 hydrophobic segments: membrane-spanning 
α-helices which form the TM channel and provide the specificity for the substrate (Figure 1.1).  
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Figure 1.1: Topology and domain arrangement of the ABC transporters ABCG2, ABCB1 and ABCC1, respectively. ABCG2 is a 
half-size transporter and consists of six membrane-spanning segments and one NBD on the N-terminal side of the TMD. 
Both the ABCB1 and ABCC1 transporter comprise two ATP-binding sites. ABCC1 additionally contains a N-terminal domain 
composed of five transmembrane helices, the physiological relevance of which is widely unknown [Deeley et al., 2006]; 
illustration adapted from [Gillet et al., 2007] with alterations. 
The ATP-binding domains contain three highly conserved motifs: Walker A and B motifs for 
nucleotide binding [Walker et al., 1982], separated by 90-120 amino acids and a signature ‘C’ motif 
located upstream of the Walker B site and unique to the ABC superfamily [Dean et al., 2001; Sharom, 
2008].  
Binding of a substrate by an ABC transporter induces a conformational change in the TMDs which is 
then transmitted to the NBDs forming a dimer responsible for ATP binding and hydrolysis as well as 
for substrate translocation [Higgins, 2001; Damas et al., 2011] with intracellular ADP and inorganic 
phosphate (Pi) as end products (Figure 1.2). Many fundamental questions concerning substrate 
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binding and the following translocation processes, including a detailed mechanism of ATP hydrolysis 
[Jones and George, 2013], are still unanswered. Latest findings, however, suggest that two ATPs are 
required for the formation of a NBD dimer [Zoghbi and Altenberg, 2014].  
 
 
Figure 1.2: Schematic molecular mechanism of substrate binding and ATP hydrolysis by ABC transporters (export pumps); 
TMD = transmembrane domain, NBD = nucleotide-binding domain, S = substrate, ATP = adenosine triphosphate, 
ADP = adenosine diphosphate, Pi = inorganic phosphate. 
1.2.2 ABC transporters and the phenomenon of multidrug 
resistance 
Cancer chemotherapy is compromised by a phenomenon known as multidrug resistance (MDR), 
defined as the cross-resistance or insensitivity of cancer cells to numerous drugs which are often 
structurally or functionally unrelated [Ullah, 2008]. MDR is often the ultimate cause of failure of 
cytotoxic drugs in cancer chemotherapy. Many mechanisms of drug resistance, such as activation of 
detoxifying systems, evasion of the apoptotic control, changes in cellular repair mechanisms or 
activation of drug efflux pumps have been identified [Gillet and Gottesman, 2010]. Based on this 
knowledge, strategies to overcome drug resistance and to increase the efficacy of cancer 
chemotherapy have been developed. Thereby, the inhibition or modulation of cellular efflux pumps 
to reverse drug resistance has been subject of research for decades.  
Despite the protective detoxifying function of ABC transporters, several complications arise in cancer 
therapy as the overexpression of ABC proteins directly leads to multidrug resistance. One of the most 
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important phenomena of MDR in cancer is an increased efflux of cytostatics from cancer cells 
mediated by transporters of the ABC protein family.  
Stimulated by the identification of the MDR1 gene [Juliano and Ling, 1976], initially many clinical 
trials in cancer therapy focused on the ABCB1 transporter. P-gp expression was considered to be 
solely responsible for the phenomenon of MDR. However, during the last two decades it became 
clear that ABCB1 is not the only member of the ABC transporter family which is involved in the 
resistance against clinically relevant chemotherapeutics. After the discovery of MRP1 (ABCC1) and its 
affiliation to the ABC transporter family [Cole et al., 1992], additional proteins contributing to 
chemoresistance were identified, including the Breast Cancer Resistance Protein. 
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Table 1.1: List of selected human ABC genes, their physiological function and localization as well as 
anticancer drugs accepted as substrates by the corresponding efflux pump.a 
HUGO  
nomen-
clature 
Synonyms,  
symbols 
TC 
identification  
number 
Localization 
Examples of 
cytostatics as 
substrates  
Function, 
involvement in 
human disease 
ABCB1 
 
MDR1, 
P-gp, PGY1 
3.A.1.201.1 BBB, kidney, 
intestine, 
placenta 
taxanes, 
epipodo-
phyllotoxines, 
anthracyclines, 
vinca alkaloids 
multidrug 
resistance 
 
 
 
ABCB4 MDR3, 
PGY3, 
MDR2 
3.A.1.201.3 liver paclitaxel, 
vinblastine 
progressive 
familial 
intrahepatic 
cholestasis (PFIC) 
ABCC1 MRP1, 
GS-X 
3.A.1.208.8 lung, testes, 
kidney 
doxorubicin, 
etoposide, 
vincristine, 
methotrexate 
(MTX) 
multidrug 
resistance 
 
 
 
ABCC2 MRP2, 
cMOAT 
3.A.1.208.2 liver, 
intestine,  
kidney 
MTX, etoposide, 
doxorubicin, 
vincristine, 
cisplatin 
multidrug 
resistance, 
Dubin-Johnson 
syndrome  
ABCC6 MRP6, 
MLP1 
3.A.1.208.10 kidney, liver  Pseudoxanthoma 
elasticum 
ABCC7  CFTR,  
MRP7 
3.A.1.202.1 exocrine 
tissues 
 cystic fibrosis 
(mucoviscidosis)  
ABCG2 MXR,  
BCRP 
3.A.1.204.2 placenta, 
breast, BBB, 
intestine 
mitoxantrone, 
topotecan, 
anthracyclines 
multidrug 
resistance 
 
 
a
 with modifications according to: [Dean et al., 2001; Borst and Elferink, 2002; Gottesman et al., 2002; Deeley et al., 2006; 
Szakacs et al., 2008].  
1.2.3 ABC Transporters expressed at the blood-brain barrier 
The blood-brain barrier (BBB) is a diffusion barrier formed by endothelial cells between the blood 
circulation and the central nervous system (CNS). The BBB controls cerebral homeostasis, protects 
the CNS from environmental toxins and restricts the access of pharmacologically active compounds 
to the brain. Therefore, various transport and carrier systems are expressed at the BBB among which 
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ABC transporters play a crucial role in pharmacotherapy [Shen and Zhang, 2010; ElAli and Hermann, 
2011] as they limit the brain uptake of numerous centrally active compounds [Begley, 2004]. 
 
 
 
 
 
 
 
 
Figure 1.3: Schematic illustration of ABCB1 and ABCG2 transporter expression at the luminal membrane of brain capillary 
endothelial cells at the blood-brain barrier. ABCB1 and ABCG2 substrates (drugs) are pumped from the basolateral to the 
blood side of brain capillaries, resulting in a decreased uptake into the brain. Illustration adapted from [Shukla et al., 2011] 
with modifications. 
Thereby, the chemotherapy of malignant central nervous system (CNS) tumors is compromised due 
to the expression of ABC proteins at the blood-brain barrier namely ABCB1 and ABCG2 [Cooray et al., 
2002; Nies et al., 2004; Miller and Cannon, 2013], restricting the access of many potent cytostatics 
such as anthracyclines, epipodophyllotoxines or taxanes [Hermann and Bassetti, 2007] to the brain, 
provided that these compounds are substrates of the respective pumps.  
The phenomenon of multidrug resistance is a major obstacle in the treatment of malignancies of the 
CNS. Strategies for drug delivery to the brain by circumventing these ABC transporters are of great 
importance. 
By analogy with an approach described for ABCB1 [Fellner et al., 2002; Hubensack et al., 2008], 
co-administration of ABCG2 modulators forms an attractive strategy to overcome MDR tumors and 
to enhance the penetration of cytostatics into the brain to improve chemotherapy of malignancies in 
the CNS [Breedveld et al., 2006].    
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 Chapter 2 
2 Scope and Objectives 
Previously, a series of new tariquidar analogs was synthesized, which were surprisingly identified as 
potent and selective ABCG2 modulators with compound UR-ME22-1 as the most promising 
representative [Kühnle et al., 2009]. Aiming at higher water solubility, compounds bearing 
triethylenglycol groups were prepared to improve efficacy [Ochoa-Puentes et al., 2011]. Indeed, the 
maximal response of this new class of 2nd generation modulators clearly increased, but 
unfortunately, by analogy with their precursors, in mouse plasma the compounds were enzymatically 
cleaved at the central core structure within 10 min. 
In continuation of the work of Matthias Kühnle [Kühnle, 2010] and Peter Höcherl [Höcherl, 2010], 
one aim of this thesis was to obtain potent and stable ABCG2 modulators with regard to planned 
in vivo studies in orthotopic brain tumor xenograft models in nude mice. For this purpose, the 
chemical structure of the already characterized 1st and 2nd generation ABCG2 modulators was 
modified in close cooperation with the group of Prof. Dr. Burkhard König (Institute of Organic 
Chemistry, University of Regensburg).  
To explore, if the new 3rd and 4th generation modulators meet the criteria of future tumor 
pharmacological studies, in this thesis bio-analytical and functional investigations had to be 
performed: 
 Firstly, the ABCG2 potency and selectivity against other ABC transporters, i.e. ABCB1 and 
ABCC1, had to be tested in vitro in fluorescent based microplate assays using ABC 
transporter overexpressing cells. To broaden the spectrum of screening methods, alternative 
new assays in the 96-well plate format had to be established. 
 Biopharmaceutical aspects, especially chemical stability, binding to plasma proteins 
(albumin) as well as potential cytotoxicity had to be considered. 
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 To get closer to the in vivo situation, selected ABCG2 modulators were tested in a 
blood-brain barrier model based on porcine brain capillary endothelial cells in cooperation 
with the group of Prof. Dr. H.-J. Galla (Institute of Biochemistry, University of Münster). 
 To examine functional interactions of the newly developed modulators with the ABCG2 
transporter, a colorimetric ATPase assay using membrane preparations from recombinant 
baculovirus infected Sf9 cells was aimed at. This assay type should give information whether 
the synthesized compounds act as ABCG2 transporter substrates or as inhibitors. 
In view of the treatment of malignant brain tumors, different human brain tumor cell types were 
characterized with regard to chemosensitivity against established anti-cancer drugs, their growth 
kinetics and their ABC transporter expression as well as their tumorigenicity in subcutaneous tumor 
xenograft models. 
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Chapter 3 
3 Modulation of the Breast Cancer 
Resistance Protein (ABCG2) 
3.1 Introduction 
ATP-binding cassette (ABC) transporters prevent the entry of a broad variety of anti-cancer drugs 
into cells, which limits their therapeutic value. In cancer, the expression of ABC transporters such as 
ABCB1 (P-gp), ABCC1 (MRP1) or ABCG2 (BCRP) is associated with the phenomenon of multidrug 
resistance (MDR) [Gottesman et al., 2002; Han and Zhang, 2004]. Hence, chemotherapy of malignant 
brain tumors is compromised by efflux pumps expressed at the blood-brain barrier (BBB), especially 
by ABCB1 and ABCG2, as numerous cytostatics are substrates of these proteins (cf. Chapter 1). 
 
3.1.1 The ABCG2 transporter 
The human ABCG2 protein is a 655 amino acid polypeptide and, like all members of the ABCG 
subfamily, a half-size transporter forming homodimers in the plasma membrane 
[Sarkadi et al., 2004]. As ABCG2 is highly expressed at the placenta [Staud et al., 2006], the mammary 
gland, the intestine and at the blood-brain barrier [Cooray et al., 2002; Robey et al., 2007] it is 
thought to play an important role in normal tissues in protecting these organs from potentially toxic 
xenobiotics. Although its role in health is not fully clear, the protection of the fetus from toxic organic 
anions by excreting metabolites into the maternal circulation seems to be a major task of the ABCG2 
transporter [St-Pierre et al., 2000; Fetsch et al., 2006]. 
Since ABCG2 was first described in drug-resistant cell lines [Chen et al., 1990; Doyle et al., 1998], 
various chemically unrelated cytoststatic agents have been demonstrated to be substrates of the 
protein, like the anthracenedione mitoxantrone, the camptothecin-derived aromatic topoisomerase I 
inhibitors topotecan and irinotecan as well as the anthracyclines daunorubicin and doxorubicin and 
many more [Bates et al., 2001; Doyle and Ross, 2003; Robey et al., 2007]. Overexpression of ABCG2 
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has also been shown to confer moderate resistance to etoposide and methotrexate, but not to 
cisplatin, paclitaxel or vinblastine [Jäger, 2009].  
3.1.2 BCRP inhibitors 
Co-administration of ABCG2 inhibitors and appropriate cytostatics might be useful to enable the 
drugs to cross the BBB and to overcome the treatment refractiveness of malignancies in the CNS by 
increasing the drug levels [Breedveld et al., 2006].  
Compared to other ABC transporters like P-glycoprotein and MRP1, the number of reported ABCG2 
inhibitors is still limited [Ahmed-Belkacem et al., 2006], although the list has grown during the last 
years: the diketopiperazine fumitremorgin C (FTC; Figure 3.1), isolated from Aspergillus fumigatus, 
was reported first [Rabindran et al., 2000], but neurotoxic effects banned the compound from in vivo 
studies. An analogue of the natural compound FTC, Ko143 [Allen et al., 2002], is known as one of the 
most potent and selective ABCG2 inhibitors. Elacridar (GF120918) [de Bruin et al., 1999], tariquidar 
(XR9576) [Kannan et al., 2011] and their common analog WK-X-34 [Jekerle et al., 2006; Jekerle et al., 
2007] are potent dual ABCB1 and ABCG2 modulators.  
Different flavonoids [Zhang et al., 2004; Zhang et al., 2005] and chromone derivatives [Valdameri et 
al., 2012; Winter et al., 2013] as well as methoxy-chalcones [Valdameri et al., 2012] were described 
as potent ABCG2 inhibitors. Previously, the same group identified resveratrol derivatives (methoxy-
stilbenes) as specific inhibitors of ABCG2 [Valdameri et al., 2012]. 
A compound called YHO-13177 and its water-soluble diethylaminoacetate prodrug were recently 
shown to reverse BCRP-mediated drug resistance in vitro and in vivo [Yamazaki et al., 2011]. 
However, despite the increased trend in identifying ABCG2 inhibitors, little research has been 
conducted with a focus on a possible in vivo application.  
Nevertheless, the co-adminstration of anticancer agents with BCRP inhibitors seems a promising 
concept to treat brain tumors by enhancing the drug delivery into the brain and will, hopefully, 
attract further attention in preclinical and clinical investigations. 
 
During the last years, our group, in corporation with the Institute of Organic Chemistry (Prof. Dr. B. 
König, University of Regensburg), was able to identify highly potent inhibitors of ABCG2 by a 
consequent straight-forward synthesis strategy optimizing the structure-activity relationships of 
recently described BCRP modulators [Kühnle et al., 2009]. Our efforts resulted in a series of 
compounds among which are the most potent ABCG2 modulators reported so far 
[Ochoa-Puentes et al., 2011; Bauer et al., 2013; Ochoa-Puentes et al., 2013].  
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3.2 Objective 
In continuation of the work of Matthias Kühnle [Egger, 2009; Kühnle, 2010] the development and 
in vitro characterization of potent and stable ABCG2 modulators was of major interest. With regard 
to structural optimization concerning chemical stability under physiological conditions, recently 
synthesized substances [Kühnle et al., 2009] were modified and further analogs were prepared. The 
compounds were characterized in view of their inhibitory potency against ABCG2, their toxicity and 
the extent of reverting ABCG2 mediated drug resistance. Additionally, the selectivity against ABCB1 
and ABCC1 was investigated using a new established fluorescence based calcein-AM assay. The most 
potent inhibitors were investigated with respect to their chemical stability in mouse plasma by 
means of HPLC-MS analysis as an assessment for planed in vivo studies in nude mice.  
3.3 Materials and methods 
3.3.1 Drugs and chemicals  
Hoechst 33342 (Invitrogen, Karlsruhe, Germany) was dissolved in sterile water to produce a 0.8 mM 
working solution. A stock solution of mitoxantrone was performed by diluting Novantron® (Wyeth 
Pharma, Münster, Germany) in 70% ethanol to a concentration of 2 mM. Pheophorbide a (PhA; 
Frontier Scientific, Logan, UT) was dissolved in DMSO to prepare a 200 µM working solution. 
Calcein-AM (4 mM in anhydrous DMSO) and pluronic F127 were obtained from Biotium (Hayward, 
CA, USA). Topotecan and vinblastine (vinblastine sulfate; both from Sigma, Munich, Germany) were 
diluted in 70% ethanol [100 µM] and stored at 4 °C. 
Bovine serum albumin (BSA) and crystal violet were purchased from Serva (Heidelberg, Germany). 
PBS (phosphate buffered saline) was made of 8.0 g/L NaCl, 1.0 g/L Na2HPO4 · 2 H2O, 0.20 g/L KCl, 
0.20 g/L KH2PO4 and 0.15 g/L NaH2PO4 · H2O. The pH-value was adjusted to 7.4 by using 1 M NaOH. 
Loading buffer was made of 120 mM NaCl, 5 mM KCl, 2 mM MgCl2 · 6 H2O, 1.5 mM CaCl2 · 2 H2O, 
25 mM HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), 10 mM glucose, pH 7.4. 
A solution of 4% (m/v) paraformaldeyde (PFA) in PBS was made by stirring 2 g of PFA per 50 mL total 
solution while heating on a magnetic stirrer for approximately 60 min.  
If not otherwise stated, chemicals (p.a. quality) were obtained from Merck (Darmstadt, Germany). 
Purified water (Milli-Q system, Millipore, Eschborn, Germany) was used throughout. 
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3.3.2 Test compounds 
The ABC-transporter modulators were synthesized by Dr. Michael Egger [Egger, 2009], Dr. Cristian 
Ochoa-Puentes, Manuel Bause and Qui Sun in the workgroup of Prof. Dr. König (Institute of Organic 
Chemistry, University of Regensburg, Germany) and dissolved in DMSO to a concentration of 10 mM 
if possible. All stocks were stored at -20 °C.  
In the following, the synthesized ABCG2 modulators are termed as 1st, 2nd, 3rd and 4th generation 
modulators, respectively, according to their structural characteristics. 
Tariquidar was synthesized in our laboratory according to literature [Dodic et al., 1995; Roe et al., 
1999] with slight modifications [Hubensack, 2005]. 
Fumitremorgin C (FTC; Merck, Darmstadt, Germany) was also dissolved in DMSO and diluted to a 
concentration of 1 mM as well as elacridar, a kind gift of GlaxoSmithKline (Munich, Germany). The 
FTC-analog Ko143 was a kind gift of Dr. A. H. Schinkel from the Netherlands Cancer Institute 
(Amsterdam, NL). Reversan was purchased from Tocris Bioscience (Bristol, UK) and diluted to a 3 mM 
working solution in DMSO.  
Figure 3.1 gives an overview of the standard ABC transporter modulators. All synthesized ABCG2 
modulators are summarized in Tables 3.1-3.7. 
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Figure 3.1: Structures of the ABCG2 modulators fumitremorgin C (a), its analog Ko143 (b), the dual ABCB1/ABCG2 inhibitors 
elacridar (c) and tariquidar (d) and the ABCC1 inhibitor reversan (e). 
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Table 3.1: Structures of the two most potent 1st generation ABCG2 modulators bearing an amide 
core [Kühnle et al., 2009]. 
 
 
 
 
 
Table 3.2: Structures of 2nd generation ABCG2 modulators with variations of R1 and R2 
[Ochoa-Puentes et al, 2011]. 
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Figure 3.2: Replacement of the central benzamide moiety according to a bioisosteric approach by a biphenyl system, an 
indole, a quinoline and a trizole core, respectively: 3
rd
 and 4
th
 generation modulators. 
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Table 3.3: Structures of 3rd generation ABCG2 modulators: biphenyl series. 
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Table 3.4: Structures of 3rd generation ABCG2 modulators: indole series. 
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Table 3.5: Structures of 3rd generation ABCG2 modulators: triazole series. 
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Table 3.6: Structures of 3rd generation ABCG2 modulators: quinoline series. 
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Table 3.7: Structures of 4th generation ABCG2 modulators: triazole series containing a ketone.
 
3.3.3 New fluorescent ABCG2 modulators 
Selected compounds of the triazole series showed distinctive fluorescence, when diluted with 
MeCN/0.05% TFA (aq.) at a ratio of 70/30 for HPLC analysis. Fluorescence spectra were recorded 
with a LS50 B spectrofluorimeter from Perkin Elmer (Rodgau, Germany) at a scan rate of 240.  
3.3.4 Cell culture 
MCF-7/Topo cells, an ABCG2 overexpressing subclone of MCF-7 cells (ATCC® HTB-22™, a human 
breast adenocarcinoma cell line), were cultured in Eagle’s Minimum Essential Medium (EMEM; 
Sigma, Munich, Germany) containing L-glutamine, 2.2 g/L NaHCO3 and 110 mg/L sodium pyruvate 
(Serva, Heidelberg, Germany) supplemented with 10% fetal calf serum (FCS; Biochrom, Berlin, 
Germany) and selected as described [Hubensack, 2005]. Briefly: treatment of MCF-7 cells with 
increasing concentrations of topotecan (final concentration: 550 nM) over approximately 40 days 
yielded sufficient quantities of the ABCG2 transporter.  
Human Kb-V1 cells, an ABCB1 overexpressing subclone [Kohno et al., 1988; Hubensack, 2005] of 
human Kb cells (ATCC® CCL-17™) were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Sigma, 
Munich, Germany) supplemented with 3.7 g/L NaHCO3 and 110 mg/L sodium pyruvate (DMEM
++) in 
addition to 10% FCS and 330 nM vinblastine to maintain sufficient ABCB1 transporter expression.  
MDCKII-MRP1 cells: MDCKII cells (Madin-Darby Canine Kidney cells, strain II; a dog epithelial cell line; 
ATCC® CRL-2936™), transfected with human ABCC1 [Bakos et al., 1998; Evers et al., 1998], were a 
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kind gift from Prof. Dr. P. Borst from the Netherland Cancer Institute (Amsterdam, NL). The cells were 
cultured in DMEM++ supplemented with 10% FCS. Trypsinization was performed at 37 °C (95% air, 
5% CO2) for 20-30 min using 0.1% trypsin / 0.04% EDTA (Roche Diagnostics, Mannheim, Germany). 
The human glioblastoma cell line U-118 MG (ATCC® HTB-15™) was maintained in DMEM++ containing 
10% FCS. 
All cells were cultured in a water-saturated atmosphere (95% air, 5% CO2) at 37 °C in 25-cm
2, 75-cm2 
or 175-cm2 cell culture flasks purchased from Nunc (Wiesbaden, Germany), Greiner (Frickenhausen, 
Germany) or Sarstedt (Nümbrecht, Germany) and passaged every 3-7 days after trypsinization using 
0.05% trypsin / 0.02% EDTA if not otherwise mentioned. Cell banking was performed according to 
the ‘seed stock concept’ [Hay, 1988]. Cells were routinely monitored for mycoplasma contamination 
by PCR (Venor® GeM, Minerva Biolabs GmbH, Berlin), and only mycoplasma negative cultures were 
used. 
3.3.5 Cell based assays for the determination of ABC transporter 
modulation 
All assays were performed in the microtiter plate format using 96-well plates (Greiner, 
Frickenhausen, Germany) and a GENios Pro microplate reader (TECAN Deutschland GmbH, 
Crailsheim, Germany) for fluorescence detection.  
3.3.5.1 ABCG2 modulation: Hoechst 33342 and pheophorbide a microplate 
assays  
The standard protocol was as follows (according to [Kühnle, 2010] with slight modifications): 
MCF-7/Topo cells were seeded into 96-well plates at a density of 20,000-25,000 cells/well (total 
volume: 100 µL) and incubated over night (95% air, 5% CO2) at 37 °C. The next day, the incubation 
medium was removed from the microplate. Afterwards, cells were incubated for 2 hours (37 °C, 
5% CO2) with loading suspension: EMEM, supplemented with 10% FCS, L-glutamine, 2.2 g/L NaHCO3, 
110 mg/L sodium pyruvate and 8 µM Hoechst 33342 (H33342) or 1 µM pheophorbide a (PhA) in 
combination with  the test compounds at increasing concentrations (10 nM-100 µM). The structures 
of H33342 and PhA are shown in Figure 3.3. 
Fumitremorgin C served as positive control at a final concentration of 10 μM, corresponding to 100% 
inhibition of H33342 and PhA efflux, respectively. The supernatants were discarded, and the cells 
were fixed for 20 min under light protection using 100 µL per well of a 4% paraformaldehyde 
solution. Finally, MCF-7/Topo cells were washed twice with 250 µL of PBS per well in order to get rid 
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of residual dye. Afterwards, cells were overlaid with 100 µL of PBS, and fluorescence was determined 
with a GENios Pro microplate reader. 
Instrument settings were as follows: measurement mode: fluorescence top; excitation filter 
(Hoechst 33342): 340/35, excitation filter (pheophorbide a): 380/10; emission filter (Hoechst 33342): 
485/20, emission filter (pheophorbide a): 670/25; number of reads: 10; integration time: 40 μs; lag 
time: 0 μs; mirror selection: automatic; plate definition file GRE96ft.pdf; multiple reads per well 
(Circle): 3x3; time between move and flash: 50 ms. 
On each plate, the optimal gain was calculated by determination of the fluorescence intensity in the 
presence of the reference compound fumitremorgin C and the microtiter plates were stored at 4 °C 
until cell quantification. To consider unspecific toxic effects of the test compounds during the 
incubation phase, the obtained fluorescence values were normalized to the biomass in each well. For 
this purpose, the cells were stained with a 0.02% aqueous crystal violet solution (100 μL/well) for 
20 min. Excess dye was removed by rinsing the microplates with water for 20 min. Crystal violet 
bound by the cells was extracted with 70% ethanol (180 μL/well) while shaking the microplates for 
2-4 h. Subsequently, the absorbance as a parameter proportional to cell mass was measured at 
590 nm with a TECAN plate reader. For normalization of the fluorescence intensities to the cell mass, 
fluorescence values were divided by the corresponding absorbances. All values were corrected with 
respect to the cellular uptake of the dye by diffusion (DMSO control value), and the data were 
referred to the maximal signal measured in the presence of the reference compound FTC at a 
concentration of 10 μM (100% inhibition).  
Addition of the modulators at increasing concentrations led to sigmoidal concentration response 
curves in semilogarithmic plots. IC50 values were calculated using SigmaPlot 11.0 software (Systat 
Software GmbH, Erkrath, Germany) by fitting ‘Four parameter logistic curve’. Errors were expressed 
as standard error of the mean (SEM).  
 
Figure 3.3: Chemical structures of the fluorescent BCRP substrates H33342 (a) and pheophorbide a (b). 
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3.3.5.2 Mitoxantrone microplate assay for the determination of ABCG2 
modulation 
Because of unfavourable fluorescent properties of some synthesized compounds and discrepencies 
between H33342 and PhA assay, another assay was established for the determination of BCRP 
modulation. With excitation and emission wavelengths far from those of the H33342 dye and the 
fluorescent modulators, mitoxantrone (Figure 3.4) was chosen as a fluorescent ABCG2 substrate, 
since a flow cytometric mitoxantrone assay protocol already existed [Kühnle, 2010].   
In terms of comparability with the H33342 and the PhA assay the mitoxantrone assay was also 
established in the 96-well format. 
 
Figure 3.4: Structure of the antineoplastic agent mitoxantrone, which is a fluorescent substrate of ABCG2. 
MCF-7/Topo cells were seeded into 96-well plates (density: 20,000 cells/well) and incubated over 
night (95% air, 5% CO2) at 37 °C. The next day, the incubation medium was removed, and the cells 
were overlaid with loading suspension (EMEM, supplemented with 10% FCS, L-glutamine, 
2.2 g/L NaHCO3, 110 mg/L sodium pyruvate and 20 µM mitoxantrone in combination with  the test 
compound at increasing concentrations) for 3 hours (37 °C, 5% CO2). 
Fumitremorgin C served as positive control at a final concentration of 10 μM corresponding to 100% 
ABCG2 inhibition. The supernatants were drained, and the cells were immediately washed twice with 
250 µL of PBS (without fixation). Afterwards, cells were overlaid with 100 µL of PBS, and the relative 
fluorescence intensities were determined with the GENios Pro microplate reader. Time between 
washing and the measurement was kept as short as possible to avoid ABCG2-independent efflux of 
mitoxantrone. 
Instrument settings were as follows: measurement mode: fluorescence top; excitation filter: 612/10; 
emission filter: 670/25; number of reads: 10; integration time: 40 μs; lag time: 0 μs; mirror selection: 
automatic; plate definition file: GRE96ft.pdf; multiple reads per well (Circle): 3x3; time between 
move and flash: 100 ms. 
The following cell quantification procedure and the calculation of IC50 values were performed by 
analogy with the H33342 assay. 
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3.3.5.3 Calcein-AM efflux assay for the determination of ABCB1 modulation 
The assay was performed as described elsewhere [Höcherl, 2010]. 
3.3.5.4 Calcein-AM efflux assay for the determination of ABCC1 modulation 
MDCKII-MRP1 cells were seeded into flat-bottomed 96-well plates at a density of about 
20,000 cells/well. On the following day, cells were washed with loading buffer in order to remove 
unspecific serum esterases. Afterwards, cells were incubated with loading suspension (loading 
buffer, 5 mg/mL BSA, 1.25 μL/mL pluronic F127 (20% (m/v) in DMSO)) containing 0.5 μM calcein-AM 
(Figure 3.5) and the test compound at increasing concentrations (10 nM-100 µM) for 60 min 
(37 °C / 5% CO2). Reversan served as positive control at a final concentration of 30 μM corresponding 
to 100% ABCC1 inhibition. In general, test compounds were investigated as triplicates, controls as 
sextuplicates, respectively.  
Subsequently, the loading suspension was discarded, and the cells were fixed with 4% PFA solution 
for 20 min. After three washing circles (loading buffer), fixed cells were overlaid with loading buffer, 
and relative fluorescence intensities were determined at 535/25 nm at the GENios Pro microplate 
reader after excitation at 485/20 nm. The following cell quantification procedure was performed by 
analogy with the H33342 assay. The obtained mean fluorescence intensities were related to the 
controls and plotted against the various concentrations of test compounds.  
TECAN instrument settings: Measurement mode: fluorescence top; number of reads: 10; integration 
time: 40 μs; lag time: 0 μs; mirror selection: Dichroic 3 (e.g. Fl.); plate definition file: GRE96ft.pdf; 
multiple reads per well (Circle): 3x3; time between move and flash: 100 ms. 
 
 
Figure 3.5: Structure of nonfluorescent calcein-AM (a), a substrate of ABCB1 and ABCC1, which is converted to 
green-fluorescent calcein (b) in live cells after acetoxymethyl ester hydrolysis by intracellular esterases. 
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3.3.6 Chemosensitivity assays 
The assays were performed as described previously [Bernhardt et al., 1992] with slight modifications. 
In brief: 100 μL/well of a tumor cell suspension, yielding a density of 500 cells per well, were seeded 
into 96-well plates and incubated over night at 37 °C / 5% CO2 in a water-saturated atmosphere. 
The next day, fresh medium (100 µL/well) was added containing the 500-fold concentrated test 
compounds (16 wells per drug concentration) giving a final drug dilution of 1:1,000. On every plate, 
untreated cells (solvent DMSO in a dilution of 1:1,000) served as growth control (vehicle), cells 
treated with a reference cytostatic (e.g. vinblastine) as a positive control. Incubation of the cells was 
stopped after different periods of time by removal of medium and fixation with 2% (v/v) 
glutardialdehyde (in PBS). All plates were stored at 4 °C until the end of the experiment and stained 
simultaneously with 100 μL/well of a 0.02% (m/v) aqueous crystal violet solution for 20 min. 
Subsequently, the trays were rinsed with water for 20 min in order to remove residual dye. Cell-
associated crystal violet was redissolved in 70% ethanol (180 μL/well) under shaking for 2-4 hours. 
Absorbance was measured at 580 nm using a GENios Pro microplate reader.  
Drug effects were expressed as corrected T/C-values for each group according to equation 1, 
 
 
            
    
    
                                 (e ua on 1) 
         
where T is the mean absorbance of the treated cells, C the mean absorbance of the controls and C0 
the mean absorbance of the cells at the time (t=0) when the drug was added.  
When the absorbance of treated cells T was less than that of the culture at t=0 (C0), the extent of cell 
death was calculated according to the following formula: 
                      
    
  
                 (e ua on 2) 
SigmaPlot analysis software 11.0 was used for the creation of growth curves. 
3.3.7 Chemical stability of ABCG2 modulators in human and 
mouse plasma 
With respect to future in vivo studies, selected candidates of potent ABCG2 modulators were 
investigated for their stability in human and mouse plasma.  
For mouse plasma, blood of NMRI (nu/nu) mice was collected by cardiac puncture in deep anesthesia 
using heparin-coated syringes. Samples were immediately centrifuged at 4,500 g (Eppendorf 
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centrifuge 5415R, Eppendorf, Hamburg, Germany) for 7 min, and the supernatant was carefully 
removed. After pooling, the plasma was fractioned into small aliquots and stored at -80 °C. Human 
CPD (citrate-phosphate-dextrose) plasma was purchased from the Bavarian Red Cross (BRK; 
Regensburg, Germany).  
3.3.7.1 Determination of the activity of unspecific esterases 
The enzymatic activity of unspecific esterases in human and murine plasma samples was determined 
spectrophotometrically. Therfore, the development of the colored product o-nitrophenol, formed by 
enzymatic cleavage of the chromogenic substrate nitrophenyl butyrate, was determined as a 
function of time: 40 µL ortho-nitrophenylbutyrate (Fluka, Munich, Germany) were mixed with 1 mL 
of 0.1 M Na2HPO4 buffer (pH 7.2). After warming to 37 °C, 10 µL of murine or human plasma were 
added and UV absorbance was measured for 2 min at 414 nm using a Cary 100 UV-Vis 
spectrophotometer (Varian, Darmstadt, Germany). Absorbance was plotted against time, and the 
linear slope at the beginning of the reaction was determined and used for the calculation of the 
volume activity according to the following equation: 
    
   
 
         
                                               (e ua on 3) 
 
VA  =  volume activity [U/mL]        
A  =  absorbance of o-nitrophenol at 414 nm 
t  =  time [min] 
V  =  total volume [mL] 
ε =  molar absorption coefficient (o-nitrophenol) [L· mol-1 · cm-1] 
d  =  path length [cm] 
v  =  plasma volume [mL] 
3.3.7.2 Assay procedure 
The test compounds were dissolved in DMSO at a concentration of 3 mM. A 1:50 dilution of the 
substances with mouse plasma was prepared in 1.5-mL polypropylene reaction vessels (Eppendorf, 
Hamburg, Germany). The samples were shortly vortexed and immediately incubated at 37 °C. After 
increasing periods of time, aliquots were taken, after the reaction had been stopped by addition of 
two volumes of ice-cold acetonitrile (MeCN). For quantitative precipitation of the denatured 
proteins, the samples were efficiently vortexed and stored at 4 °C for 30 min. Finally, samples were 
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centrifuged at 14,000 g for 5 min, and the supernatants were transferred to new Eppendorf reaction 
vials. For HPLC analysis, the samples were diluted (1:2) with MeCN and stored at -80 °C until 
measurement. 
3.3.7.3 HPLC and HPLC-MS analysis 
3.3.7.3.1 HPLC analysis 
Subsequent RP-HPLC analysis was performed with a Waters (Eschborn, Germany) system composed 
of a 600S controller and pump, a Waters degasser, a temperature control module, a 717 plus 
autosampler and a 2487 UV detector. A Luna RP-18 (Phenomenex, Aschaffenburg, Germany) 
analytical column (3 μm, 150 mm x 4.6 mm) thermostatted at 30 °C was used with a flow rate of 
1.0 mL/min.  
Samples were thawn at room temperature, and 100 μL were injected. UV detection was performed 
at 210 nm. During recovery analysis, the applied gradient was as following:  
MeCN/0.05% TFA (aq.): 0 min: 15/85, 25 min: 80/20, 26 min: 95/5, 36 min: 95/5, 37 min: 15/85, 
45 min: 15/85. 
3.3.7.3.2 HPLC-MS analysis 
Determination of cleavage products was performed by HPLC-MS analysis using an Agilent 1100 
(Agilent Technologies, Palo Alto, CA) HPLC system equipped with a Luna C18, 3 μm, 100 mm x 2 mm 
column (Phenomenex, Aschaffenburg, Germany) at 40 °C. Gradient elution with water containing 
formic acid (0.1%) and MeCN (0 min: 3%, 15 min: 95%, 17 min: 95%, 17.5 min: 3%, 19 min: 3%) was 
performed at a flow rate of 0.4 mL/min with UV detection at 220 nm. The HPLC was coupled to a 
Finnigan ThermoQuest TSQ (Triple-Stage-Quadrupol) 7000 ESI mass spectrometer. 
3.3.8 ABC transporter modulation in a blood-brain barrier model 
To get closer to in vivo conditions at the BBB, selected compound were tested in an in vitro 
blood-brain barrier model (Figure 3.6) imitating the physiological situation using endothelial cells, 
expressing the brain multidrug resistance protein (BMDP), the porcine homolog to the human ABCG2 
gene [Hoheisel et al., 1998; Franke et al., 1999; Franke et al., 2000]. Thereby, the transport of the 
ABCG2 substrate 3H-daunorubicin across a ‘membrane’ (cell monolayer of primary cultured brain 
capillary endothelial cells) was measured in the presence of selected ABCG2 modulators. The 
experiments were performed by Sabine Hüwel at the Institute of Biochemistry (Prof. Dr. H.-J. Galla) 
at the University of Münster.  
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Figure 3.6: Simplified illustration comparing the in vivo situation at the BBB with the in vitro BBB model. The right panel 
shows a schematic cross-section through a brain capillary, the left panel shows the corresponding compartment in the 
experimental set-up of the transcellular transport model with a monolayer of porcine brain capillary endothelial cells 
expressing the brain multidrug resistance protein (BMDP). Illustration adapted from [Franke et al., 2000].  
The transport assay protocol was as following [Eisenblätter et al., 2003]: the isolation of porcine 
capillary endothelial cells (PBCEC) has been described elsewhere [Franke et al., 2000]. DMEM/Ham’s 
F12 medium (serum-free) containing L-glutamine (0.7 mM), penicillin/streptomycin (100 µg/mL), 
gentamicin (100 µg/mL) and hydrocortisone (550 nM) was used throughout with cells cultured on 
Transwell™ microporous polycarbonate filter membranes (0.4 µm pore size, 1 cm2 growth area; 
Costar, Cambridge, MA) to prepare confluent cell monolayers. By supplementing the medium with 
hydrocortisone at physiological concentrations, the endothelial monolayer shows a transendothelial 
electrical resistance (TEER) of up to 1800 Ω/cm2 similar to the situation in vivo and low paracellular 
permeabilities for sucrose [Levin, 1980; Crone and Olesen, 1982]. The barrier properties were 
quantified in terms of TEER determined by AC (alternating current) impedance analysis 
[Wegener et al., 2000] . The cells were incubated with the inhibitor at a specific concentration 60 min 
prior to the experiment, which was started by replacing the medium on both sides of the cell layer 
with fresh medium, containing 0.2 µM 3H-daunorubicin (NEN Life Science Products; 5 Ci/mmol; 
185 GBq/mmol) and the inhibitor at the corresponding concentration. After 0.5, 6, 12, 24, 36, 48 and 
72 h, samples were taken from each compartment. The radioactivity at 0.5 h was set to 100% for 
each compartment. The tightness of the monolayer was monitored by the paracellular flux of 
14C-sucrose (Amersham Biosciences; 740 mCi/mmol; 27 GBq/mmol) from the apical to the 
basolateral compartment (2 µCi/mL or 1 µCi per filter). Three independent experiments were 
performed with three filters each.  
  
endothelium
microvessel lumen
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astrocytes
brain
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3.4 Results and discussion 
The following results were published in part [Bauer et al., 2013; Ochoa-Puentes et al., 2013]. Selected 
data, statements and figures are quoted with the permission of the corresponding journal. 
3.4.1 Inhibition of ABCB1, ABCC1 and ABCG2 
General procedure of ABC transporter inhibition assays: 
In ABC transporter overexpressing cell lines, a fluorescent substrate of the corresponding ABC 
protein is not accumulated but extruded by the efflux pump. In combination with ABC 
modulators/inhibitors, the intracellular levels of the dyes increase resulting in higher fluorescence 
intensities, which can be directly referred to the extent of ABC transporter inhibition. 
Intracellular fluorescence was monitored with a plate reader in a concentration-dependent manner. 
The relative fluorescent intensities allowed the construction of sigmoidal concentration response 
curves and the calculation of IC50 (respective concentration of the inhibitor required for half-maximal 
inhibition) and Imax values (inhibition by the highest concentration of the compound expressed in 
percent relative to the control compound). 
The synthesized new compounds as well as the reference substances tariquidar, elacridar and Ko143 
were investigated for ABCB1, ABCC1 and ABCG2 modulation in a concentration range from 10 nM to 
100 µM. Precipitate formation in the loading suspension became visible for a number of modulators 
at final concentrations above 10 µM. These concentrations were not included in the calculation of 
IC50 and Imax values. Constructed concentration-response curves of selected ABCG2 modulators and 
the reference compounds are displayed in Figures 3.7-3.8. 
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Figure 3.7: Inhibition of ABCG2 
by the reference compounds 
tariquidar (filled circles), 
elacridar (open circles), Ko143 
(open triangles) and compounds 
2 (filled triangles) and 4 (filled 
squares). 
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Figure 3.8: Inhibition of ABCG2 
by 3
rd
 and 4
th
 generation 
modulators: 12 (open diamonds), 
33 (filled inverted triangles), 42 
(filled diamonds), and 52 (open 
inverted triangles), each 
representing the most potent 
compound of its series. 
 
All results of the test compounds and the reference compounds regarding ABC transporter 
modulation are summarized in Tables 3.8-3.13. If not otherwise stated, mean values were calculated 
from two to three independent experiments performed in sextuplicate (ABCG2) or triplicate (ABCB1 
and ABCC1). Maximal inhibitory effects are expressed as percental inhibition caused by the highest 
concentration of the compound tested (70 or 100 µM, respectively) relative to the control compound 
(100%). Compounds without an effect up to a concentration of 100 µM are designated as ‘inactive’.  
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Table 3.8: Inhibition of ABCG2 and ABCB1 by compounds 1-5 and reference compounds. 
Compound 
ABCG2 ABCB1 
IC50 [nM]
a Imax (%) IC50 [nM]
b 
Fumitremorgin C 731 ± 92 100 n.d. 
Ko143c 117 ± 53 103 ± 7 inactive 
Elacridarc 127 ± 41 63 ± 7 193 ± 18d 
Tariquidarc 526 ± 85 69 ± 5 223 ± 8d 
1 (UR-ME1-4)c 104 ± 16 50 ± 1 9,450 ± 417d 
2 (UR-ME22-1)c 65 ± 8 63 ± 2 >29,000d 
3 (UR-COP77)e 183 ± 32 83 ± 5 >50,000 
4 (UR-COP78)e 130 ± 29 88 ± 3 >50,000 
5 (UR-COP134)e 508 ± 191 61 ± 4 >50,000 
a
 Mean values ± SEM calculated from two to three independent experiments performed in triplicate; 
b
 Calcein-AM 
micorplate assay (unless otherwise indicated); n.d.: not determined; 
c
 [Kühnle, 2010]; 
d
 data from flow cytometric 
calcein-AM assay; 
e
 [Ochoa-Puentes et al., 2011].  
Table 3.9: Inhibition of ABCG2, ABCB1 and ABCC1 by 3rd generation modulators: biphenyl series, 
compounds 6-17.  
Compound 
ABCG2 ABCB1 ABCC1 
IC50 [nM] Imax (%) IC50 [nM] Imax (%) IC50 [nM] 
  6 (UR-COP142) 1,540 ± 110 92 ± 6 >10,000 119 ± 2 n.d. 
  7 (UR-COP145) 943 ± 79 87 ± 5 inactive  n.d. 
  8 (UR-COP147) 641 ± 175 94 ± 2 4,490 ± 160 100 ± 2 n.d. 
  9 (UR-COP153) 1,461 ± 169 85 ± 7 inactive  n.d. 
10 (UR-COP154) 1,031 ± 170 114 ± 20 inactive  n.d. 
11 (UR-COP157) 237 ± 65 67 ± 1 >18,000 105 ± 4 n.d. 
12 (UR-COP228) 591 ± 87 109 ± 8 1230 ± 30 21 ± 8 n.d. 
13 (UR-COP245) 3,214 ± 1,050 126 ± 15 inactive  n.d. 
14 (UR-COP246) 1,100 ± 156 90 ± 2 inactive  n.d. 
15 (UR-COP248) 760 ± 67 98 ± 6 5,420 ± 230 52 ± 5 n.d. 
16 (UR-COP258) 544 ± 53 112 ± 19 5,990 ± 520 55 ± 6 n.d. 
17 (UR-COP270) 839 ± 105 103 ± 3 4,430 ± 300 53 ± 7 inactive 
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Table 3.10: Inhibition of ABCG2, ABCB1 and ABCC1 by 3rd generation modulators: indole series, 
compounds 18-33.  
Compound 
ABCG2 ABCB1 ABCC1 
IC50 [nM] Imax (%) IC50 [nM] Imax (%) IC50 [nM] 
18 (UR-COP224) 603 ± 204 56 ± 10 inactive  inactive 
19 (UR-COP235) 1,264 ± 345 46 ± 2 inactive  inactive 
20 (UR-COP236) 1,185 ± 272 50 ± 7 2,048 ± 47 17 ± 2 inactive 
21 (UR-COP237) 683 ± 253 54 ± 4 1,076 ± 106 30 ± 7 inactive 
22 (UR-COP238) 2,238 ± 202 22 ± 0 inactive  inactive 
23 (UR-COP239) 639 ± 20 39 ± 2 1,068 ± 239 13 ± 4 inactive 
24 (UR-COP256) 920 ± 145 49 ± 1 1,323 ± 368 28 ± 4 inactive 
25 (UR-COP271)a n.d.  n.d.  n.d. 
26 (UR-COP240) 384 ± 47 98 ± 2 inactive  inactive 
27 (UR-COP251) 140 ± 40 99 ± 6 1,341 ± 399 13 ± 4 inactive 
28 (UR-COP254) 368 ± 63 97 ± 4 7,906 ± 595 15 ± 0 inactive 
29 (UR-COP260) 132 ± 6 121 ± 19 3,940 ± 629 56 ± 10 inactive 
30 (UR-COP264) 316 ± 83 96 ± 9 inactive  inactive 
31 (UR-COP268) 160 ± 4 99 ± 1 inactive  inactive 
32 (UR-COP269) 59 ±11 101 ± 5 7,299 ± 910 14 ± 2 inactive 
33 (UR-COP272) 46 ± 1 111 ± 9 3,570 ± 640 36 ± 4 inactive 
a
 Insufficient stability excluded compound 25 from testing. 
Table 3.11: Inhibition of ABCG2, ABCB1 and ABCC1 by 3rd generation modulators: triazole series, 
compounds 34-40.  
Compound 
ABCG2 ABCB1 ABCC1 
IC50 [nM] Imax (%) IC50 [nM] Imax (%) IC50 [nM] 
34 (UR-MB19-5) 392 ± 40 92 ± 1 inactive  inactive 
35 (UR-MB81-2) 426 ± 38 103 ± 1 inactive  inactive 
36 (UR-MB83-2) 168 ± 81 96 ± 1 5,371 ± 1624 68 ± 1 inactive 
37 (UR-MB84-3) 137 ± 4 88 ± 10 >35,000 34 ± 8 inactive 
38 (UR-MB86-2) 371 ± 15 90 ± 2 >15,000 39 ± 4 inactive 
39 (UR-MB95-2) 108 ± 24 97 ± 7 1,270 ± 313 91 ± 11 inactive 
40 (UR-MB113-3) 145 ± 35 85 ± 6 inactive  inactive 
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Table 3.12: Inhibition of ABCG2, ABCB1 and ABCC1 by 3rd generation modulators: quinoline series, 
compounds 41-49.  
Compound 
ABCG2 ABCB1 ABCC1 
IC50 [nM] Imax (%) IC50 [nM] Imax (%) IC50 [nM] 
41 (UR-QQS-1) 536 ± 160 77 ± 1 2,709 ± 158 41 ± 15 n.d. 
42 (UR-QQS-2) 1,043 ± 53 107 ± 7 inactive  n.d. 
43 (UR-QQS-3) 602 ± 44 60 ± 0 inactive  n.d. 
44 (UR-QQS-4) 851 ± 93 81 ± 14 inactive  n.d. 
45 (UR-QQS-5) 1,467 ± 568 70 ± 5 inactive  n.d. 
46 (UR-QQS-6) 1,167 ± 214 61 ± 7 >15,000 25 ± 2 n.d. 
47 (UR-QQS-7) 1,820 ± 861 75 ± 7 inactive  n.d. 
48 (UR-QQS-10) 904 ± 45 58 ± 3 8,571 ± 211 21 ± 1 n.d. 
49 (UR-QQS-9) 513 ± 101 53 ± 6 inactive  n.d. 
Table 3.13: Inhibition of ABCG2, ABCB1 and ABCC1 by 4th generation modulators: triazole series 
bearing a ketone, compounds 50-52.  
Compound 
ABCG2 ABCB1 ABCC1 
IC50 [nM] Imax (%) IC50 [nM] Imax (%) IC50 [nM] 
50 (UR-MB107-6) 48 ± 10 98 ± 11 inactive  inactive 
51 (UR-MB108-4) 64 ± 3 95 ± 3 inactive  inactive 
52 (UR-MB136-4) 55 ± 14 110 ± 17 2,551 ± 57 156 ± 2 inactive 
Elacridar strongly inhibited the ABCG2 and the ABCB1 transporter, although without preference for 
one of the two targets, whereas tariquidar was about four times less potent at ABCG2, but almost 
equipotent with elacridar at ABCB1. The ABCG2 inhibitor Ko143, inactive at ABCB1, showed an IC50 
value of 117 nM with a maximal inhibitory effect comparable to that of fumitremorgin C. Compounds 
1 and 2 were comparable to Ko143 regarding potency and selectivity, but produced a lower maximal 
response. Aiming at structural optimization of potent and selective ABCG2 inhibitors like 2, 
compounds bearing triethyleneglycol ether groups at the tetrahydroisoquinoline moiety were 
synthesized (compounds 3-5). Compounds 3 and 4 were comparable to UR-ME22-1 in potency, but 
considerably more efficient (maximal inhibition of 83% and 88% vs. 63%, relative to FTC). These 
results support the hypothesis that poor solubility of the ABCG2 modulators 1 and 2 in aqueous 
media is the factor limiting efficacy.  
Compounds such as UR-COP78 (4) are highly potent and selective ABCG2 modulators, but prone to 
rapid enzymatic cleavage (cf. section 3.4.5.2) at the central benzanilide moiety. In search for more 
stable analogs, according to a bioisosteric approach, new series of potential modulators, bearing a 
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biphenyl, a quinoline, an indole and a triazole core, respectively, were prepared by conventional or 
solid phase synthesis. 
All newly synthesized compounds showed a marked preference for ABCG2 inhibition.  
Within the biphenyl series compounds 7, 9, 10, 13 and 14 were completely inactive at the ABCB1 
transporter, whereas the IC50 values of compounds 12 and 16 (~600 nM) were comparable to that of 
tariquidar, the maximal inhibitory effects were significantly higher, achieving 109% and 112%, 
respectively, relative to FTC. Except for 11, all modulators show a maximal ABCG2 inhibition of 90% 
or higher. Compound 12, the most potent - but not completely selective - BCRP modulator in this 
series, showed a maximum inhibition at the ABCB1 transporter of only 20%.  
The potency of compounds 13-16, bearing an ethylene linker, was not increased compared to that of 
the lower homolog 12, suggesting that the distance between the tetrahydroisoquinoline core and the 
biphenyl motif may be varied within this class of ABCG2 modulators. Compounds 12 and 16, indeed, 
showed higher IC50 values compared to all reference compounds, but, with respect to the maximal 
inhibitory effects, they were superior to tariquidar, elacridar, compounds 1-5 and comparable to 
Ko143.  
Subsequent compounds of the indole, quinoline and triazole series, were designed with a 
quinoline-2-carboxamido substituent at the central benzamide. 
Compounds 18-33 represent the indole series. Initial problems with deprotection during synthesis led 
to compounds 18-24, the N-mesylated precursors of 25-33. In general, the N-mesylated indoles 
showed higher IC50 values and lower maximal responses (~50%) compared to the unprotected 
analogs, suggesting that the unsubsituted NH-group of the indole core is essential for ABCG2 
inhibition. Most of the indoles 25-33 inhibited the ABCG2 transporter at low nanomolar 
concentrations with maximal inhibitory effects of 100% or even surpassing that of FTC. Compounds 
26, 30 and 31 were selective for ABCG2, whereas the other compounds showed also activity at the 
P-glycoprotein with IC50 values in the micromolar range (e.g. selectivity ratio of compound 32: 124 in 
favor of ABCG2). Compounds 29, 32 and 33 were the most potent BCRP modulators of this series 
with IC50 values of 132 nM, 59 nM 46 nM, respectively, and maximal inhibitory effects higher than 
100%. These indoles were superior to tariquidar, FTC and even to Ko143, the most potent ABCG2 
transporter inhibitor reported so far.  None of the compounds showed activity at the ABCC1 
transporter. In general, the potencies of compounds with a methylene linker (n=1) at the indole core 
were comparable to those of compounds with an ethylene bridge (n=2). 
Compounds 34-40 and 50-52 (triazole series) produced similar results with IC50 values in the low 
nanomolar range and potencies comparable to fumitremorgin C (100%). Together with 32 and 33, 
compounds 50-52 are the most potent ABCG2 modulators reported so far. 
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Compounds 39 and 52 also showed distinct activity at the P-gp and work as potent dual 
ABCB1/ABCG2 transporter modulators with a maximal ABCB1 inhibition of 91% and 156% compared 
to tariquidar [1 µM], respectively. 
The introduction of one or two triethylene glycol chains at the tetrahydroisoquinoline core in the 
series of 3rd generation modulators, in general, on the one hand increased the inhibitory activity 
compared to UR-ME22-1 (2), probably due to improved water solubility, on the other hand ABCG2 
selectivity was decreased. 
In another synthesis approach, a quinoline instead of an indole was introduced as a putative anilide 
bioisostere resulting in compounds 41-49. Compounds 41 and 42, bearing one or two triethylenglycol 
chains, respectively, were indeed the two most potent representatives of this series, but in general, 
the quinoline bearing compounds turned out to be hardly soluble and less potent compared to the 
indole series regarding ABCG2 modulation, suggesting that the extension of the indole ring system to 
a quinoline reduces ABCG2 inhibition. 
Compounds 44-49 contain linkers with various basic heterocycles instead of a methoxy group or a 
triehylenglycol chain and were generally less potent and efficient in comparison to compounds of the 
indole and the triazole series. 
3.4.2 Fluorescence properties of selected ABCG2 modulators  
Besides modulators 38, 51 and 52 only compounds 35 and 36 showed weak fluorescence (spectra 
not shown) in mobile phase with an emission maximum at 470 nm after excitation at 370 nm 
(Figures 3.9-3.10). 
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Figure 3.9: A) Excitation spectrum (λem: 480 nm; Ex Slit: 5; Em Slit: 10) of compound 51 [1 µM] in MeCN/0.05% TFA (aq.) at a 
ratio of 70/30; B) Emission spectrum (Ex Slit: 10, Em Slit: 5) of compound 51 [1 µM] after excitation at 310 nm (blue) and 
370 nm (red), respectively. 
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Figure 3.10: Emission spectra of compounds 38 (A) and 52 (B) [1 µM] in MeCN/0.05% TFA (aq.) at a ratio of 70/30 at two 
different excitation wavelengths: 310 nm (blue) and 370 nm (red); Ex Slit: 10, Em Slit: 5. 
3.4.3 Alternative fluorescence based ABCG2 inhibition assays  
Fluorescent ABC modulators like compounds 51 and 52 (λex: 370 nm; λem: 480 nm) partially overlap 
with the excitation and emission spectra of the intercalated Hoechst 33342 dye (λex: 340 nm, 
λem: 485 nm). To exclude that the fluorescence of these compounds interferes with the Hoechst 
assay, causing false positive results, a microplate assay was established, using mitoxantrone as a 
fluorescent ABCG2 substrate with spectral properties different from those of 51 and 52 and that of 
intercalated Hoechst 33342. Selected compounds were investigated in the Hoechst 33342, the 
mitoxantrone (λex: 612 nm, λem: 670 nm) and additionally in the pheophorbide a (PhA; λex: 380 nm, 
λem: 670 nm) microplate assay using MCF-7/Topo cells (Table 3.14). 
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 If not otherwise stated, mean values and maximal inhibitory effects were calculated from two to 
three independent experiments performed in sextuplicate (Hoechst 33342 assay) or two experiments 
performed in triplicate (mitoxantrone and PhA assay).  
 
Table 3.14: Inhibition of ABCG2 by selected modulators, determined in three different microplate 
assays using MCF-7/Topo cells. Fluorescent compounds are highlighted in blue. 
Compound 
H33342 Assay 
λex: 340 nm; λem: 485 nm 
Mitoxantrone Assay 
λex: 612 nm; λem: 670 nm 
PhA Assay 
λex: 380 nm; λem: 670 nm 
IC50 [nM] Imax (%) IC50 [nM] Imax (%) IC50 [nM] Imax (%) 
12 591 ± 94 109 ± 8 796 ± 146 94 ± 6 566 ± 74 65 ± 7 
15 760 ± 67 98 ± 6 505 ± 13 89 ± 3 973 ± 87a 81 ± 2 
26 384 ± 47 98 ± 2 275 ± 66 84 ± 2 710 ± 87a 71 ± 3 
29 132 ± 6 121 ± 19 137 ± 4 100 ± 6 488 ± 56 a 146 ± 5 
31 160 ± 4 99 ± 1 151 ± 16 101 ± 9 278 ± 22a 125 ± 2 
32 59 ± 11 101 ± 5 94 ± 33 99 ± 0 117 ± 34 103 ± 11 
33 46 ± 1 111 ± 9 55 ± 13 104 ± 4 101 ± 11 90 ± 2 
34 392 ± 40 92 ± 1 627 ± 127 88 ± 5 978 ± 67a 56 ± 1 
38 371 ± 90 90 ± 2 426 ± 172 70 ± 6 856 ± 167 53 ± 7 
40 145 ± 35 85 ± 6 251 ± 22 90 ± 2 141 ± 21 69 ± 6 
51 64 ± 3 95 ± 3 49 ± 6 95 ± 2 480 ± 238 80 ± 2 
52 55 ± 14 110 ± 17 115 ± 69 91 ± 12 94 ± 4 89 ± 0 
a
 Mean values were calculated from a single experiment performed in triplicate.  
As shown in Table 3.14, IC50 values as well as Imax values obtained in the Hoechst 33342 and the 
mitoxantrone assay are in a very good accordance. In general, the pheophorbide a assay yielded 
lowest activities with the exception of compounds 29, 31 and 32. The fact that these compounds all 
belong to the indole series and are substituted at the tetrahydroisochinoline suggests that the 
different potencies and efficacies obtained in the PhA assay and the other two ABCG2 modulator 
assays are substrate dependent. Besides assay-dependent differences and variable extents of 
precipitation of the modulators, the low maximal inhibitory effects in the PhA assay may result from 
absorption of the excitation light for PhA by some of the compounds. Figures 3.11-3.13 display the 
concentration-response curves for all compounds tested in the Hoechst 33342, the mitoxantrone and 
the pheophorbide a microplate assay, respectively. 
Whereas compound 51 and 52 yielded almost identical results in the H33342 and the mitoxantrone 
assay (λex: 380 nm; λem: 670 nm), compound 38 differs in the efficacy in the two assays. 
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As shown in Figure 3.13 (B), the inhibition for compound 38 from the mitoxantrone assay does not 
deviate from that of the Hoechst assay up to a concentration of 1 µM. As 38 showed very poor 
solubility (even in DMSO), it is likely that precipitation was the cause of the discrepancies in the 
different ABCG2 assays.  
In general, with the establishment of the mitoxantrone assay, a well-suited alternative test system in 
terms of ABCG2 inhibition was adjusted. As mitoxantrone fluorescence efflux assays in literature are 
mainly performed at the flow cytometer [Matsson et al., 2007], the here arranged assay in the 
96-well format represents a comfortable alternative for the screening of a large variety of 
compounds. 
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Figure 3.11: ABCG2 inhibition by compounds 12 (A), 15 (B), 26 (C) and 29 (D), respectively, in the Hoechst33342 (open 
circles), the mitoxantrone (open triangles) and the pheophorbide a (open squares) microplate assay. 
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Figure 3.12: ABCG2 inhibition by compounds 31 (A), 32 (B), 33 (C) and 34 (D), respectively, in the Hoechst33342 (open 
circles), the mitoxantrone (open triangles) and the pheophorbide a (open squares) microplate assay. 
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Figure 3.13: ABCG2 inhibition by 40 (A) and fluorescent compounds 38 (B), 51 (C) and 52 (D), respectively, in the 
Hoechst33342 (open circles), the mitoxantrone (open triangles) and the pheophorbide a (open squares) microplate assay. 
3.4.4 Effect of co-administration of ABCG2 inhibitors with 
topotecan on the proliferation of MCF-7/Topo cells 
To confirm ABCG2 transporter inhibition, resulting in a reversal of ABCG2 mediated drug resistance, 
the effect of the five most potent modulators (compounds 32, 33, 50-52) on the proliferation of two 
cell lines was investigated using a kinetic crystal violet chemosensitivity assay (Figures 3.14-3.18). 
ABCG2-overexpressing MCF-7/Topo cells show resistance against the cytostatic drug topotecan, a 
known BCRP substrate, up to concentrations of 550 nM. The cells were incubated with topotecan 
alone and in combination with different concentrations of the new modulators. Considering potential 
cytotoxicity of the ABCG2 modulators, the cells were also treated with modulators alone. 
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Figure 3.14: Effect of compound 32 (UR-COP269) alone (A) and in combination with topotecan (B) on proliferating 
MCF-7/Topo cells; vehicle (open stars); A) 32 [1 µM] (filled circles) and [5 µM] (filled triangles), positive control vinblastine 
[1 µM] (filled squares); B) topotecan [100 nM] (open circles), topotecan [100 nM] + 32 [100 nM] (filled inverted triangles), 
topotecan [100 nM] + 32 [500 nM] (filled diamonds). 
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Figure 3.15: Effect of compound 33 (UR-COP272) alone (A) and in combination with topotecan (B) on proliferating 
MCF-7/Topo cells; vehicle (open stars); A) 33 [1 µM] (filled circles) and [5 µM] (filled triangles), positive control vinblastine 
[1 µM] (filled squares); B) topotecan [100 nM] (open circles), topotecan [100 nM] + 33 [100 nM] (filled inverted triangles), 
topotecan [100 nM] + 33 [500 nM] (filled diamonds). 
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Figure 3.16: Effect of compound 50 (UR-MB107-6) alone (A) and in combination with topotecan (B) on proliferating 
MCF-7/Topo cells; vehicle (open stars); A) 50 [1 µM] (filled circles) and [5 µM] (filled triangles), positive control vinblastine 
[1 µM] (filled squares); B) topotecan [100 nM] (open circles), topotecan [100 nM] + 50 [100 nM] (filled inverted triangles), 
topotecan [100 nM] + 50 [500 nM] (filled diamonds). 
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Figure 3.17: Effect of compound 51 (UR-MB108-4) alone (A) and in combination with topotecan (B) on proliferating 
MCF-7/Topo cells; vehicle (open stars); A) 51 [1 µM] (filled circles) and [5 µM] (filled triangles), positive control vinblastine 
[1 µM] (filled squares); B) topotecan [100 nM] (open circles), topotecan [100 nM] + 51 [100 nM] (filled inverted triangles), 
topotecan [100 nM] + 51 [500 nM] (filled diamonds). 
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Figure 3.18: Effect of compound 52 (UR-MB136-4) alone (A) and in combination with topotecan (B) on proliferating 
MCF-7/Topo cells; vehicle (open stars); A) 52 [1 µM] (filled circles) and [5 µM] (filled triangles), positive control vinblastine 
[1 µM] (filled squares); B) topotecan [100 nM] (open circles), topotecan [100 nM] + 52 [100 nM] (filled inverted triangles), 
topotecan [100 nM] + 52 [500 nM] (filled diamonds). 
The modulators alone did not affect the proliferation of MCF-7/Topo cells at high concentrations, i.e. 
1 µM and 5 µM, respectively. Only compound 32 led to a temporary growth retardation [5 µM] 
24 hours after addition of the compound.  
The combination of topotecan at a nontoxic concentration of 100 nM with compounds 32 and 33, 
respectively, resulted in a cytotoxic drug effect, even at a low modulator concentration of 100 nM. A 
higher concentration of the modulator did not increase cyctotoxicity. Compounds 50-52 caused a 
strong cytostatic effect on MCF-7/Topo cells in combination with topotecan. 
In general, the combination with the cytostatic drug topotecan led to a total reversal of ABCG2 
mediated drug resistance by all compounds tested. 
As negative control, analogous experiments were performed using U-118 MG cells, which do not 
express the ABCG2 transporter. A nontoxic concentration of 10 nM topotecan in combination with 
different concentrations of the modulators did not influence cell proliferation at all (as an example 
shown for compound 32 in Figure 3.19). 
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Figure 3.19: Effect of compound 32 (UR-COP269) in 
combination with topotecan on proliferating U-118 MG 
cells; vehicle (open stars), topo [10 nM] (open circles), 
topo [10 nM] + 32 [100 nM] (filled inverted triangles), topo 
[10 nM] + 32 [500 nM] (filled diamonds). 
 
 
3.4.5 Chemical stability of selected ABCG2 transporter modulators 
under physiological conditions 
As a prerequisite for planned in vivo studies, the most potent inhibitors were subjected to 
preliminary biopharmaceutical investigations with a focus on stability in mouse plasma. Because of 
the lack of drug like properties (rapid enzymatic cleavage in mouse plasma) of recently described and 
characterized 1st and 2nd generation modulators like compounds  1, 2 and 4 [Kühnle, 2010; Ochoa-
Puentes et al., 2011], the chemical structures of these target compounds were modified in a 
bioisosteric approach (replacement of the amide) with a main focus on stability resulting in a 3rd and 
4th generation of modulators. 
Bioisosteric replacements to create new molecules with improved biological properties to the parent 
compound are major objectives in successful structure-based drug design. Modification of a 
compound can attenuate toxicity and chemical stability, modify activity or alter pharmacokinetics. 
Whereas the classical bioisosteres involve structurally simple atoms or groups, nonclassical 
bioisosteres replace functional groups with a different number of atoms and/or different steric and 
electronic properties [Patani and LaVoie, 1996]. Classical bioisosterism comprises e.g. the 
replacement of hydrogen by fluorine classically exemplified by 5-fluoruracil derived from uracil or the 
isosteric substitution of an amino group for a hydroxyl group (folic acid and aminopterin).  
Nonclassical bioisosterism includes the replacement of noncyclic structures with cyclic residues and 
vice versa or the replacement of functional groups [Lemke and Williams, 2012]. A successful story of 
bioisosteric replacement in drug discovery was shown for the angiotensin II receptor antagonist 
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losartan: With the replacement of the carboxylic acid residue of its lead structure by a tetrazol the 
oral bioavailabilty could significantly be improved [Herr, 2002; Dinges and Lamberth, 2012].  
By analogy with the synthesis strategy described in this work, the replacement of a metabolic 
instable ester or amide with different heterocycles was shown previously [Eastwood et al., 2011; 
Monceaux et al., 2011]. Many other amide and ester isosteres are known including 
trifluoroethylamines (successfully shown for the cathepsin K inhibitor odanacatib [Gauthier et al., 
2008]) and oxadiazolines [Sun et al., 2012] as well as isoxazole-ether scaffolds as acetyl group 
replacement of acetylcholine [Yu et al., 2012]. 
3.4.5.1 Chemical stability in culture medium and human CPD plasma 
To investigate the stability of the new classes of modulators, the compounds were incubated in 
different media, including DMEM supplemented with 10% FCS as well as in murine and human 
plasma over a period of 24 hours. HPLC was used for analysis. 
Compounds 7-10, 12, 19 and 34, selected representatives of the biphenyl, indole and triazole series, 
respectively, were incubated at 37 °C in human plasma or DMEM + 10% FCS. All compounds were 
completely stable over a period of 24 hours in both media. Stabilities of compounds 12 and 19 after 
24 h are displayed in Figures 3.20-3.21. 
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Figure 3.20: Chromatogram of a DMEM (+ 10% FCS) sample (A) and a human (CPD) plasma sample (B) containing 
compound 12 (final concentration: 3 µM) after 24 h of incubation at 37 °C; the respective chromatogram of a blank DMEM 
and plasma sample, processed by the same method, is shown as red dotted line. 
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Figure 3.21: Chromatogram of a DMEM (+ 10% FCS) sample (A) and a human (CPD) plasma sample (B) containing 
compound 19 (final concentration: 3 µM) after 24 h of incubation at 37 °C; the respective chromatogram of a blank DMEM 
and plasma sample, processed by the same method, is shown as red dotted line. 
3.4.5.2 Chemical stability in mouse plasma 
As compounds 1, 2 and 4 are prone to rapid enzymatic cleavage in mouse plasma at the central 
benzanilide moiety within 30 min (displayed in Figure 3.22 for compound 4) the new 3rd generation 
modulators were also investigated for their chemical stability in murine plasma.  
Surprisingly, in mouse plasma, in all compounds of these new series of modulators the ester group is 
prone to enzymatic cleavage yielding the inactive carboxylic acid. However, hydrolysis of the ester 
occurs much slower than cleavage of the benzanilide of the 1st and 2nd generation modulators. 
Regarding stability in murine plasma, all ester bearing indole-, biphenyl- and triazole-type 
modulators, respectively, have a half-life of about 24 h compared to 10 min in case of compounds 
1, 2 and 4. Additionally, the quinoline carboxamide group was cleaved, though to a very small extent 
(as an example: see compound 12 in Figure 3.24).  
Although the chemical stability in murine plasma was improved by the renunciation of the lable 
amide core, the results are not yet satisfactory. In search for completely stable ABCG2 modulators, 
the hydrolysis-sensitive ester group of the 3rd generation triazole series was replaced by a ketone 
(compounds 50-52). These ‘4th generation modulators’ were completely stable in murine plasma over 
a period of 24 h (Figure 3.26) and are therefore appropriate for in vivo investigations in nude mice. 
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Figure 3.22: Enzymatic degradation of UR-COP78 (4), when incubated in mouse plasma over a period of 24 h at 37 °C: 
Complete decomposition to compounds A and B (main cleavage products) within 30 minutes. Additionally, the ester group 
and the quinoline carboxamide group were cleaved (HPLC analysis, UV detection at 210 nm). The cleavage products were 
identified by HPLC-MS analysis. Fragment E was only detectable by HPLC-MS-analysis (Figure 3.23) 
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Figure 3.23: HPLC-MS analysis of compound 4 in mouse plasma: Detection of the cleavage products A-E in plasma of NMRI 
(nu/nu) mice, 24 h after incubation at 37 °C. 
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Figure 3.24: Enzymatic degradation of UR-COP228 (12), when incubated in mouse plasma over a period of 24 h at 37 °C. 
Main cleavage product: compound A, the inactive caboxylic acid after ester hydrolysis. Additional fragments appeard after 
degradation of the quinoline carboxamide group (HPLC analysis, UV detection at 210 nm). The cleavage products were 
identified by HPLC-MS analysis. Fragment C was only detectable by HPLC-MS-analysis (Figure 3.25) 
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Figure 3.25: HPLC-MS analysis of compound 12 in mouse plasma: Detection of the cleavage products A-D in plasma of NMRI 
(nu/nu) mice, 24 h after incubation at 37 °C. 
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Figure 3.26: Chemical stability of compound 51 when incubated in mouse plasma over a period of 24 h at 37 °C (HPLC 
analysis, UV detection at 210 nm). 
3.4.5.3 Esterase activity in human and murine plasma 
Because of the different stabilities of 3rd generation modulators after incubation for 24 h in human 
and murine plasma, respectively, the enzymatic activity of unspecific esterases was compared 
spectrophotometrically. Murine plasma showed a 1.5-fold higher esterase activity [6.04 ± 0.20 U/mL] 
in comparison to human CPD plasma [4.26 ± 0.26 U/mL] (Stefan Huber, personal communication). 
3rd generation modulators bearing an ester group where therefore hydrolyzed in murine, but not in 
human plasma. There was no activity difference between CPD and heparinized human blood. 
3.4.6 Effect of selected ABCG2 transporter modulators on the 
transport of Daunorubicin in a blood-brain barrier model 
It was previously shown that the brain multidrug resistance protein (BMDP), the porcine homolog to 
the human ABCG2 gene, is highly expressed in porcine brain capillary endothelial cells (PBCEC) 
[Eisenblätter and Galla, 2002]. Thus, these cells can be used for transport studies in an established 
blood-brain-brain barrier model measuring the capability of BMDP to transport 3H-daunorubicin 
across a monolayer of PBCEC grown on porous filters in the presence of ABCG2 inhibitors. 
Daunorubicin was previously shown to be a substrate of the human homolog of BMDP [Doyle et al., 
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1998]. PBCECs cultured on filter inserts, with the apical chamber corresponding to the blood and the 
basolateral chamber corresponding to the brain side in vivo, are morphologically polarized. 
Tritium labeled daunorubicin was added to both compartments at identical concentrations. Upon 
addition of an ABCG2 inhibitor, the daunorubicin transport across the cell monolayer is hindered. The 
amount of daunorubicin which is transported from the basolateral to the apical compartment 
inversely correlates with the potency of an ABCG2 modulator. 
The selective ABCG2 inhibitors fumitremorgin C (FTC), reference compound for ABCG2 inhibition in 
the used fluorescence-based microplate assays, and the two 1st generation modulators UR-ME4-1 (1) 
and UR-ME22-1 (2) were used for inhibition studies in the blood-brain barrier (BBB) model 
(Figure 3.27). Whereas at a concentration of 1 µM compounds 1 and 2 inhibit the transport of 
daunorubicin from the basolateral to the apical side of the PBCEC monolayer almost completely, FTC 
produced only moderate inhibition even at a concentration of 10 µM.  
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Figure 3.27:  
A: Transendothelial transport of 
3
H-daunorubicin across a PBCEC monolayer in presence of ABCG2 inhibitors: 
Fumitremorgin C [10 µM] (squares), compound 1 (UR-ME1-4) [1 µM] (triangles), compound 2 (UR-ME22-1) [1 µM] 
(diamonds), control (circles). 
Concentrations of 
3
H-daunorubicin were measured after 0.5, 6, 12, 24, 36, 48 and 72 h in each compartment (apical: blue; 
basolateral: red) and normalized to measurements at 0.5 h. The vertical bars for each data point represent the standard 
deviation of three replicate determinations. Transendothelial electrical resistance (n = 3): 1310 ± 379 Ωcm
2
. 
B: Corresponding tightness control of the endothelial cell monolayer in presence of ABCG2 inhibitors indicated by 
paracellular permeability of 
14
C-sucrose.  
 
In the Hoechst 33342 assay, the use of fetal calf serum (FCS) and the contained proteins may be 
beneficial for solubility properties of the ABCG2 modulators providing a reservoir in aqueous 
systems. Tests in the BBB model, however, were performed under serum-free conditions. Therefore, 
it is even more astonishing that compounds 1 and 2 were obviously superior to FTC [10 µM] in the 
BBB model at a concentration of 1 µM, whereas in the Hoechst 33342 they only reached 2/3 of the 
efficacy of FTC [10 µM] in the presence of FCS. The effective concentrations of free compounds may 
be much lower in the BBB model in comparison to the Hoechst 33342 assay.  
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Compounds 32 (UR-COP269) and 33 (UR-COP272) are among the most potent ABCG2 inhibitors 
known so far with IC50 values of 59 nM and 46 nM, respectively, and maximal inhibitory effects of 
over 100% (Hoechst33342 assay). Although comparable to compounds 1 and 2 in potency and clearly 
superior in efficacy (H33342 assay), the extent of daunorubicin transport inhibition was not as 
significant as for the aforementioned ABCG2 modulators in the blood-brain barrier model 
(Figure 3.28). In general, daunorubicin transport did not significantly change in presence of 
compounds 32 and 33, respectively, at a concentration of 1 µM in comparison to the control. A 
concentration of 2 µM in case of 32 produced a moderate transport inhibition. The results for 33 
[3 µM] are not reliable as sucrose permeability obviously increased when incubating the monolayer 
with this high modulator concentration.  
Besides different grades of precipitation (water solubility) due to milieu differences between the 
Hoechst assay and the BBB model (buffer composition, pH value, hydrocortisone supplementation), 
species differences (human ABCG2 transporter in the H33342 assay vs. the porcine homolog in the 
BBB model) have to be considered for the inconsistent testing results in the two test system.  
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Figure 3.28:  
A: Transendothelial transport of 
3
H-daunorubicin across a PBCEC monolayer in presence of ABCG2 inhibitors: Compound 32 
[1 µM] (filled squares) and [2 µM] (open squares), compound 33 [1 µM] (filled triangles) and [3 µM] (open triangles), control 
(circles). 
Concentrations of 
3
H-daunorubicin were measured after 0.5, 6, 12, 24, 36, 48 and 72 h in each compartment (apical: blue; 
basolateral: red) and normalized to measurements at 0.5 h. The vertical bars for each data point represent the standard 
deviation of three replicate determinations. Transendothelial electrical resistance (n = 3): 1617 ± 128 Ωcm
2
. 
B: Corresponding tightness control of the endothelial cell monolayer in presence of ABCG2 inhibitors indicated by 
paracellular permeability of 
14
C-sucrose.  
To elucidate, whether the synthesized modulators act as substrates or as inhibitors of the ABCG2 
transporter, the BBB model experiment was performed as described above with a fixed 
concentration of the modulator on both sides of the monolayer. After different periods of time 
samples of each compartment were collected and changes in the modulator concentration on the 
two sides tried to be calculated by means of HPLC analysis. Unfortunately the concentration of the 
compounds in the samples was too low to be significantly quantified by HPLC analysis. The way of 
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detection was not sensitive enough as only UV detection was available for these classes of 
compounds. 
3.5 Summary and conclusions 
During this work, a series of about 50 new putative ABCG2 transporter modulators was synthesized 
in dependence on former described tariquidar analogs [Kühnle, 2010] with a major focus on the 
design of more stable, drug-like compounds.  
Firstly, the problem of insufficient water solubility of the lead compound UR-ME22-1 (2) was 
attempted to be solved by the introduction of triethylenglycol chains resulting in a 2nd generation of 
ABCG2 modulators with compound 4 (IC50 130 nM, Imax 88%) as most promising representative. The 
insertion of polyethylene glycol moieties led to a clearly increased efficacy.  
Secondly, the instable benzamide moiety, point attack of esterases in mouse plasma, was replaced in 
a bioisosteric approach giving four new classes of 3rd generation modulators with a biphenyl system, 
an indole, a triazole and a quinoline, respectively, as central core structure. 
Among these four new classes of BCRP modulators, compounds 29, 32 and 33 bearing an indole are 
the most potent ones with IC50 values in the H33342 assay of 132 nM, 59 nM and 46 nM, 
respectively, and maximal inhibitory effects of over 100% in comparison to the standard ABCG2 
inhibitor fumitremorgin C. Stability tests in mouse plasma revealed that these 3rd generation 
modulators are neither immune against enzymatic degradation with the ester as new hydrolysis 
weak point.  
In search for completely stable ABCG2 modulators, the synthesized structures were further improved 
replacing the hydrolysis-sensitive ester by a ketone giving compounds 50-52 which are stable in 
mouse plasma over a period of 24 hours. Additionally, together with 32 and 33, compounds 50-52 
turned out to be the most potent ABCG2 modulators reported so far.  
The results were confirmed in a kinetic chemosensitivity assay where the incubation of topotecan 
resistant MCF-7/Topo cells with a combination of topotecan and the modulators led to a complete 
reversal of ABCG2-mediated drug resistance.  
Because of coincident fluorescent properties of some compounds with the Hoechst 33342 dye, a 
second assay system was established using mitoxantrone as fluorescent substrate. Additionally, the 
selectivity against other ABC proteins was tested using an already existing calcein-AM assay for tests 
at the P-gp [Höcherl, 2010] and a new arranged microplate assay for inhibition tests at the ABCC1 
transporter with reversan as standard compound. 
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Inconsistent results were obtained for the testing of compounds 1, 2, 32 and 33 in a porcine blood-
brain barrier model. Although less efficient compared to FTC in the Hoechst 33342 assay, compounds 
1 and 2 were clearly superior to the standard compound in the serum-free BBB model. The inhibitory 
effect of compounds 32 and 33 in the in vitro model was not as significant as for 1 and 2 although 
superior in the cell based microplate assay in both potency and efficacy.  
The question rises whether species differences of the expressed ABCG2 transporters contributes to 
these results. 
Subsequent projects with a major focus on the determination of the way of ABCG2 modulation are of 
major interest. The question has to be answered whether the synthesized compounds act as 
substrates or as inhibitors at the ABCG2 transporter. Therefore, different approaches are 
conceivable, either the use of radio-labeled ABCG2 modulators in the BBB model as a sensitive 
method or the testing of the compounds in an ATPase assay (see Chapter 6).  
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 Chapter 4 
4 Drug-like properties of new 
ABCG2 modulators  
4.1 Introduction 
4.1.1 Trends in medicinal chemistry and drug development 
Nowadays, pharmaceutical companies mainly perform high-throughput screening to discover so 
called ‘hits’, which are subject of hit-to-lead processes to identify lead compounds for further 
optimization, aiming at the development of potential drug candidates. Computational methods as 
well as automated sample preparation and screening procedures led to drug libraries with an 
enormous number of new compounds. These techniques are used to improve chemical structures 
regarding biological activity to predict the compounds’ physicochemical properties as well as drug 
absorption or oral bioavailability [Stegemann et al., 2007]. However, improving a compound’s 
potency at the cost of solubility and bioavailability is a prominent negative trend in ‘rational drug 
design’ mainly resulting from higher H-bonding properties and increasing molecular weights 
attended by a enhanced lipophilicity, [Lipinski, 2000]. As a consequence, numerous compounds 
never pass clinical trials or become commercially available drugs.  
4.1.2 The ‘Rule of Five’ 
Lipinski’s ‘Rule of 5’ is based on the drug-like properties of several thousand drugs [Lipinski et al., 
2001] and a useful fingerpost or starting point in drug design and discovery with regard to 
bioavailability.  
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According to this rule, good absorption and permeation is more likely when: 
1. There are not more than 5 H-bond donors (sum of OHs and NHs); 
2. There are not more than 10 H-bond acceptors (sum of Os and Ns); 
3. The molecular weight is ≤ 500 Da;  
4. The logP is ≤ 5. 
The ‘Rule of 5’ addresses all therapeutic areas. Nonetheless, there are occasional limitations.  It 
should be modified for centrally active compounds [Pajouhesh and Lenz, 2005; Reichel, 2006] as CNS 
penetration is more likely if: 
1. There are ≤ 3 H-bond donors; 
2. There are ≤ 7 H-bond acceptors; 
3. The molecular weight is < 400-500 Da;  
4. The logP is ≤ 5.  
Furthermore, it is limited, if there is a biological transporter involved. The commonly applied 
molecular weight cutoff of 500 Da per se, is not an excluding criterion regarding acceptable 
bioavailability [Veber et al., 2002], as shown for successful big drug molecules such as cyclosporine 
[Ptachcinski et al., 1986] or tacrolimus (FK506) [Venkataramanan et al., 1995]. 
4.1.3 Plasma protein binding 
Besides the fulfillment of various physicochemical requirements, information about plasma protein 
binding (PPB) of drug candidates is key in drug development to enable estimates and extrapolations 
to in vivo kinetics as early as possible. Different methods for quantifying the binding of drugs to 
plasma proteins are available: equilibrium dialysis, ultrafiltration and ultracentrifugation are the most 
common ones. The results are usually expressed as %PPB (equation 4), where [D] is the free drug 
concentration and [DP] is the concentration of the drug protein complex: 
          
             
          
     
                     (e ua on 4) 
  
Based on binding experiments, actual concentrations of the free drug are calculated and used as a 
base for in vivo experiments. Information on PPB is also of great importance with regard to toxicity, 
because plasma proteins may act as reservoirs, and accumulation of drugs in tissues may 
substantially influence their plasma concentrations and retention times in the body. 
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The extent of drug distribution into tissues mainly depends on the degree of binding to the plasma 
proteins albumin, alpha-1-acid glycoprotein and lipoproteins. As only the free (unbound) drug is 
available for distribution in the body to get access to cellular targets, extensive PPB limits a drug’s 
efficacy and influences its pharmacokinetics. On the other hand, drugs (mostly with relatively poor 
solubility), are often more easily transported in vivo when bound to plasma proteins. 
Prominent clinical drugs with a high protein binding of over 90% are the antieptileptic drug 
phenytoin [Lund et al., 1972; Peterson et al., 1982], the anticoagulant warfarin [Mungall et al., 1984] 
or the anti-diabetic agent tolbutamide [Miners et al., 1982]. 
A further phenomenon observed in binding studies, is displacement of the drug from protein: 
interactions between two compounds can increase the free fraction of a drug highly bound to plasma 
proteins as the interacting drug displaces the substance of interest from its binding site. Drug 
displacement from PPB has to be regarded with suspicion due to potential clinically relevant 
interactions [Rolan, 1994] including unanticipated cross-reactions in terms of toxicity.  
The phenomenon of poor water solubility and high lipophilicity is often associated with increased 
binding to proteins. However, for targeting the CNS, lipophilicity of compounds is favorable to 
overcome the endothelium of the blood-brain barrier [Waterhouse, 2003].   
The discrepancies between solubility, plasma protein binding and BBB penetration of drug 
candidates pose a challenge even in case of ‘drug-like’ compounds, as the physico-chemical 
properties are not always predictive for adequate access to the brain  and a corresponding biological 
activity in the CNS [Abbott et al., 2010]. 
To find candidates for future in vivo studies in nude mice, the characterization of the most potent 
ABCG2 modulators with respect to solubility and plasma protein binding is required. Attempts are 
described in this chapter. 
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4.2 Materials and methods 
4.2.1 Drugs and chemicals  
PBS was made of 8.0 g/L NaCl, 1.0 g/L Na2HPO4 · 2 H2O, 0.20 g/L KCl, 0.20 g/L KH2PO4 and 0.15 g/L 
NaH2PO4 · H2O (pH 7.4). Fetal calf serum (FCS) was obtained from Biochrom (Berlin, Germany) and 
Hoechst 33342 from Invitrogen (Karlsruhe, Germany). Fluorescence was measured with a LS50 B 
spectrometer from Perkin Elmer (Rodgau, Germany). If not otherwise stated, chemicals (p.a. quality) 
were obtained from Merck (Darmstadt, Germany). Milli-Q system (Millipore, Eschborn, Germany) 
was used for water purification. 
4.2.2 Solubility 
4.2.2.1 Comparison of solubilities in different media 
As poor water solubility is a characteristic feature of the classes of ABCG2 modulators synthesized in 
our group, the solubility of representative examples, compounds 32, 33, 51, and 52, in DMSO was 
compared to the solubility in PBS (pH 7.4), determined by HPLC. Therefore, the same concentrations 
of the compound (0.5-20 µM) were prepared in DMSO and PBS, respectively. The samples were 
centrifuged (10 min, 16,000 g) with an Eppendorf centrifuge 5415R (Eppendorf, Hamburg, Germany) 
to separate undissolved compound, and the supernatants were filtered through Phenex™-RC 4 mm 
Syringe Filters 0.2 µm (Phenomenex, Aschaffenbug, Germany). As the compounds are readily soluble 
in DMSO, a linear calibration curve was calculated from the peak areas obtained for the samples 
diluted with DMSO, assuming that the compounds were completely dissolved. The peak areas for the 
corresponding centrifuged PBS samples were referred to the calibration line to calculate solute 
concentrations in buffer. 
UV detection of compounds 32, 51 and 52 was performed at 210 nm with a Waters (Eschborn, 
Germany) system using a 2487 UV detector (described in section 3.3.7.3) or a Merck-Hitachi HPLC 
system composed of a L-5000 controller, a 655A-12 pump, a 655A-40 autosampler, a F-1050 
fluorescence spectrometer and a L-4250 UV-VIS detector on a Eurospher-100 C18 column 
(250 × 4 mm, 5 μm; Knauer, Berlin, Germany) at a flow rate of 0.8 mL/min under helium degassing 
and the following gradient: MeCN/0.05% TFA (aq.): 0 min: 60/40, 30 min: 95/5, 31 min: 95/5, 33 min: 
95/5. UV detection for compound 33 was performed at 280 nm and fluorescence detection for 
compound 51 at 470 nm after excitation at 370 nm. 
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4.2.2.2 Fluorescence spectra of Hoechst 33342 after intercalation in DNA in 
the absence and presence of test compounds 
All ABC transporter inhibition assays, described in Chapter 3, were performed either in culture 
medium supplemented with FCS or in buffer containing serum albumin. The question arose, why the 
newly synthesized compounds are so potent and efficient in these aqueous assay systems despite 
obviously limited water solubility. In this context it is of utmost importance to ensure that the 
measured increase in fluorescence in the assay, resulted from ABC transporter modulation and 
subsequent DNA intercalation of the dye (Hoechst 33342), but not from, cell-dependent interference 
between the Hoechst dye and the compounds. Therefore, compounds 33, 34 and 51 were incubated 
without MCF-7/Topo cells in the presence and the absence of Hoechst 33342 on the basis of the 
protocol of the ABCG2 inhibition assay: the compounds were diluted in PBS containing 10% FCS and 
8 µM of the Hoechst 33342 dye to a final concentration of 10 µM according to the standard 
procedure described in section 3.3.5.1. DNA (10 µg/mL), isolated from calf thymus, was added to the 
mixture to allow a DNA intercalation. DMSO served as negative control. The fluorescence spectrum 
of Hoechst 33342 in the presence of 1% (v/v) DMSO was compared with the spectra in the presence 
of the modulators. 
 
4.2.3 Plasma protein binding studies  
The binding of hydrophobic molecules to human serum albumin (HSA) or bovine serum albumin 
(BSA), an ortholog of HSA, has been extensively studied for years. Albumins are the most abundant 
proteins in the blood circulation (55% of all serum proteins) [Anderson and Anderson, 2002] and 
known to act as transporters for various drugs [Takehara et al., 2009]. To determine the extent of 
plasma protein binding of the newly synthesized modulators, the applicability of different methods 
was explored. 
 
4.2.3.1 Ultrafiltration  
Ultrafiltration was performed with Amicon Ultra-0.5 mL Centrifugal Filters (regenerated cellulose 
membrane, nominal molecular weight limit: 10 kDa) from Merck Millipore (Darmstadt, Germany) and 
Nanosep® Centrifugal Devices (modified polyethersulfone membrane) from Pall GmbH (Dreieich, 
Germany), respectively, at 16,000 g using an Eppendorf 5415R centrifuge.  
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4.2.3.2 Isothermal titration calorimetry  
Isothermal titration calorimetry (ITC) is a widely used technique to study biological processes at the 
molecular level, especially to characterize binding affinities of ligands to a protein. Thereby, ITC 
measures small changes of temperature during the reaction and allows the simultaneous 
determination of thermodynamic parameters such as heat of binding (enthalpy; ∆H), number of 
binding sites (n) or the calculation of the binding constant K [Santos et al., 2007]. ITC experiments 
and the instrumental set-up (Figure 4.1) are described below.  
The solution in the syringe containing the test compound 
was titrated into the sample cell (37 °C) with the protein 
solution. Every injection causes a change in heat, resulting in 
a change in temperature in the sample cell in comparison to 
the reference cell. The change in power, which was required 
to return the sample cell to 37 °C, was recorded with every 
injection till all binding sites of the protein in the sample cell 
were saturated (heat signal diminishes).  
Isothermal titration calorimetry was carried out at the 
Institute of Organic Chemistry (Prof. Dr. B. König) using a 
VP-ITC Micro Calorimeter (MicroCal, Northhampton, MA). 
Selected synthesized modulators were used as titrants and 
were pipetted into a BSA solution (sample cell). To ensure 
that the established method and instrumental set-up 
worked, a standard compound was tested: propranolol 
hydrochloride (Sigma, Munich, Germany), soluble in water, 
was chosen as test compound because corresponding 
binding constants are extensively referenced in the 
literature. Therefore, a solution of 5 mM propranolol HCl (in 
PBS) was injected in 5 µL-steps into the sample cell 
containing a 1 mM protein (BSA) solution (in PBS). 
4.2.3.3 Equilibrium dialysis 
To evaluate the extent of protein binding, equilibrium dialysis was performed with DispoEquilibrium 
DIALYZERS and a Fast Micro-Equilibrium DIALYZER dialysis chamber (250 µL chamber; polycarbonate 
membrane, 0.01 µm pore size) from Harvard Apparatus (Holliston, MA, USA).  
 
Figure 4.1:  An ITC instrument consists of 
two identical cells surrounded by an 
adiabatic jacket (yellow). Reference heater 
(green), cell feedback heater (black) and 
calibration heater (red) detect temperature 
differences between the reference and the 
sample cell upon ligand titration into the 
sample cell containing the protein; 
illustration adapted from [Pierce et al., 
1999]. 
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Figure 4.2: A, B) Fast Micro-Equilibrium DIALYZER dialysis chamber (250 µL); C) DispoEquilibrium DIALYZER; Harvard 
Apparatus (Holliston, MA). 
The theory behind is as follows (according to ‘Guide to Equilibrium Dialysis’, Harvard Apparatus; 
http://www.nestgrp.com/pdf/Ap1/EqDialManual.pdf): two chambers are separated by a dialysis 
membrane with a defined molecular weight cut off (MWCO) such that the protein-bound compound 
is retained. A known concentration of a compound - small enough to pass freely through the 
membrane - is placed into one of the chambers (total volume: 250 µL). An equivalent volume of 
protein (BSA), dissolved in the same solvent at defined concentration is then placed in the other 
chamber. The compound diffuses across the membrane and either binds to the protein to a certain 
extent or remains free in solution. Diffusion across the membrane and binding continues until 
equilibrium has been reached. At equilibrium, the concentration of the free compound in solution is 
the same in both chambers and can be used to evaluate the binding characteristics of the sample. 
To consider that the used compounds show sufficient solubility and cross the membrane, recovery 
studies were performed without protein with different synthesized modulators and quantified by 
HPLC. Recovery analysis was performed at 37 °C (water bath) under stirring for 4 h or overnight. For 
this purpose, compounds 4, 50, 51 and 52, respectively, were dissolved at a concentration of 100 µM 
in PBS or PBS supplemented with various amounts of DMSO (5%, 10%, 15% or 20%).  
4.2.3.4 Protein binding analysis via fluorescent spectroscopy 
Fluorescence measurements were performed at the LS50 B spectrometer from Perkin Elmer at a scan 
rate of 240. Hellma® fluorescence cuvettes (SUPRASIL® quartz, semi Micro, pathlength 10 mm) and 
fatty acid/globulin free bovine serum albumin (BSA; ≥98% purity) were both purchased from Sigma 
(Munich, Germany). Fluorescence spectra were recorded after excitation at 280 nm (BSA) or 370 nm 
(fluorescent ABCG2 modulators).  
 
A B C
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4.2.3.5 HPLC-based methods to determine protein binding of selected 
ABCG2 modulators  
Three representative ABCG2 modulators were kindly characterized in the laboratory of Origenis 
GmbH (Martinsried, Germany) by means of three different methods to estimate the extent of plasma 
protein binding. 
The chromatographic hydrophobicity index (CHI) was calculated using a C18 column by converting 
retention times to volume percentage organic-phase concentrations. The CHI scale can be related to 
octanol/water partition coefficients (logD values at pH 7.4) by taking the number of H-bond donor 
groups in the molecules into account. 
Binding was measured on a column containing immobilized HSA, and membrane affinity was 
calculated via immobilized artifical membrane (IAM) HPLC analysis to model drug partitioning 
between an aqueous (mobile) phase and a cell membrane (IAM column). By all three methods, 
basically, the retention times of the compounds were measured (UV/VIS detection) and linearly 
(y = a·Tr + b) converted into the corresponding parameter based on a calibration data set of 
thousands of compounds (Dr. M. Thormann, personal communication, 2013).  
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4.3 Results and discussion 
4.3.1 Solubility of selected ABCG2 modulators   
All investigations described in this chapter were severely compromised by poor water solubility of 
the synthesized ABCG2 modulators. To obtain at least a rough estimation of lipophilicity and 
solubility in water, different methods were applied. 
4.3.1.1 Computational calculations 
First calculations of the lipophilicity of selected ABCG2 modulators were performed with the 
ACD/Labs chemistry software 12.0 (Advanced Chemistry Development, Inc., Toronto, Canada). 
 Table 4.1: Computational predictions regarding water solubility of selected ABCG2 modulators. 
Compd.  Molecular Weight  
[Da] 
logP a logD b 
 
Solubility c 
[mg/L] 
4  776.87 4.65 4.12 0.12 
12  719.82 4.90 4.66 0.36 
16  866.01 4.45 3.91 9.49 
31  640.73 5.68 5.08 0.04 
32  772.88 4.91 4.32 0. 44 
33  891.02 3.66 3.08 14.00 
40  654.71 4.98 4.56 0.95 
50  652.74 4.90 4.48 1.28 
51  666.77 5.42 5.05 0.47 
52  798.93 4.65 4.28 4.12 
42  770.87 4.76 4.69 0.08 
47  721.84 5.75 3.52 1.97 
a
 Octanol-water partition coefficient: ratio of a compound’s concentration in octanol and 
water at equilibrium, expressed as its decadic logarithm logP; 
b
 distribution constant at 
pH 7.4; 
c
 solubility in water at pH 7.4. 
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4.3.1.2 Solubility in DMSO and PBS 
Compounds 32, 33, 51, and 52 were investigated for their solubility in PBS and DMSO by means of 
HPLC analysis. Compounds 32, 33 and 51 were neither detectable by UV absorbance in the 
supernatant of the centrifuged PBS samples at 210 nm (Waters HPLC system) or 280 nm (compound 
33; Merck HPLC system), respectively, nor by fluorescence detection (compound 51; Merck HPLC 
system). Although the detection limit of the used UV detector and different spectral properties of the 
modulators have to be considered, these negative results reveal that compounds 32, 33 and 51 are 
virtually insoluble in aqueous media. By contrast, compound 52 was detectable in PBS though at a 
very low concentration (Figure 4.3).  
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Figure 4.3: Main peak areas of 
compound 52 when diluted in DMSO 
(circles) or PBS (squares) at various 
concentrations obtained after RP-HPLC 
analysis performed with a Waters 
(Eschborn, Germany) HPLC system (UV 
detection at 210 nm); the applied 
gradient was as following: MeCN/0.05% 
TFA (aq.): 0 min: 15/85, 25 min: 80/20, 
26 min: 95/5, 36 min: 95/5, 37 min: 
15/85, 45 min: 15/85 at a constant flow 
rate of 1.0 mL/min. 
 
The peak areas in the chromatograms of compound 52 for the centrifuged PBS samples were 
equivalent to the following free concentrations in buffer: 
applied  
concentration  
[µM] 
 found  
concentration  
[µM] 
  
0.50  -   
1  0.04   
5  0.34   
10  0.60   
Table 4.2: Found concentrations of compound 52 in PBS after 
centrifugation.  20  0.53  
The highest concentration determined for compound 52 (0.6 µM) corresponds to a solubility of 
0.48 mg/L in PBS. This value is ten times lower than the solubility calculated with ACD/Labs. 
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4.3.1.3 Fluorescence spectra of the Hoechst 33342 dye in the presence of 
different modulators   
The fluorescence intensity of the Hoechst 33342 dye in presence of a modulator does not differ from 
the negative control (H33342 + DMSO) (Figure 4.4).  
Fluorescence of the Hoechst 33342 dye is not affected by the combination with different modulators 
under Hoechst assay conditions, suggesting that the measured increase in fluorescence intensities in 
the Hoechst 33342 microplate assay, indeed, results from ABCG2 inhibition and subsequent DNA 
intercalation. 
Hence, the modulators work in an aqueous assay system, despite low water solubility. It may be 
speculated that the synthesized compounds are actually much more potent than observed, i.e. lower 
concentrations suffice to reach a high ABCG2 inhibition, or they bind to protein in the medium 
(supplemented with FCS) and are thus brought into solution. 
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Figure 4.4: Fluorescence spectra of the Hoechst 33342 
dye [8 µM] in PBS containing 10% FCS and 10 µg/mL 
DNA in presence of DMSO (black line) or compound 
33 (A), 34 (B) and 51 (C) (red) performed at a LS50 B 
spectrofluorimeter from Perkin Elmer (Rodgau, 
Germany). The corresponding compounds diluted in 
PBS/FCS without H33342 are displayed in blue. 
Instrument settings were as follows: λex: 340 nm; 
Ex/Em Slit: 10. 
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4.3.2 Extent of plasma protein binding  
4.3.2.1 Ultrafiltration and ITC 
Determination of plasma protein binding by ultrafiltration failed. Recovery studies revealed that the 
tested compounds completely adsorbed to the cellulose membranes. 
Isothermal titration calorimetry was successfully performed for the test compound propranolol HCl 
(cf. Figure 4.5).  
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Figure 4.5: Titration thermogram of raw 
injection heats for titration of propranolol 
HCl [5 mM] into a BSA solution [1 mM]. 
 
 
In contrast, binding experiments via ITC were not successful with the synthesized ABCG2 modulators 
as these compounds are almost insoluble in water, and the composition of the solvent should be 
exactly the same for the titrant and the cell solution. Blank-experiments (negative control) with 
DMSO (titrant) as appropriate solvent for the synthesized compounds and BSA (in H20; sample cell) 
were performed prior to experiments, but produced unreliable results when the organic solvent was 
mixed with water. As DMSO causes protein precipitation and denaturation, pure DMSO is 
inappropriate as solvent for both titrant and BSA.  
4.3.2.2 Equilibrium dialysis  
Prior to PPB studies via equilibrium dialysis, recovery tests were performed with selected 
modulators. Compounds 4, 50, 51 and 52 were dissolved in PBS supplemented with DMSO (5%, 10%, 
15% and 20%, respectively) and added to the sample chamber of the Fast Micro-Equilibrium 
DIALYZER. Unfortunately, after incubation over night at 37 °C, only compound 4 could be recovered 
to a small extent in PBS/DMSO at a ratio of at least 85/15 (HPLC analysis, UV detection at 210 nm), 
though, inadequate for PPB tests.  
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In general, all tested compounds were insoluble in pure PBS buffer. Likewise, DispoEquilibrium 
DIALYZERS were inappropriate for dialysis experiments as all tested compounds were adsorbed to 
the regenerated cellulose membrane.   
4.3.2.3 Investigations on fluorescent modulators to determine protein 
binding 
Intrinsic fluorescence of proteins is mainly due to the aromatic amino acids tryptophan (Trp) and 
(Tyr) (Figure 4.6), whereas the indole groups of Trp residues are the dominant source of emission.  
 
Figure 4.6: Chemical 
structures of the 
aromatic amino 
acids tryptophan 
and tyrosine. 
Protein-protein association, protein unfolding as well as the binding of a ligand to a protein alters the 
sensitive microenvironment of Trp and its particular location within the protein thereby causing 
changes in the protein’s tertiary and quaternary structure, resulting in changes in the fluorescence 
spectrum like maximum shifts to the red or the blue as well as intensity changes [Vivian and Callis, 
2001].  
Bovine serum albumin (66.2 kDa) contains 21 tyrosine and 2 tryptophan residues [Peters, 1985] that 
possess intrinsic fluorescence with Trp212, located in the core of the protein and Trp134 found on 
the surface of albumin. HSA, which shares 76% homology to BSA, contains only one Trp214 residue 
[Moriyama et al., 1996; Bujacz, 2012; Majorek et al., 2012; Patra et al., 2012]. 
 
Selected compounds of the triazole series described in Chapter 3, show distinctive fluorescence in 
organic solvents like chloroform (Figure 4.7). As fluorescent spectroscopy in protein analysis for 
investigations concerning protein binding and protein-ligand interactions is widely described in 
literature [Moriyama et al., 1996; Ladokhin, 2000; Takehara et al., 2009; Galecki et al., 2012], 
fluorescence may be used to determine the binding of the synthesized ABCG2 modulators to serum 
albumin. 
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Changes in either the fluorescence of the protein or the compounds upon binding can be exploited to 
study protein-ligand interactions. With excitation wavelengths between 370 and 380 nm and an 
emission around 470 nm, the fluorescence properties of the compounds do not interfere with those 
of serum albumin (λex: 280 nm; λem: 350 nm). 
Compound 52, which is insoluble and therefore non-fluorescent in PBS (pH 7.4), shows weak 
fluorescence in DMSO (Figure 4.8). As described in Chapter 3, selected compounds show 
fluorescence under acidic HPLC conditions. With the addition of trifluoroacetic acid (TFA; Sigma, 
Munich, Germany) to the DMSO samples, the fluorescence intensity of 52 significantly increased (for 
further details also cf. section 4.3.3). 
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Figure 4.8: Fluorescence spectra of compound 52 
[1 µM] after excitation at 370 nm in PBS (pH 7.4) 
(black dotted line), DMSO (black) and DMSO/TFA 
(aq.) at pH 5 (blue) and pH 3 (red); Ex/Em Slit: 5. 
Due to insufficient solubility of fluorescent compounds in aqueous media, a minimum amount of 15% 
DMSO is required for spectroscopy. The pH dependent fluorescence of compound 52 at a 
concentration of 1 µM in PBS/DMSO (85/15) is shown in Figure 4.9.  
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Figure 4.7: Emission spectrum of compound 
34 in chloroform after excitation at 380 nm 
recorded at a Horiba ‘Fluoromax 4’ 
fluorescence spectrophotometer (HORIBA 
Jobin Yvon GmbH, Unterhaching, Germany) 
with Hellma® quartz cuvettes (1 cm); slit 
width: 10 nm.  
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Figure 4.9: Fluorescence spectra of 52 [1 µM] in 
PBS/DMSO 85/15 at pH 6.5 (gray), pH 6.0 (green), 
pH 5.5 (orange), pH 5.0 (blue) and pH 3.0 (red), 
respectively; λex: 370 nm; Ex/Em Slit: 10. 
As fluorescence of albumin is affected by the local environment and thereby depending upon the 
solvent polarity, the effect of DMSO on the structural conformation of bovine serum albumin was 
estimated by monitoring the fluorescence properties of the protein.  
Fluorescence spectra of BSA (λex: 280 nm) dissolved in different PBS/DMSO combinations are shown 
in Figure 4.10: The fluorescence intensity decreased with increasing amounts of DMSO and a slight 
shift of the emission maximum from 350 nm (PBS) to 335 nm (PBS/DMSO 1:1) was visible.  
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Figure 4.10: Fluorescence spectra of BSA 
[0.05 mg/mL] after excitation at 280 nm in different 
media: PBS (black) or PBS/DMSO: 95/5 (dark blue), 
90/10 (blue), 85/15 (pink), 80/20 (green), 75/25 
(orange), 70/30 (gray), 50/50 (red); Ex/Em Slit: 5.  
 
In general, two contrary effects have to be considered influencing the fluorescent properties of 
albumin: by raising the percentage of DMSO, on the one hand, the polarity of the microenvironment 
of the protein (especially of the aromatic amino acid tryptophan) is drastically changed, and, on the 
other hand, an increasing DMSO concentration is assumed to denature and thereby unfold the 
protein. Precipitation also contributes to the decrease in fluorescence intensity so that a linear 
correlation between fluorescence intensities and the DMSO content cannot be hypothesized 
especially at a high DMSO content of 30% or 50%. 
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Similar results were recently published by Pabbathi et al. [Pabbathi et al., 2013]. The study revealed a 
doubling of the hydrodynamic radius of BSA in presence of 40% DMSO, suggesting complete 
unfolding of the protein. 
A required amount of 15% DMSO due to solubility problems of ABCG2 modulators, indeed, hardly 
influenced the fluorescence properties of BSA (cf. Figure 4.10) suggesting that the native structure of 
BSA was retained under these conditions.  
However, the attempt to quantify the extent of protein binding to BSA of the fluorescent compounds 
51 and 52 in a mixture of PBS and DMSO at a ratio of 85:15 at pH 7 failed,  due to lack of fluorescence 
emission at neutral pH. To guarantee sufficient fluorescence intensity of compounds 51 and 52, 
protein binding investigations by means of fluorescent measurement have to be performed at pH 
values below 6.5 (Figure 4.9).  
Moreover, the isoelectric point (IEP) of BSA is at pH 4.7 [Ge et al., 1998]. At pH 5 and below, acid-
induced unfolding and denaturation of the protein occurs [Estey et al., 2006]. As shown in 
Figure 4.11, the fluorescence intensities of BSA are decreasing from pH 5.5 to pH 3 as a result of 
denaturation.  
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Figure 4.11: A) Fluorescence spectra of BSA [0.01 mg/mL] after excitation at 280 nm in PBS (pH 7; black dotted line) and in 
PBS/DMSO (85/15) at pH 7.0 (black), pH 6.5 (gray), pH 6.0 (green), pH 5.5 (orange), pH 5.0 (blue) and pH 3.0 (red), 
respectively; B) Maximal fluorescence intensities of BSA in PBS/DMSO 85/15 at 350 nm at descreasing  pH value; 
Ex/Em Slit: 10. 
Based on these results, a pH of 6.0 and a combination of PBS/DMSO at a ratio of 85/15 seems to be 
appropriate for fluorescence based binding experiments with compounds 51 and 52, performed at 
the excitation and emission wavelengths of the modulators as sensitive changes in the fluorescence 
properties of BSA due to the use of DMSO may be mistaken for binding effects. Figure 4.12 shows 
the fluorescence emission of compound 52 [1 µM] in the presence of bovine serum albumin at a 
molar ratio of 1/1.5 and 1/15 (BSA/ligand), respectively, over 60 minutes. The addition of BSA is 
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accompanied by an increase in the quantum yield of the fluorescent compound. Afterwards, the 
intensity continuously decreases within 30 minutes followed by a slight increase after 45 min to a 
constant value. The fluorescence intensity of compound 52 in presence of 0.1 mg/mL BSA halved 
within 1 h, whereas in presence of 1.0 mg/mL it was diminished to 70%. The effect of an increased 
quantum yield did not change significantly with different protein concentrations added.  
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Figure 4.12: A,B) Fluorescence spectra of compound 52 [1 µM] after excitation at 370 nm in PBS/DMSO (85/15) at pH 6.0 
alone (black dotted line) and in the same solvent in the presence of BSA [0.1 mg/mL] (A) or [1.0 mg/mL] (B) at different 
periods of time after BSA addition: 0 min (black), 5 min (red), 10 min (green), 20 min (orange), 30 min (gray), 45 min (blue), 
60 min (dark blue); C) Maximal fluorescence intensities of 52 at 470 nm in PBS/DMSO containing 0.1 mg/mL (filled circles) 
and 1.0 mg/mL BSA (filled trianlges), respectively, as a function of time after protein addition; Ex/Em Slit: 10. 
The gradient in fluorescence intensity over 60 min is difficult to interpret. It is conceivable that 
equilibrium between free and bound compound is reached after one hour. However, it cannot be 
ruled out that precipitation of the compound also contributes to the change in fluorescence meaning 
that an amount of 15% DMSO is insufficient to hold compound 52 permanently in solution.  
In general, the estimation of %PPB by fluorescence measurements is impossible in case of 
compounds 51 and 52, mainly due to the lack of emission at physiological pH in combination with 
precipitation, effects of DMSO on the structure and solubility of BSA.   
 
 
82 Chapter 4 
 
4.3.2.4 Determination of lipophilicity parameters by HPLC 
As all the aforementioned approaches for the estimation of protein binding failed, HPLC-based 
methods (experiments performed in cooperation with Origenis GmbH, Martinsried, Germany) were 
used to determine lipophilicity parameters for the prediction of PPB based on the work of Valko et. 
al. [Valko et al., 1997; Valko et al., 2000; Valko et al., 2003; Valko et al., 2011]. As displayed in 
Table 4.3 compounds 31, 32 and 51 (Figure 4.13) were estimated to bind to human serum albumin to 
almost 100%.    
 
Figure 4.13: Chemical structures of ABCG2 modulators 31, 32 and 51 with a molecular weight of 640, 772 and 666 Da, 
respectively. 
 
Table 4.3: HSA binding affinities and chromatographically determined lipophilicity parameters of 
compounds 31, 32 and 51, respectively, each calculated in 2 independent experiments. 
Cpd. %PPBa 
logK 
(HSA) 
logkA 
(HSA) 
Confid.b 
HSA CHIc logd 
Confid.b 
logd 
CHI 
IAMd 
Confid.b 
IAM 
31 
98.37 1.78 4.96 1 123.61 3.59 2 74.50 1 
99.02 2.00 5.19 0    74.61 1 
32 
21.45 -0.56 2.62 1 105.03 3.17 0 57.19 1 
98.07 1.71 4.89 1    58.26 1 
51 
98.58 1.84 5.02 2 125.35 3.62 2 62.40 2 
98.33 1.77 4.95 1    62.57 1 
a
 Calculated percental plasma protein binding; HPLC conditions: solvent A (5% (v/v) isopropanol in 50 mM ammonium 
acetate buffer; pH 7,4)/isopropanol (100%): 0 min: 100/0, 3.5 min: 0/30, 4.5 min: 0/30, 4.6 min: 100/0, 6 min: 100/0. 
b
 Confidence: 2 = without any doubt, 1 = likely, 0 = unlikely. 
c
 A C18 column (40 °C) was  used with an ammonium acetate 
buffer [50 mM; pH 7.4] + 5% (v/v) MeCN  as solvent (solvent B) under the following gradient conditions: solvent B/MeCN: 
0 min: 100/0, 3 min: 0/100, 4 min: 0/100, 4.2 min: 100/0, 6 min: 100/0.  
d
 IAM column at 40 °C with the following gradient: 
solvent  B/MeCN: 0 min: 100/0, 5 min: 0/100, 5.5 min: 0/100, 6.5 min: 100/0, 8.2 min: 100/0. 
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The HSA binding values were derived from the gradient retention times and converted in its linear 
free energy-related logK value using data from a calibration set of molecules: 
  
log         
    
         
                                  (e ua on 5) 
 
Percental value data and logK values can be converted to binding affinity constant (logkA) according 
to the following formula: 
 
log          
    
         
                        (e ua on 6  
          
kA represents the binding affinity to HSA under the assumption that binding occurs exclusively to 
HSA, a binary complex is formed between the ligand and HSA, and the albumin concentration in 
plasma is around 0.0006 M ([HSA]) [Kratochwil et al., 2002; Borchardt et al., 2004]. 
Characterizing interactions of drugs via immobilized artificial membrane (IAM) chromatography is an 
efficient and time-saving method to obtain membrane interaction parameters of drugs, enabling the 
estimation of a compound’s lipophilicity. With a calibration set of standard compounds, the gradient 
retention times can be converted to chromatographic hydrophobicity index (CHI) values (CHI IAM). 
As CHI correlates closely with traditional octanol-buffer distribution coefficient logD, CHI values were 
projected to a logarithmic scale by an intralaboratory equation that is more appropriate for a 
comparison (logd).  
In general, the investigated ABCG2 modulators show very high protein (>98%) and membrane 
binding due to high lipophilicity. 
 
4.3.3  pH-dependent fluorescence of ABCG2 modulators 
As described in 4.3.2.3, selected ABCG2 modulators of the triazole series like compound 52 show an 
increase in fluorescence with decreasing pH values of the solvent.  
A strong acid milieu of pH 1.5 even results in fluorescence emission in case of the biphenyl 
compound 12, which is non-fluorescent in neutral milieu (Figure 4.14).  
This fact suggests that the pH-dependent increase in fluorescence results from the protonation at the 
common quinoline substructure, thereby extending the conjugation of the π-electron system. 
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Figure 4.14: Fluorescence spectra of compounds 12 [1 µM] (A) and 52 [1 µM] (B) in DMSO (black) and DMSO/TFA (aq.) at 
pH 1.5 (red) after excitation at 370 nm; Ex/Em slit 10. In case of 52, a slight shift of the emission maximum to the blue was 
visible with the addition of TFA. 
 
ACD labs chemistry software identified the quinoline as a weak base with a pKa value around 1, 
whereas the 1,2,3-triazole substructure is not involved in an pH dependent fluorescence according to 
these calculations at pH 1.5 (Figure 4.15). 
 
Figure 4.15: Calculated pKa values for compounds 12 and 52 by ACD/Labs chemistry software 12.0. 
However, these pKa values have to be examined critically as they can strongly depend on the 
electronic charge distribution of the compound resulting in enormous differences in acidity between 
the ground and excited states [Marciniak et al., 1992] as is the case for six-membered aromatic 
nitrogen heterocyclic compounds, which are generally known to be more basic in the lowest excited 
state than in the ground state usually by at least five orders of magnitude [Schulman and 
Capomacchia, 1973].  
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Intramolecular proton transfer of organic compounds can result in drastic changes in their 
fluorescence properties. Detailed reaction dynamics and the influence of the microenvironment on 
the mechanism of reaction are often not completely understood. 
The polymer photostabilizer Tinuvin P (2-(2’-hydroxy-5’-methylphenyl)benzotriazole), the  
photostability of which has been attributed to a very fast reversible intramolecular proton transfer, is 
shown in Figure 4.16. Keto-enol-like tautomers can be distinguished and different fluorescence 
properties (in various solvents) are due to different energy states: ground and excited states 
[Wiechmann et al., 1991]. 
 
 
 
 
 
 
Figure 4.16: Keto- and enol-like tautomers of 
Tinuvin P. 
 
Related results were obtained for 2-(2‘-hydroxyphenyl)oxazole and 2-(2’-hydroxyphenyl)-4-
methylthiazole [LeGourrierec et al., 1998].  
A similiar pH- dependent tautomeric mechanism as well as solvent-dependent influences on the 
energy state in terms of fluorescence properties are also conceivable for the synthesized ABCG2 
modulators both with the quinoline and the triazole substructre (Figure 4.17). 
 
 
Figure 4.17: Hypothetical highly protonated form of compound 51. 
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4.4 Summary and conclusions 
The attempts to determine protein binding failed irrespective of the applied methods (equilibrium 
dialysis, ITC, ultracentrifugation, fluorescence spectroscopy). Very poor water solubility of the 
investigated ABCG2 modulators is the major reason for insufficient drug-like properties. High 
molecular weights (between 600 and 900 Da) and high logP values usually result in poor absorption 
and permeation. In addition the extent of plasma protein binding is probably very high, as predicted 
on the basis of HPLC measurements. However, despite these unfavorable properties, the compounds 
show high potency in cell-based in vitro assays suggesting that they are either actually much more 
potent than calculated on the basis of the added concentration, i.e., the effective concentrations of 
free compounds are much lower, or the binding to proteins is beneficial to provide a reservoir of the 
compounds in the aqueous systems. It has to be further elucidated whether these ABCG2 modulators 
are suitable for in vivo studies in nude mice. 
To come to more ‘drug-like’ compounds, the chemical structures have to be modified by introducing 
more hydrophilic moieties and/or by reducing the molecular weight.  
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 Chapter 5 
5 Characterization of human brain 
tumor cell lines  
5.1 Malignant brain tumors 
5.1.1 Classification 
According to the classification of central nervous system (CNS) malignancies recommended by the 
World Health Organization (WHO), brain tumors are grouped in tumor types and grades ranging from 
grade I (least malignant) to grade IV (most malignant) based on their histopathology [Louis et al., 
2007]. Brain cancer can be categorized into primary brain tumors, originating from a brain cell type, 
and secondary tumors, i.e. brain metastases originating from malignancies in the periphery. 30% of 
all primary brain tumors are gliomas, descending from the glial (supportive) tissue [Dolecek et al., 
2012]. Gliomas are grouped in several subtypes, including astrocytomas, ependymomas and 
oligodendrogliomas. 
Glioblastoma multiforme (GBM) is the most common and aggressive form of all malignant primary 
brain tumors with a median survival time of only 15 months [Wen and Kesari, 2008]. It belongs to the 
group of astrocytic tumors and is classified as grade IV. About 15% of all brain tumors are GBM. 
The aggressive and malignant medulloblastomas belong to the group of embryonal tumors and 
commonly occur in the cerebellum. Medulloblastomas and gliomas are the most common brain 
tumors in children (20% of childhood brain tumors) and carry the most malignant WHO designation 
(grade IV) [Huse and Holland, 2010; Cook and Freedman, 2012].  
5.1.2 Incidence and mortality 
As results of a project coordinated by the International Agency for Research on Cancer (IARC; Lyon, 
France) [Ferlay et al., 2013] the incidence and mortality data of different cancers in 40 European 
countries were presented for the year 2012. There were 3.45 million new cases of cancer and an 
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estimated number of 1.75 million deaths from cancer in Europe in 2012 with female breast, 
colorectal, prostate and lung cancer as the most common manifestations. The estimated number of 
new brain cancer cases in Europe was 57,100 with a concomitant mortality of 45,000.  
Though new brain tumor incidences represent only 2% of all estimated new cancer cases, efficient 
treatment is urgently required, as the trend of new cases is rising (190,000 sufferers in the year 2002 
worldwide, 238,000 in 2008) [Ferlay et al., 2010] and the five-year relative survival rates (percentage 
of people who are alive 5 years after their diagnosis) are still very low. Worldwide, every day about 
650 people are diagnosed with a malignant brain tumor.  
5.1.3 The blood-brain barrier and brain cancer therapy 
The blood-brain barrier separates the brain and cerebrospinal fluid from the blood and is composed 
of high-density endothelial cells. As a regulatory barrier, it controls the entry and elimination of ions, 
neurotransmitters, macromolecules, neurotoxins or water soluble nutrients from and into the brain 
and, hence, sustains ionic homeostasis [Abbott et al., 2010]. Tight junctions are cell-cell junctional 
complexes in the apical region of cell membrane and form the intercellular barrier between the 
epithelial cells, thereby, almost completely obstructing paracellular diffusion under normal 
conditions [Stamatovic et al., 2008]. Transcellular pathways over the BBB include passive diffusion, 
adsorptive-mediated transcytosis and the active transport of molecules via various transporter-
mediated shuttle systems (Figure 5.1).  
 
 
Figure 5.1: Schematic illustration of transport ways and mechanisms at the blood-brain barrier. Tight junctions are 
displayed in red.
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The transporters expressed in the BBB comprise carrier-mediated, receptor-mediated and active 
efflux transporters [Pardridge, 2005] including organic anion and cation transporter systems [Sekine 
et al., 2000], nucleoside transporters and ABC efflux transporter like P-gp, BCRP and MRPs [Lee et al., 
2001]. The BBB protects the CNS from xenobiotics including a large variety of pharmacotherapeutics. 
As a consequence, the medical treatment of CNS diseases like brain tumors is compromised. Several 
strategies were developed to overcome or bypass the BBB, aiming at improved therapies of CNS 
malignancies. 
BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; carmustine), an alkylating agent of the group of 
nitrosoureas included in standard regimen for nearly 30 years [Walker and Hurwitz, 1970], as well as 
the DNA methylating agent temozolomide (Temodal®) are the drugs frequently used in systemic 
chemotherapy [Newlands et al., 1997; Stupp et al., 2005]. Promising strategies for an enhanced drug 
delivery into the brain have been developed, for instance, the therapeutic application of ‘vectors’ 
such as peptides [Rousselle et al., 2001] and viruses [Pertschuk et al., 2012; Robbins et al., 2012] or 
nanoparticles as carriers for the transport of packaged drugs to the brain [Martin-Banderas et al., 
2011; Orthmann et al., 2012; Tosi et al., 2013].  
Another field of current research in brain tumor treatment is the use of monoclonal antibodies. Since 
May 2009, bevacizumab (Avastin®) is approved by the Food and Drug Administration (FDA) for 
second-line treatment of glioblastoma in the USA [Cohen et al., 2009]. It is a recombinant humanized 
monoclonal antibody that binds to human vascular endothelial growth factor (VEGF) inhibiting 
intratumoral angiogenesis and, thereby, tumor growth and proliferation [Shih and Lindley, 2006].  
Advances in chemotherapy also include more invasive approaches namely intracerebral (i.c.) and 
intracerebroventricular (i.c.v.) applications as well as the direct placement of the anticancer agent 
into the tumor cavity via convection enhanced delivery (CED) by means of a catheter or an implanted 
drug reservoir [Saito and Tominaga, 2012]. Biodegradable implants have been approved for the 
treatment of CNS tumors. The Gliadel® wafer, containing BCNU embedded in a polyanhydride matrix, 
is indicated in newly-diagnosed high-grade glioma and recurrent GBM patients. It is planted into the 
surgical cavity post surgery to release the cytostatic directly to the tumor site [Panigrahi et al., 2011]. 
In general, invasive methods mostly require a complex surgical intervention and are precarious not 
least because of unpredictable risks of infection, injury and long-term effects. 
 
A better understanding of the pharmacology of brain tumors and the growth behavior and pathology 
of available human brain tumor cell lines in vitro is of major importance with respect to optimization 
of treatment therapies aiming at extending the average survival times and reducing the size and 
progression of malignant brain tumors. During this work, three different brain tumor cell lines were 
comprehensively characterized in vitro and partially in vivo. 
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5.2 Materials and methods 
5.2.1 Drugs and chemicals 
PBS (phosphate buffered saline) was made of 8.0 g/L NaCl, 1.0 g/L Na2HPO4 · 2 H2O, 0.20 g/L KCl, 
0.20 g/L KH2PO4 and 0.15 g/L NaH2PO4 · H2O. The pH-value was adjusted to 7.4.  
Bouin’s solution (fixative for histopathology) was made of saturated picric acid, formaldehyde and 
glacial acetic acid in a ratio of 15:5:1. Giemsa solution for chromosomal staining was from AppliChem 
(Darmstadt, Germany) and Tris base as buffer constituent from usb (Cleveland, OH). The 
PerfectBlue™ Double gel system Twin S for SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) as well as the nitrocellulose membrane and the PerfectBlue™ ‘Semi-Dry’ electro blot 
apparatus for Western Blotting were obtained from Peqlab (Erlangen, Germany). Topotecan, 
etoposide, doxorubicin, methotrexate and vinblastine were purchased from Sigma (Munich, 
Germany). Paclitaxel (6 mg/mL; Bristol-Meyers Squibb, Wien, Austria) was obtained from the 
pharmacy of the University Hospital Regensburg. A solution of mitoxantrone (1 mM) was obtained by 
diluting Novantron® (Wyeth Pharma, Münster, Germany) in 70% ethanol. 
If not otherwise stated, chemicals (p.a. quality) were obtained from Merck (Darmstadt, Germany) 
and antibodies from Santa Cruz Biotechnology (Heidelberg, Germany). Milli-Q system (Millipore, 
Eschborn, Germany) was used for the purification of water. 
5.2.2 Cell lines and culture conditions 
The human brain tumor cell lines SW 1783 (ATCC® HTB-13™; astrocytoma, grade III), Daoy (ATCC® 
HTB-186™; desmoplastic cerebellar medulloblastoma) and LN-18 (ATCC® CRL-2610™; glioblastoma 
grade IV) as well as the murine cell line P388D1 (ATCC® CCL-46™; murine lymphoid neoplasm with 
macrophage-like morphology) were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Sigma, 
Munich, Germany) supplemented with 10% FCS (fetal calf serum; Biochrom, Berlin, Germany), 3.7 g/L 
sodium hydrogen carbonate and 110 mg/L sodium pyruvate (Serva, Heidelberg, Germany).  
Immortalized human microvascular endothelial cells (HMEC-1) [Ades et al., 1992] were kindly 
provided by Prof. Dr. J. Heilmann (Institute of Pharmaceutical Biology, University of Regensburg) and 
cultured in DMEM containing 15% FCS and 2 mM L-glutamine (Biochrom).  
Cells were cultured in a water-saturated atmosphere (95% air, 5% CO2) at 37 °C in 25-cm
2 or 75-cm2 
cell culture flasks purchased from Nunc (Wiesbaden, Germany), Greiner (Frickenhausen, Germany) 
and Sarstedt (Nümbrecht, Germany), respectively. 
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5.2.3 Cell staining  
Microscopic slides were immersed in 200 mL 70% ethanol, containing 6 mL of concentrated HCl, for 
24 h, washed with distilled water and dried. Dry coverslips were placed between filter papers and 
sterilized by autoclaving (121 °C, 15 psi) [Rooney and Czepulkowski, 1992]. 
Cells were seeded on the prepared slides for 1 day (5% CO2, 37 °C), afterwards fixed for 1 h with 
Carnoy´s solution (ethanol/chloroform/glacial acetic acid 6:3:1) and stored in PBS containing 
0.1% NaN3. Sections were evaluated with a BH-2 microscope (Olympus, Hamburg, Germany) after 
Papanicolaou staining [Takahashi, 1987] using ScopePhoto 3.0 software. 
5.2.4  Genetic stability - Karyology 
The assay was performed as described previously [Jarzyna, 2007]: Cells were cultured on immersed 
and sterilized microscopic slides in Quadriperm 4-well lux-multiplates (Greiner) up to a confluency of 
15-25% and afterwards overlaid with cell culture medium containing 0.5 µg/mL colcemide to arrest 
mitosis of the cells during metaphase.  
After an incubation time of 3 h (37 °C, 5% CO2), the medium was removed and a hypotonic potassium 
chloride solution (75 mM) preheated to 37 °C was carefully added to lyse the cells. After 30 min, an 
equal volume of ice-cold fixative (methanol/glacial acetic acid 3:1) was added and carefully removed 
at once. After two additional fixation steps on ice (last step: 10 min fixation) the fixative was 
removed and the slides were dried. Slides were stained for 8 min with a diluted Giemsa staining 
solution (10 mL filtered Giemsa solution, 90 mL of 25 mM KH2PO4, pH 6.8), thoroughly washed, dried 
and mounted with DePex (EMS, Hatfield, PA). Chromosome numbers of at least 50 cells in metaphase 
were determined per cell line with an Olympus BH-2 microscope using 40x and 100x Planapo oil 
immersion objectives (Zeiss, Jena, Germany). 
5.2.5 Chemosensitivity against common cytostatic drugs and 
growth kinetics 
The aforementioned human brain tumor cell lines were investigated for their chemosensitivity 
against common cytostatic drugs by means of a crystal violet assay as described in section 3.3.6. 
In vitro growth behavior was determined in a similar manner: Cells were seeded in 96-well plates, 
fixed with glutardialdehyde after different times of incubation (37 °C, 5% CO2) and stained with 
crystal violet. The absorbance, proportional to cell mass/number, was measured at 580 nm using a 
GENios Pro microplate reader (TECAN Deutschland GmbH, Crailsheim, Germany) and plotted on a 
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log-linear scale against the incubation time. The population doubling time was determined along the 
exponential phase of the curve. 
5.2.6 Tumorigenicity and growth kinetics of subcutaneous tumors 
in nude mice 
For tumor cell implantation into nude mice, human brain tumor cells were washed twice with 5 mL of 
pre-warmed serum-free culture medium and carefully harvested using a cell scratcher. After 
centrifugation at 1,000 rpm for 7 min at room temperature, using a Minifuge 1.0R (Heraeus 
Instruments GmbH, Hanau, Germany), the obtained cell pellet was resuspended in serum-free 
medium and the cell number was adjusted to a density of 1-3 x 106 cells per 100 µL by means of a 
Casy® 1 TTC cell counter (Schärfe System GmbH, Reutlingen, Germany) or a Neubauer counting 
chamber.  
100 µL of the cell suspension were injected under the thoracic dermis of each mouse. Once a week, 
the bodyweight was controlled and the tumor diameters were monitored with a sliding caliper. To 
ensure tumor growth over various passages, 1 mm3 tumor pieces were prepared from an excised 
non-necrotic tumor and again transplanted into nude mice by means of a trocar.  
5.2.7 Histology  
Solid tumors were prepared for histological staining by the following procedure: 
After dissection, tumor tissue was fixed in Bouin´s solution and embedded in paraffin after 
dehydration with increasing concentrations of ethanol by a standard procedure (described in detail in 
[Müller, 2007]). Sections (6 μm) were cut by a Leica RM2255 microtome (Leica, Bensheim, Germany) 
and mounted on microscope slides. After deparaffinization with xylene and rehydration in decreasing 
concentrations of ethanol, slides were subsequently stained by the procedure of Masson-Goldner 
(MG) or with haematoxylin-eosin (HE) [Mulisch and Welch, 2010], dried and mounted with DePeX.  
5.2.8 Induction of BCRP overexpression in brain tumor cells 
To determine the ABCG2 transporter expression in the aforementioned human brain tumor cells 
Western Blot (WB) analysis of total cell lysates was performed. BCRP-positive cell types were further 
cultured and treated with topotecan at increasing concentrations over a period of approximately 
10 weeks to amplify the transporter expression. 
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5.2.9 ABC transporter detection by Western Blot analysis 
5.2.9.1 Cell lysis and protein quantification 
Cell lines were lysed by physical disruption. Cells were harvested with a cell scratcher and washed 
three times with PBS. After centrifugation, the cell pellet was homogenized in PBS containing a 
protease inhibitor cocktail (SIGMAFAST™ Tablets; Sigma, Munich, Germany) followed by 5-6 
repetitive freeze-thaw cycles in liquid nitrogen to disrupt the cells through ice crystal formation. 
After homogenization the protein content of each cell lysate was determined in a Bio-Rad Protein 
Assay (Bio-Rad Laboratories, Munich, Germany) based on the method of Bradford [Bradford, 1976] 
according to the standard procedure described in the manual. UV detection was performed with a 
Cary 100 UV-Vis spectrophotometer (Varian, Darmstadt, Germany). 
5.2.9.2  SDS-PAGE and Western blot 
Proteins were analyzed by SDS-PAGE. The basic procedure was that of Laemmli [Laemmli, 1970], 
using a 12% acrylamide resolving gel. The composition of all used buffers (in millipore water) was as 
follows: 
Buffer A:   1.5 M Tris, 0.4% (m/v) SDS, pH 8.8 
Buffer B:  0.5 M Tris, 0.4% (m/v) SDS, pH 6.8 
Running buffer:  0.025 M Tris, 0.2 M glycine, 0.1% (m/v) SDS, pH 8.3 
Blotting buffer:  (always freshly prepared) 0.025 M Tris, 0.2 M glycine, 20% (v/v) methanol 
TBS-T buffer:  0.02 M Tris, 0.14 M NaCl in millipore water (pH 7.6), 0.1% (v/v) Tween 20 
   (Carl Roth GmbH, Karlsruhe, Germany)  
Sample buffer (6x): 0.15 M Tris, 1.0 M glycine, 0.6% (m/v) SDS, 9.0% (v/v) glycerol, 0.1% (m/v) 
   bromophenol blue, 2% (v/v) β-mercaptoethanol, pH 6.8 
Leammli buffer (6x): 0.38 M Tris, 12% (m/v) SDS, 60% (v/v) glycerol, 0.06% (m/v) bromophenol 
   blue, 10 mM DTT 
A 12% separation gel mixture for one gel contained 2.65 mL of millipore water, 2 mL of buffer A and 
3.1 mL of acrylamide/bisacrylamide 30% solution (acrylamide/bisacrylamide 29/1; Sigma, Munich, 
Germany). Polymerization was started by addition of 3.5 μL of N,N,N',N'-tetramethylethylenediamine 
(TEMED; Serva, Heidelberg, Germany) and 35 μL of a 10% (m/v) ammonium peroxodisulfate solution 
(APS; Serva). 
The mixture was filled into gel chambers (10 x 10 x 0.8 cm) and covered with a layer of 
water-saturated isobutyl alcohol. After complete polymerization (ca. 45 min) and discarding the 
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isobutyl alcohol layer, a stacking gel (3%) was poured on top of the separation gel. The stacking gel 
mixture contained 3.25 mL of millipore water, 1.25 mL of buffer B and 0.5 mL of 
acrylamide/bisacrylamide 30% solution. Polymerization was initiated as described above.  
A defined amount of protein per cell lysate was mixed with 1/6 volume of Laemmli buffer (6x) or 
sample buffer (6x) and heated for 5 min at 100 °C before filling in the stacking gel pockets. 
Electrophoresis was performed in a PerfectBlue™ gel electrophoresis chambers filled with running 
buffer at 150 V for approximately 90 min.  
The unstained protein marker peqGOLD Protein Marker I (14.4-116 kDa; Peqlab, Erlangen, Germany) 
or the Biotinylated Protein Ladder (9-200 kDa) with the Anti-biotin HRP-linked Antibody (1 : 1,000) 
from Cell Signaling Technology (Danvers, MA) were used. 
WB was performed in a Perfect-Blue™ ‘Semi-Dry’ electro blot apparatus by placing the gels on top of 
a nitrocellulose membrane (0.2 μm) between 6 filter slides soaked in blotting buffer. The proteins 
were transferred to the membrane by blotting for 45 min at 250 mA. Then, the membrane was 
blocked by washing in 5% fat-free milk (in TBS-T buffer; block solution) for 2 h at room temperature 
or overnight at 4 °C. After three washing steps (5 min each) in TBS-T buffer, the primary antibody was 
incubated with the membrane for 2 h (rt) in block solution. After washing, the secondary antibody, 
conjugated with horseradish peroxidase, was diluted in block solution, added to the membrane and 
shaken at rt for 1 h. Immunoreactive bands were visualized via enhanced chemoluminescence (ECL) 
using the Pierce® ECL Western Blotting substrate kit (Thermo Scientific, Dreieich, Germany) according 
to the manufacturer’s instructions. 
Blots and gels were scanned using a GS-710 imaging densitometer (Bio-Rad Laboratories, Munich, 
Germany). Quantity One (Bio-Rad) software was used for band analysis. 
A total protein content of 20 µg was blotted for each cell line. The primary rat monoclonal 
antibody ABCG2 (BXP-53) was used in a 1: 1,000 dilution, the secondary AB (goat anti-rat IgG-HRP) in 
a 1: 10,000 dilution. 
5.2.10 ABC transporter detection by flow cytometry 
To further characterize the ABC transporter expression, a flow cytometric FACS (fluorescence 
activated cell sorting) assay was performed. Confluent cells were trypsinized into a 1.5 mL Eppendorf 
reaction vessel, suspended in PBS and centrifuged at 1,000 g for 5 min. After resuspension in PBS 
supplemented with 10% FCS, cells were counted in a Casy® 1 TTC cell counter and the density was 
adjusted to a number of 2 x 106 cell/mL with PBS/FCS. Aliquots of 500 µL were taken and incubated 
with the primary antibody in an appropriate dilution. After 1 h of incubation at 4 °C under shaking, 
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three washing steps with PBS (1,000 g, 5 min each) followed. Cells were resuspended in a solution of 
3% (m/v) BSA (bovine serum albumin) in PBS containing the phycoerythrin (PE)-conjugated 
secondary antibody and incubated for an additional hour in the dark. Then, cells were washed three 
times with PBS, resuspended in 500 µL BSA/PBS and measured at a FacsCalibur™ (Becton Dickinson, 
Heidelberg, Germany). Instrument settings were as follows:  
FSC: E-1; SSC: 350, Fl-2, high flow. WinMDI 2.9 software was used for data analysis. 
Antibodies and dilutions used for FACS analysis: 
ABCB1:  Primary AB:  Mdr (C-19) goat polyclonal antibody, 1:50  
Secondary AB:  rabbit anti-goat IgG-PE, 1:100  
ABCC1:  Primary AB:  MRP1 rabbit polyclonal antibody (abbiotec; Hoelzel Diagnostika 
GmbH, Köln, Germany), 1:30  
Secondary AB:  goat anti-rabbit IgG-PE (Rockland Inc.; Biomol GmbH, Hamburg, 
Germany), 1:100  
ABCG2:  Primary AB:  ABCG2 (BXP-53) rat monoclonal antibody, 1:50  
Secondary AB:  goat anti-rat IgG-PE, 1:100  
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5.3 Results and discussion 
5.3.1 Morphology 
Doay, LN-18 and SW 1783 cells, grown on tissue slides, were stained according to the method of 
Papanicolaou to illustrate plasma turquoise and nuclei blue (Figures 5.2-5.4). 
 
Figure 5.2: Microscopic images (Papanicolaou staining) of human Daoy cells (passage 7) with a high mitotic activity (A, 
objective: 20x); B) Magnification (objective: 40x) of highly malignant multi-nucleated cells.  
 
Figure 5.3: Microscopic images (Papanicolaou staining) of human LN-18 cells (passage 18); the cells show distinctive 
anisomorphism, an increased nucleoplasmatic ratio (A, objective: 20x) and multiple prominent nucleoli (B, lower left 
corner; objective: 40x). 
A B 
A B 
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Figure 5.4: Microscopic images (Papanicolaou staining) of human SW 1783 cells (passage 42); highly anisomorphic cells (A, 
objective: 20x) with a high mitotic activity and multiple prominent nucleoli (B, objective: 40x). 
5.3.2 In vitro growth of brain tumor cells 
To evaluate growth characteristics like the doubling time or saturation density of the aforementioned 
brain tumor cell lines, growth curves were generated before starting any experiments. The growth of 
cells in culture is characterized by a lag phase, the time it takes for the cells to recover from 
subculture, attach and spread, a log phase in which an exponential increase in cell density arises and 
a stationary phase in which cell proliferation slows down due to the cell culture becoming confluent. 
The growth of Daoy (5th passage), LN-18 (7th passage) and SW 1783 (31st passage) cells over two 
weeks is shown in Figure 5.5.  
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Figure 5.5: In vitro growth curves of LN-18 (squares), Daoy (triangles) 
and SW 1783 (circles) cells determined spectrophotometrically (UV 
detection, 580 nm). 
 
 
The Daoy and LN-18 cell lines show similar growth rates with a mean doubling time of 40 h and 47 h, 
respectively. The SW1783 cell line shows the slowest proliferation kinetics with a mean doubling time 
of 64 h.  
A B 
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Doubling times of the three brain tumor cell lines did not significantly vary over different in vitro 
passages (data not shown) indicating that growth rates and chemosensitivities are independent of 
the utilized passage. 
5.3.3 Aneuploidy 
A prominent feature of cancer cells is an abnormal number of chromosomes (aneuploidy) caused by 
genomic instability inherent to most cancers. It occurs through chromosomal instability (CIN) by 
missegregation of whole chromosomes [Thompson and Compton, 2011]. CIN and aneuploidy are 
correlated with metastatic potential and contribute to resistance against chemotherapeutics in solid 
tumors [Kuukasjarvi et al., 1997; McClelland et al., 2009; Swanton et al., 2009]. 
Daoy, LN-18 and SW 1783 cells were investigated with regard to their chromosome distribution to 
evaluate their genetic stability and malignancy. Characteristic images obtained after cell preparation 
and Giemsa staining for the determination of the chromosomal number in the corresponding cell line 
are displayed in Figure 5.6.  
 
Figure 5.6: Metaphase chromosomes of Daoy (A), LN-18 (B) and SW 1783 cells (C) in the 7
th
, 18
th
 and 81
st
 passage, 
respectively, stained with Giemsa.  
The number of chromosomes was plotted against the frequency in which the respective number was 
observed (Figure 5.7). 
A B C
10 µm
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Figure 5.7: Chromosome distribution of human Daoy (A), LN-18 (B) and SW 1783 cells (C) in the 7
th
, 18
th
 and 81
st
 passage, 
respectively. For each passage the chromosomes of 50 well-spread metaphases were counted. 
According to the information provided by the American Type Culture Collection (ATCC; 
Manassas, VA) the Daoy and SW 1783 cell lines are hypertetraploid with a modal chromosome 
number between 93 and 99. No karyotypical description was available for LN-18 cells. Whereas the 
obtained modal number of 84 for the Daoy cell line was in good greement withliterature, the main 
chromosome number of 56 determined for SW 1783 cells was different (Table 5.1). Unlike the Daoy 
cells, SW 1783 and LN-18 cells revealed a comparatively uniform chromosomal distribution. 
 
Table 5.1: Karyology of the used human brain tumor cell lines 
cell line Passage 
obtained modal 
chromosome number 
range 
modal chromosome 
number (ATCC) 
Daoy 7 84 65 - 96 93 - 99 
LN-18 18 54 34 - 60 - 
SW 1783 81 56 42 - 96 96 
 
For all three cell lines only minor changes in the chromosomal distribution were recognized over 
various in vitro passages (data not shown).  
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5.3.4 Chemosensitivity against cytostatic drugs 
The cell lines Daoy, LN-18 and SW 1783 were tested for their chemosensitivity against selected 
anticancer drugs (Figure 5.8). The Daoy cell line was quite sensitive against all used cytostatics 
(Figure 5.9). Mitoxantrone, vinblastine or paclitaxel (10 nM each) and methotrexate or etoposide at a 
concentration of 1 µM yielded strong cytotoxic or cytocidal effects. Topotecan and doxorubicin 
caused a cytostatic drug effect at 10 nM. 
The LN-18 (Figure 5.10) and SW 1783 cells (Figure 5.11) tolerated topotecan and doxorubicin at 
concentrations up to 10 nM. A concentration of 30 nM caused only a weak cytotoxic effect. 
Etoposide was well tolerated up to 1 µM by LN-18 cells and produced a weak toxic effect on SW 1783 
cells.  
The effects of all used anticancer drugs on the proliferation of the three cell lines are summarized in 
Figure 5.12. As topotecan, doxorubicin, mitoxantrone and etoposide were identified as ABCG2 
substrates [Mo and Zhang, 2012], the results of the chemosensitivity studies suggest that both the 
LN-18 and SW 1783 cell line express the ABCG2 protein in the wildtype. 
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Figure 5.8: Chemical structures of anticancer drugs used for chemosensitivity studies: Doxorubicin (Doxo), Mitoxantrone 
(Mito), Etoposide (Etp), Topotecan (Topo), Paclitaxel (Pac), Vinblastine (Vbl), Methotrexate (MTX). 
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Figure 5.9: Chemosensitivity of Daoy cells against topotecan (A), mitoxantrone (B), doxorubicin (C), vinblastine (D) and 
paclitaxel (E) at the following concentrations: 1 nM (filled circles), 10 nM (filled squares), 30 nM (filled triangles), 100 nM 
(filled diamonds); F) Etoposide: 100 nM (filled circles), 1 µM (filled squares), 3 µM (filled triangles), 10 µM (filled diamonds); 
G) Methotrexate: 1 µM (filled circles), 10 µM (filled squares), 30 µM (filled triangles), 100 µM (filled diamonds); vehicle 
(open circles). 
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Figure 5.10: Chemosensitivity of LN-18 cells against topotecan (A), mitoxantrone (B), doxorubicin (C), vinblastine (D) and 
paclitaxel (E) at the following concentrations: 1 nM (filled circles), 10 nM (filled squares), 30 nM (filled triangles), 100 nM 
(filled diamonds); F) Etoposide: 100 nM (filled circles), 1 µM (filled squares), 3 µM (filled triangles), 10 µM (filled diamonds); 
G) Methotrexate: 1 µM (filled circles), 10 µM (filled squares), 30 µM (filled triangles), 100 µM (filled diamonds); vehicle 
(open circles). 
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Figure 5.11: Chemosensitivity of SW 1783 cells against topotecan (A), mitoxantrone (B), doxorubicin (C), vinblastine (D) and 
paclitaxel (E) at the following concentrations: 1 nM (filled circles), 10 nM (filled squares), 30 nM (filled triangles), 100 nM 
(filled diamonds); F) Etoposide: 100 nM (filled circles), 1 µM (filled squares), 3 µM (filled triangles), 10 µM (filled diamonds); 
G) Methotrexate: 1 µM (filled circles), 10 µM (filled squares), 30 µM (filled triangles), 100 µM (filled diamonds); vehicle 
(open circles). 
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Figure 5.12: Summary of the different effects of the used anticancer drugs on the proliferation of Daoy, LN-18 and SW 1783 
cells. 
5.3.5 Characterization and growth kinetics of human brain tumor 
cell lines in a subcutaneous tumor model in nude mice 
5.3.5.1 In vivo growth kinetics 
With respect to their potential use in a new orthotopic brain tumor model, Daoy, LN-18 and SW 1783 
cells were investigated in vivo. The cells were subcutaneously injected into nude NMRI (nu/nu) mice. 
Unfortunately, only the Daoy medulloblastoma cells were tumorigenic. Figure 5.13 shows the in vivo 
growth kinetics of Daoy xenografts in consecutive passages when injected as cell suspension or 
implanted as solid tumor pieces.  
In general, Daoy tumors were hardly supplied with blood resulting in a long phase of tumor 
formation (about 70 days) and a slow growth rate, especially in passages 0-2. Primarily in passage 3 
the growth behavior changed. Take rates increased from 20% in passage 0 to 40-60% in the following 
passages. Nevertheless, the growth rates of Daoy tumors have not been reproducible till the end of 
this work. The body weight of animals was controlled as an indication of the general state of health. 
For future work tumor pieces were cryopreserved and afterwards stored in liquid nitrogen. 
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Figure 5.13: Growth curves of subcutaneous Daoy 
tumors over various passages after injection as cell 
suspension (passage 0; passage 25 in cell culture; 
black circles) or 1 mm
3
 tumor pieces (passages 
1-3); passage 1: red triangles, passage 2: blue 
squares, passage 3: green diamonds. 
 
5.3.5.2 Histology 
Figure 5.14 shows the morphology of a human Daoy medulloblastoma tumor grown in nude mice 
after Masson-Goldner (MG) and haematoxylin-eosin (HE) staining. MG staining works with three 
different stains allowing a differentiated visualization of tissues: Cell nuclei are displayed in dark 
brown, cytoplasm and muscle fibers in red, connective tissue in green. 
Attributes like anisomorphism and multiple prominent nucleoli highlight the malignant character of 
the Daoy cell line. Mitotic activity, however, is low, resulting in a very slow in vivo growth. 
   
Figure 5.14: MG (A) and HE (B) staining of a subcutaneous Daoy tumor (passage 0), 150 days after implantation 
(BH-2 microscope, Olympus; objective 20x). 
5.3.6 Investigations on ABCG2 induced cell lines 
5.3.6.1 Western Blot analysis of wildtype and induced cell lines 
Western Blot (WB) analysis and chemosensitivity tests (cf. section 5.3.4) revealed that LN-18 and 
SW 1783 cells express the ABCG2 protein in the wildtype (Figure 5.15, lanes b and c). Besides these 
two cell lines, additionally, Daoy and P388D1 cells were treated with increasing topotecan 
A B 
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concentrations to yield sufficient ABCG2 transporter expression. Induction of BCRP overexpression 
was monitored via WB analysis at different times after starting the topotecan treatment. 
 
 
Figure 5.15: Immunological detection of ABCG2 expressed in various tumor cell lines. 20 µg of protein per cell lysate were 
loaded on each lane. a: Daoy; b: LN-18; c: SW 1783; d: peqGold Protein Marker I; e: P388D1; f: P388D1/Topo (350 nM); g: 
MCF-7/Topo (550 nM); numbers on the right designate masses of marker proteins in kDa. 
 
After 10 weeks of treatment with topotecan up to a final concentration of 800 nM and 400 nM, 
respectively, LN-18 and SW 1783 cells (in the following designated as LN-18/Topo and SW 1783/Topo 
cells) show ABCG2 transporter expression (Figure 5.16) comparable to the standard cell line 
MCF-7/Topo. The predicted molecular weight of the ABCG2 transporter monomer is 72 kDa. Band 
analysis was performed with Quantity One (Bio-Rad) software and revealed a band of ~70 kDa for 
MCF-7Topo cells (positive control) as well as for induced SW 1783 and LN-18 cells (Figure 5.16, lanes 
d and g). Some diffuse bands were found at ~35 kDa, probably resulting from unspecific antibody 
binding or proteolysis of the target BCRP protein. 
To have access to a murine ABCG2 transporter system with regard to investigations in animal models, 
the induction of ABCG2 was explored in the mouse cell line P388D1. However, although topotecan 
concentrations as high as 1 µM were tolerated, there was no induction of ABCG2 transporter 
expression detectable (Figure 5.16, lane b). By contrast, the Daoy cell line did not tolerate ascending 
topotecan concentrations beyond a concentration of 30 nM. 
a b c d e f g
116
66
45
35
 
 Characterization of human brain tumor cell lines 115 
 
 
Figure 5.16: Immunological detection of ABCG2 in tumor cell lines 10 weeks after starting BCRP induction by incubation 
with topotecan. 20 µg of protein per cell lysate were loaded on each lane. a: Daoy/Topo (30 nM); b: P388D1/Topo (1 µM); 
c: SW 1783; d: SW 1783/Topo (400 nM); e: peqGold Protein Marker I; f: LN-18; g: LN-18/Topo (800 nM); h: MCF-7/Topo 
(550 nM); i: Kb-V1 (ABCG2-negative control); j: Biotinylated Protein Ladder (9-200 kDa, Cell Signaling); numbers on the right 
designate masses of marker proteins in kDa. 
For a rough estimation of the expression level in the newly induced cell lines in comparison to the 
standard MCF-7/Topo cell line, the specular optical densities (OD) of the bands around 70 kDa were 
calculated after calibration by the Quantity One software for the GS-710 Imaging Densitometer 
(Table 5.2). The three topotecan treated cells types seemed to express the ABCG2 protein to a 
similar extent. 
Table 5.2: Comparison of Western Blot band analysis for induced cell lines.   
lane cell line calculated MW [kDa] band OD 
d SW 1783/Topo (400 nM) 69.24 2.07 
g LN-18/Topo (800 nM) 68.36 2.15 
h MCF-7/Topo (550 nM) 70.02 2.00 
  
5.3.6.2 Determination of ABCG2 overexpression by flow cytometry 
In addition to the Western Blot analysis, an indirect flow cytometric FACS assay was performed to 
compare the ABCG2 transporter expression in LN-18 and SW 1783 wildtype cells to the expression in 
the corresponding topotecan treated cells. By analogy with the Western Blot analysis, an increased 
ABCG2 transporter expression was determined for LN-18/Topo (Figure 5.17) and SW 1783/Topo cells 
(Figure 5.18) compared to the wt cells. The quantification was based on the differences between the 
corresponding geometrical mean (GeoMean) values. Autofluorescence and the fluorescence of the 
cells under treatment with the secondary antibody alone were used as negative controls.  
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Figure 5.17: A) ABCG2 transporter expression determined by flow cytometric analysis on human LN-18 wildtype (blue) and 
LN-18/Topo (800 nM) cells (red); autofluorescense (black), secondary antibody (green). B) GeoMean values (+ SEM) of 
LN-18 wild type and topotecan induced cells calculated from 2 independent experiments. 
Only for SW 1783 cells, marginal non-specific binding of the secondary antibody (goat anti-rat IgG-PE) 
was detectable. The GeoMean value of LN-18 cells was doubled by the treatment with topotecan, 
whereas the GeoMean of SW 1783/Topo cells was three times as high as for the wildtype cells. The 
induced SW 1783 cells contained a subpopulation, which was not further influenced by the 
treatment with topotecan (Figure 5.18 (A), red graph). 
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Figure 5.18: A) Graphical illustration of ABCG2 transporter expression via flow cytometric analysis in human SW 1783 
wildtype (blue) and in SW 1783/Topo (400 nM) cells (red); autofluorescense (black), secondary antibody (green). 
B) GeoMean values (+ SEM) of SW 1783 wild type and topotecan induced cells calculated from 2 independent experiments. 
5.3.6.3 Hoechst 33342 assay using ABCG2 induced cancer cells 
The Hoechst 33342 assay was performed with the ABCG2 overexpressing brain tumor cells to 
determine the transporter inhibition by a selection of synthesized modulators according to the 
B 
A B 
A 
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standard procedure described for MCF-7/Topo cells in section 3.3.5.1 using fumitremorgin C as the 
reference substance.  
Table 5.3: Inhibition of ABCG2 by selected modulators in the Hoechst 33342 assay using three 
different BCRP overexpressing cell lines.  
Compound 
MCF-7/Topoa SW 1783/Topob LN-18/Topob 
IC50 [nM] Imax (%) IC50 [nM] Imax (%) IC50 [nM] Imax (%) 
FTC 731 ± 92 100 842 ± 101 114 ± 19 1,129 ± 203 113 ± 12 
12 (UR-COP228) 591 ± 87 109 ± 8 625 ± 52 117 ± 12 633 ± 255 105 ± 2 
32 (UR-COP269) 59 ± 11 101 ± 5 68 ± 21 108 ± 6 71 ± 18 104 ± 13 
33 (UR-COP272) 46 ± 1 111 ± 9 40 ± 9 112 ± 22 60 ± 16 109 ± 10 
36 (UR-MB83-2) 168 ± 81 96 ± 1 173 ± 98 105 ± 18 257 ± 174 86 ± 9 
41 (UR-MB108-4) 64 ± 3 95 ± 3 48 ± 10 101 ± 2 120 ± 42 103 ± 9 
a
 Mean values (+ SEM) were calculated from two to three independent experiments performed in sextuplicate; 
b
 Mean 
values (+ SEM) were calculated from two independent experiments performed in triplicate. 
As shown in Table 5.3 and displayed in Figure 5.19 for compounds 32 and 33, the obtained IC50 
values and the maximal inhibitory effects are almost identical in the Hoechst 33342 assay, 
independent from the used cells. Therefore, these three cell lines are considered to be useful for the 
study of ABCG2 modulators in the H33342 assay. 
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Figure 5.19: Inhibition of ABCG2 by compounds 32 (A) and 33 (B) using MCF-7/Topo (filled circles), SW 1783/Topo (filled 
triangles) and LN-18/Topo cells (filled squares). 
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5.3.6.4 Chemosensitivity of LN-18/Topo cells against selected cytostatics 
The effect of mitoxantrone, doxorubicin (ABCG2 substrates) and vinblastine on the proliferation of 
ABCG2 overexpressing LN-18/Topo cells were investigated by means of a kinetic chemosensitivity 
assay. The results of the drug effects on wildtype (cf. section 5.3.4) and ABCG2 induced LN-18 cells 
are shown in Figure 5.20 and Figure 5.21. 
The treatment of LN-18 wildtype cells with mitoxantrone at concentrations of 30 nM and 100 nM, 
respectively, caused a strong cytocidal drug effect. LN-18/Topo cells, however, were resistant against 
this ABCG2 substrate at concentrations up to 100 nM. 
In case of doxorubicin, a moderate substrate of BCRP, the differences between the effects on the two 
cell types were less significant as for mitoxantrone. Nevertheless, a high concentration of 100 nM 
resulted in a strong cytotoxic effect on LN-18 wt cells and only in a weak toxic effect on the ABCG2 
induced cells. 
As expected, the chemosensitivity against vinblastine (P-gp substrate) did not differ between the 
wildtype and LN-18/Topo cells (data not shown). 
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Figure 5.20: Chemosensitivity of LN-18 wt (A) and LN-18/Topo (B) cells against mitoxantrone at the following 
concentrations: 10 nM (filled circles), 30 nM (filled squares), 100 nM (filled triangles); vehicle (open circles). 
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Figure 5.21: Chemosensitivity of LN-18 wt (A) and LN-18/Topo (B) cells against doxorubicin at the following concentrations: 
10 nM (filled circles), 30 nM (filled squares), 100 nM (filled triangles); 300 nM (filled diamonds); vehicle (open circles). 
5.3.7 ABC transporter expression in HMEC-1 cells 
Immortalized human microvascular endothelial cells (HMEC-1) were investigated for ABCB1, ABCG2 
and ABCC1 expression by means of a FACS assay as described in section 5.2.10 (GeoMean values cf. 
Table 5.4). The endothelial cells (EC) revealed moderate expression of MRP1 (ABCC1) and ABCG2, 
whereas P-gp (ABCB1) was not detected.  
The test for ABC transporter expression via flow cytometric analysis was performed only once due to 
a very slow in vitro growth of the cells. The results have to be confirmed by additional experiments, 
nevertheless they are in a good agreement with recently published data [Eilers et al., 2008]. 
Eilers et al. monitored the expression of ABC transporters in primary EC from different human 
tissues, including dermal microvascular endothelial cells. The authors report on a significant ABCC1 
transporter expression in all investigated ECs, whereas P-gp levels were lowest for microvessel 
derived ECs. 
  
 ABCB1 ABCC1 ABCG2  
 
Table 5.4: GeoMean values for ABC transporter expression in 
HMEC-1 cells determined by flow cytometry. Background 
fluorescence of HMEC-1 cells and non-specific binding of the 
secondary antibody were detected and used as negative 
controls. 
autofluorescence 72.4 72.1 72.6 
sec. AB 122.0 79.0 89.9 
prim. + sec. AB 118.4 147.0 129.3 
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Figure 5.22: Flow cytometric analysis of ABCG2 (A), 
ABCC1 (B) and ABCB1 (C) transporter expression in 
HMEC-1 cells; primary and secondary antibody (red), 
secondary antibody (green), autofluorescense 
(black). 
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5.4 Summary 
The malignant brain tumor cells Daoy, LN-18 and SW 1783 were investigated with regard to their 
morphology, in vitro growth kinetics, chemosensitivity against anticancer drugs, chromosome 
distribution and ABC transporter expression. All cell lines show pronounced features of high 
malignancy and genetic instability. Chemotoxicity studies revealed a high sensitivity of the Daoy cell 
line against almost all used cytotstatics whereas LN-18 and SW 1783 cells were at least partially 
resistant, for instance, against topotecan, doxorubicin and etoposide. Western Blot analysis and 
chemosensitivity tests indicated a slight ABCG2 transporter expression in LN-18 and SW 1783 
wildtype cells. Treatment of these cells with increasing concentrations of topotecan yielded two 
BCRP overexpressing cell lines which are comparable to the standard MCF-7/Topo cell line and are 
therefore suitable for the use in in vitro assays. 
The Daoy medulloblastoma cells were successfully established as subcutaneously growing tumors in 
nude mice, whereas LN-18 and SW 1783 cells were not tumorigenic under the same conditions. 
Results of FACS investigations on HMEC-1 cells suggest expression of the ABCC1 transporter in these 
endothelial cells.  
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Chapter 6 
6 Towards an ATPase assay for the 
human ABCG2 transporter 
 
6.1 Introduction 
ABC transporter-mediated drug transport across membranes against a concentration gradient is 
driven by energy provided by the hydrolysis of ATP. Generated inorganic phosphate (Pi) is 
proportional to the ATPase activity of the transporter and can, in principle, be quantified by a 
colorimetric assay on cell membranes. Membrane preparations of recombinant baculovirus infected 
Sf9 cells are widely used to investigate the interaction of compounds with different members of the 
ABC transporter family [Germann et al., 1990; Sarkadi et al., 1992]. Activation as well as inhibition of 
ABC transporters can be investigated by measuring ATPase activity: Compounds that stimulate 
ATPase activity are generally considered substrates of the transporter whereas inhibitors decrease 
stimulated activity. 
An ABCG2 ATPase assay harbors the potential of providing information on the mechanism of action 
of the synthesized ABCG2 modulators described in Chapter 3.  
In the present work, an ATPase assay for the human ABCG2 transporter was established using 
membrane preparations of Sf9 insect cells. The gene encoding ABCG2 was cloned into the pVL1392 
vector, expressed in Sf9 cells and an experimental protocol for the ATPase assay was set up. 
 
6.2 Materials and Methods 
6.2.1 Materials 
The pcDNA5/FRT-ABCG2 and pcDNA5/FRT-ABCB1 plasmids were a kind gift of Prof. Dr. Deanna 
Kroetz (Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, University of 
California, San Francisco, CA). Phusion® High-Fidelity DNA Polymerase (2 U/µL) and the 
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corresponding HF Buffer (5x), deoxynucleotide solution mix (dNTPs), the restriction enzymes XbaI 
and NotI-HF™, Antarctic Phosphatase, purified BSA (100x) and NEBuffer 4 for digestion, 6x Loading 
Dye, 100 bp DNA Ladder, 2-log DNA Ladder (0.1-10.0 kb) as well as T4 DNA Ligase (6 Weiss U/μL) and 
T4 DNA Ligase Reaction Buffer (10x) were all purchased from New England Biolabs (NEB; Ipswich, 
MA). All used primers were from Eurofins MWG Synthesis GmbH (Ebersberg, Germany). Melting 
temperatures (Tm) of the primers for estimating annealing temperatures were calculated 
using the online Tm Calculator of Thermo Scientific (www.thermoscientificbio.com/webtools/tmc/). 
Agarose and gel chambers of the perfectBlue™ Mini S gel system were obtained from 
Peqlab (Erlangen, Germany). QIAquick Gel Extraction, QIAquick PCR Purification, QIAprep Spin 
Miniprep and QIAGEN Plasmid Maxi Kits were from QIAGEN (Hilden, Germany). 
TAE buffer was made of 48.4 g/L Tris base (usb, Cleveland, OH), 11.42 mL glacial acetic acid and 
20 mL EDTA solution (0.5 M, pH 8.0) in 1000 mL purified water. Ampicillin was obtained from Sigma 
(Munich, Germany).  
PCR reactions were performed in a Mastercycle gradient Thermocycler (Eppendorf, Hamburg, 
Germany) and sequencing was performed by Entelechon (Bad Abbach, Germany) or Eurofins MWG 
Synthesis GmbH. 
RIPA buffer for cell lysis was made of 20 mM Tris, 200 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 
5 mM K2HPO4. The pH was adjusted to 7.8 and 100 mL of buffer were supplemented with a protease 
inhibitor tablet (SIGMAFAST™ Tablets; Sigma).  
All used antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany).  
3-Morpholinopropane-1-sulfonic acid (MOPS), sodium orthovanadate and EGTA for ATPase reaction 
buffer were purchased from Sigma. If not otherwise stated, chemicals (p.a. quality) were from Merck 
(Darmstadt, Germany). Purified water (Milli-Q system, Millipore, Eschborn, Germany) was used.
6.2.2 Transformation of E. coli 
LB and recovery (SOC) media, selective agar plates and competent bacteria E. coli (TOP10 strain) 
were prepared as described before [Pop, 2010].  
For chemical transformation, 200 μL of a suspension of competent E. coli cells were thawed on ice 
and approximately 1 ng of the plasmid DNA of interest was added prior to incubation on ice (30 min). 
Cells were heat-shocked (42 °C) for 90 sec and subsequently put on ice for 2 min. 1 mL of pre-
warmed SOC medium was added and the bacteria were incubated for 45 min at 37 °C under shaking 
(200 rpm). The suspension was centrifuged for 5 min at 2,300 g. The bacterial pellet was 
resuspended in 20-50 μL of the residual medium and plated on ampicillin-containing (100 µg/mL) 
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agar plates for selection, as the used vectors included an ampicillin resistance gene. Plates were 
incubated overnight at 37 °C. Resistant colonies were picked the next day and used for overnight 
cultures in LB medium supplemented with 100 µg/mL ampicillin (amp-LB medium). 
6.2.3 General procedures for preparation of plasmid DNA 
6.2.3.1 Mini- and Maxi-Prep 
For quick purification of up to 20 µg of high-copy plasmid DNA from 5 mL overnight culture of E. coli 
(in amp-LB medium), QIAprep Spin Miniprep Kit was used according to the manual for 
microcentrifugation. 
For large scale preparations of DNA, 250 mL of amp-LB medium were inoculated with 250 µL of 
bacterial overnight culture suspension. QIAGEN Plasmid Maxi Kit was used for pure DNA isolation 
according to the manufacturer’s instructions. 
Usually, a 1:20 dilution of Mini-Prep or Maxi-Prep DNA was prepared and DNA concentration was 
determined at a BioPhotometer (Eppendorf; Hamburg, Germany). 
6.2.3.2 Restriction enzyme digestion and dephosphorylation of plasmid ends 
For restriction enzyme analysis of plasmid DNA and the subcloning of PCR products, the enzymes 
NotI-HF™ (20 U/µL) and XbaI (20 U/µL) were used. Double digestion was performed in a final volume 
of 50 µL of millipore water containing 5 µL NEBuffer 4 (10x), 0.5 µL BSA (100x), 1 μL of each enzyme 
and 2 μg of DNA or pVL1392 Baculovirus Transfer Vector (5 µg in 50 µL; BD Biosciences, Heidelberg, 
Germany) for 2 h at 37 °C in an Eppendorf reaction vessel. Enzymes were heat-inactivated for 
additional 20 min at 65 °C. 
In order to avoid self-ligation, the DNA ends of the digested pVL1392 vector were dephosphorylated 
by incubating for 1 h at 37 °C with 1/10 volume of Antarctic Phosphatase (10x) followed by 5 min 
heat-inactivation at 65 °C.  
6.2.3.3 Agarose gel electrophoresis 
Agarose gels (1% or 3%) were prepared by dissolving 0.5 g or 1.5 g of agarose under heating and 
stirring in 50 mL of TAE buffer in a microwave. To visualize DNA, 1 μL of an ethidium bromide 
(Janssen Chimica; Beerse, Belgium) solution (10 mg/mL) was added. Gelling of the warm agarose 
solution was performed in a gel chamber for 30 min using a comb as placeholder to create gel 
pockets. 
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For analytical gels usually 5 μL of DNA products mixed with 1 μL of 6x DNA loading dye were applied. 
For quantitative gels after restriction enzyme digestion volumes up to 50 μL were pipetted into gels 
with larger pockets. 
The 2-log DNA ladder (0.1-10.0 kb; 7-10 μL of) was used as reference to estimate the length of PCR or 
digestion products. Electrophoresis (in TAE buffer) was performed at 150 V (ca. 90 min) until the 
track dye has moved 2/3 of the gel length. After removing the gel tray from the electrophoresis 
chamber, DNA bands were visualized by illumination with UV light at 254 nm (Gel Doc 2000; Bio-Rad 
Laboratories, Munich, Germany) using Quantity One (Bio-Rad) software for data analysis. 
6.2.3.4 Purification of PCR products and recovery of DNA fragments from 
agarose gels 
DNA from PCRs was desalted and the polymerase was removed with the QIAquick PCR Purification 
Kit. DNA fragments after restriction enzyme digestion were first separated by agarose gel 
electrophoresis. Afterwards, bands with the correct sizes were excised from the gel under UV light 
(λex: 254 nm) and extracted with the QIAquick Gel Extraction kit according to the manual.  
6.2.4 Preparation of the S-ABCG2 construct via sequential overlap 
extension PCR 
Primers were designed to provide two different PCR products, the signal peptide sequence (ATG AAG 
ACG ATC ATC GCC CTG AGC TAC ATC TTC TGC CTG GTA TTC GCC), a domain of 48 bp necessary for a 
correct transporter expression in Sf9 cells, and the ABCG2 template, with a region of common 
sequence. The two overlapping fragments were fused in a subsequent PCR amplification to obtain 
the extended ABCG2 template (Figure 6.1). 
In PCR 1a, the DNA sequence of the signal peptide (S) was amplified. A plasmid containing the signal 
peptide sequence and the FLAG (F) epitope was used as template with the sense primer SF_NotIfor 
encoding the NotI restriction site followed by the first 18 bp of the signal peptide and the antisense 
primer Signal_rev comprising the final part (18 bp) of the signal peptide sequence.  
In PCR 1b the cDNA of the ABCG2 receptor was amplified using the pcDNA5/FRT-ABCG2 vector as 
template. PCR 1b was performed with the sense primer ABCG2_for encoding the final 18 bp of the 
signal peptide followed by the initial 23 bp of the ABCG2 receptor and the antisense primer 
ABCG2_XbaI_rev comprising 31 bp of the C-terminal sequence of the ABCG2 receptor and the XbaI 
restriction site.  
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Due to their terminal complementarity, PCR products 1a and 1b, templates for PCR 2, will overlap 
and subsequently be extended. 
 
PCR 1a: 
 
 
 
 
 
 
 
PCR 1b: 
 
 
 
 
 
PCR 2: 
 
 
 
 
 
Figure 6.1: Strategy for the construction of the S-ABCG2 insert via overlap extension PCR. In separate PCR reactions (PCR 1a 
and 1b), two fragments of the target sequence are amplified. PCR 1a product contains the complete signal peptide 
sequence (S), whereas PCR 1b product comprises the complete sequence of the ABCG2 transporter and the final 18 bp of 
the signal peptide. In PCR 2 the two intermediate products with terminal complementarity form a new template DNA, 
annealing at the overlapping 18 bp of the signal peptide sequence. Primers are displayed as blue arrows. 
ABCG2 XbaI      S 
     S NotI 
PCR product 1b 
PCR 1a product  
ABCG2       S NotI XbaI 
PCR 2 product  
FLAG 
    S NotI 
PCR  1a product  
    S 
pcDNA3.1(+)-SF-mH4R-His6 
PCR 1b product  
ABCG2 
    S ABCG2 XbaI 
pcDNA/FRT-ABCG2 
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6.2.4.1 PCR 1a for the S-ABCG2 construct 
The template pcDNA3.1(+)-SF-mH4R-His6 containing the signal peptide sequence was kindly provided 
by  Dr. Uwe Nordemann (Institute of Pharmacy, University of Regensburg).  
sense primer SF_NotIfor:   5’- AGC TGC GGC CGC ATG AAG ACG ATC ATC GCC - 3’ 
               NotI  signal peptide  
antisense primer Signal_rev:  5’- GGC GAA TAC CAG GCA GAA - 3’ 
The PCR reaction mixture contained 1 ng template DNA, 0.5 µL (1 U) of Phusion® High−Fidelity DNA 
polymerase, 10 μL of 5x HF buffer,  1 µL dNTP Mix (10 mM), primers (0.5 μM each) and water up to a 
volume of 50 μL.  
PCR reaction was performed with a gradient at 3 different 
annealing temperatures: 
(1) initial denaturation 98 °C, 30 sec 
(2) denaturation  98 °C, 10 sec 
(3) annealing   55 °C, 60 °C or 65 °C, 15 sec 
(4) extension  72 °C, 5 sec 
(5) final extension  72 °C, 5 min 
(6) hold   4 °C 
Steps 2-4 were repeated 30 times. 
 
 
Figure 6.2 shows the expected product (60 bp) of PCR 1a on a 3% 
agarose gel. All three annealing temperatures (lanes a-c) are 
suitable for this PCR reaction with a preference for 55 °C. The 
PCR product (lane a) was purified using the QIAquick PCR 
Purification Kit without further separation from possible side 
products. The DNA concentration was determined. 
Figure 6.2: Agarose gel (3%) 
electrophoresis of PCR 1a product; 
numbers indicate the sizes of the 
bands in base pairs (bp); Lanes a-c 
represent PCR products at 3 different 
annealing temperatures: 55 °C (a), 
60 °C (b), 65°C (c). 
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6.2.4.2 PCR 1b for the S-ABCG2 construct 
PCR reaction mixture was the same as described for PCR 1a. 1 ng of the pcDNA5/FRT-ABCG2 vector 
was used as template. 
sense primer ABCG2_for:   
5’- TTC TGC CTG GTA TTC GCC ATG TCT TCC AGT AAT GTC GAA GT - 3’ 
 signal peptide              ABCG2  
antisense primer ABCG2_XbaI_rev:   
5’- ATA TCT AGA TTA AGA ATA TTT TTT AAG AAA TAA CAA TTT C - 3’ 
    XbaI             ABCG2  
PCR reaction was performed with a gradient at 3 different 
annealing temperatures: 
(1) initial denaturation 98 °C, 30 s 
(2) denaturation  98 °C, 10 s 
(3) annealing   52 °C, 57 °C or 62 °C, 15 sec 
(4) extension  72 °C, 40 s 
(5) final extension  72 °C, 5 min 
(6) hold   4 °C 
Steps 2-4 were repeated 30 times.  
 
Figure 6.3 shows the expected ABCG2 construct (1992 bp) 
of PCR 1b on a 1% agarose gel. All three annealing 
temperatures (lanes a-c) are appropriate for this PCR 
reaction. The PCR product (lane a) was purified using the 
QIAquick PCR Purification Kit without further separation. 
The DNA concentration was determined.  
 
Figure 6.3: Agarose gel (1%) 
electrophoresis of PCR 1b product; lanes 
a-c indicate the 3 different annealing 
temperatures: 52 °C (a); 57 °C (b); 62°C (c). 
6.2.4.3 PCR 2 for the S-ABCG2 construct 
The annealed products of PCR 1a and PCR 1b served as template for the amplification of the new 
insert S-ABCG2 flanked by the restriction sites NotI (5’ end) and XbaI (3’ end) in PCR 2.  
The sense primer NotI_for  (5’- AGC TGC GGC CGC - 3’) encoding the NotI restriction site was used. 
ABCG2_XbaI_rev from PCR 1b served as antisense primer.  
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Due to the extremely different base pair lengths of PCR products 1a (60 bp) and 1b (1992 bp) three 
different PCR reactions were performed varying the ratio of concentrations of template 1a and 1b. 
Figure 6.4 shows the results of PCR 2 fusing PCR 1a product with product 1b. The template 
concentrations of PCR reactions shown in lanes a and b were calculated according the DNA length 
ratio of the PCR products. All other reagents were used as described above in a total volume of 50 µL 
under cycling conditions according to PCR 1b with an annealing temperature of 57 °C. QIAquick PCR 
Purification Kit was used for purification. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Agarose gel (1%) electrophoresis of PCR product 2 
(2034 bp); lanes a-c indicate 3 different ratios: a: 0.03 ng (PCR 1a 
product) + 1 ng (PCR 1b product), b: 0.3 ng (1a) + 10 ng (1b), c: 1 ng 
(1a) + 10 ng (1b). 
 
6.2.5 Preparation of the S-ABCB1 construct 
Overlap extension PCR performed in the same way as for the S-ABCG2 construct was not successful 
for the ABCB1 transporter. In a second approach, the signal peptide sequence was completely 
inserted in the sense primer, flanked by the NotI restriciton site and the first 19 bp of the ABCB1 
transporter (ordered as unmodified DNA oligo from Eurofins MWG Synthesis GmbH). 
ABCB1_XbaI_rev served as antisense primer comprising the XbaI restriction site and the final 17 bp of 
the ABCB1 transporter. 
sense primer ABCB1_for(+S): 
5‘- AGC TGC GGC CGC ATG AAG ACG ATC ATC GCC CTG AGC TAC ATC TTC TGC CTG GTA TTC GCC ATG 
GAT CTT GAA GGG GAC C - 3‘ 
antisense primer ABCB1_XbaI_rev: 
5’- ATA TCT AGA TCA CTG GCG CTT TGT TC - 3’ 
    XbaI               ABCB1  
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Two different PCR strategies were chosen: 
1. PCR 3a reaction was performed with a gradient at 3 different annealing temperatures: 
(1) initial denaturation  98 °C, 30 s 
(2) denaturation  98 °C, 10 s 
(3) annealing    57 °C, 62 °C or 67 °C, 15 s 
(4) extension   72 °C, 2 min 
(5) final extension  72 °C, 5 min 
(6) hold   4 °C 
Steps 2-4 were repeated 30 times.  
2. Due to the length and the associated high melting temperature of the sense primer 
ABCB1_for(+S), additionally, PCR 3b reaction was performed in two cycles with an initial low 
and a following high annealing temperature: 
(1) initial denaturation  98 °C, 30 s 
(2) denaturation  98 °C, 10 s 
(3) annealing    60 °C, 15 s 
(4) extension   72 °C, 2 min 
Steps 2-4 were repeated 5 times. 
(5) denaturation  98 °C, 10 s  
(6) annealing   70 °C, 15 s 
(7) extension   72 °C, 2 min 
Steps 5-7 were repeated 25 times. 
(8) Final extension  72 °C, 5 min 
(9) hold   4 °C 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Agarose gel (1%) electrophoresis of PCR products 3a 
and 3b; lanes a-c indicate PCR 3a at three different annealing 
temperatures: 57 °C (a), 62 °C (b), 67°C (c); lane d indicates 
PCR 3b. 
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Figure 6.5 shows the expected product (3909 bp) of PCR 3a and PCR 3b on a 1% agarose gel. All three 
annealing temperatures of PCR 3a (lanes a-c) are suitable for this PCR reaction with a preference for 
57 °C. PCR 3b (lane d) with the two different annealing cycles did not give the desired product. PCR 
product of lane a was purified and the DNA concentration was determined. 
6.2.6 Subcloning of the S-ABCB1 and the S-ABCG2 construct into 
pVL1392 vector 
For Sf9 cell line transfection, the S-ABCB1 and the S-ABCG2 fragment, respectively, were each 
subcloned into the pVL1392 plasmid in its multiple cloning site with the XbaI and NotI restriction sites 
(Figure 6.6) giving the pVL1392/S-ABCB1 and pVL1392/S-ABCG2 plasmid, respectively. 
 
Figure 6.6: Vector map of pVL1392 vector (adopted from manual 
provided by BD biosciences). 
Digestion of ABC transporter fragments and the pVL1392 transfer vector was prepared as described 
in section 6.2.3.2. The corresponding agarose gel electrophoresis is illustrated in Figure 6.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Agarose gel (1%) electrophoresis of digestion 
products: pVL1392 vector (a), S-ABCB1 fragment (b), 
S-ABCG2 fragment (c). 
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After gel electrophoresis and gel extraction (cf. sections 6.2.3.3 and 6.2.3.4), ligation was performed 
at 16 °C overnight in a 20 µL reaction mixture containing 1 µL T4 DNA Ligase and 2 µL of T4 DNA 
Ligase Reaction Buffer (10x) as well as the pVL1392 transfer vector (50 ng) and the insert in a molar 
ratio of 1:3 (vector to insert). The next day the samples were stored at -20 °C. After transformation of 
competent E. coli, Mini-Preps were prepared with colonies picked from ampicillin-containing agar 
plates, and a positive clone was chosen for Maxi-Prep.  
Plasmid DNA was sequenced using the standard primers pVL1392for and pVL1392rev. 
6.2.7 Sf9 insect cell culture and generation of recombinant 
baculoviruses 
Sf9 insect cell culture and generation of recombinant baculoviruses has been described recently 
[Brunskole, 2011]. Sf9 cells (ATCC® CRL-1711™) were cultured in 250 or 500 mL disposable 
Erlenmeyer flasks at 28 °C under rotation at 150 rpm in Insect Xpress medium supplemented with 
5% (v/v) fetal calf serum. Recombinant baculoviruses encoding the S-ABCG2 construct were 
generated in Sf9 insect cells using the BaculoGold™ transfection kit (BD Biosciences, Heidelberg, 
Germany) according to manufacturer’s protocol.  
After initial transduction, high-titer virus stocks were generated by two sequential virus 
amplifications: in the first amplification, 50 mL cell suspension (density: 2.0 x 106 cells/mL) were 
infected with 1 mL of the supernatant fluid from the initial transduction. Cells were cultured for one 
week in a 125 mL Erlenmeyer flask, resulting in death of the cell population. As a control for 
infectious viruses, 3 mL of this culture were transferred into a 25 cm2 flask and kept at 28 °C in 
parallel. The supernatant was harvested and stored under light protection at 4 °C.  
In a second amplification, cells were cultured at a density of 3.0 x 106 cells/mL (total 
volume: 100 mL), infected with 5 mL of the supernatant fluid from the first amplification and 
cultured for two days. After 48 hours the supernatant was harvested. Cells showed signs of infection 
(altered morphology, viral inclusion bodies), but the majority of cells was still intact. The supernatant 
fluid from the second amplification step was stored under protection from light at 4 °C and used as 
high-titer virus stock to infect Sf9 cells. All supernatants were routinely filtered through Millex® filters 
(0.22 µm pore size; Merck Millipore, Darmstadt, Germany) to avoid bacterial or fungal 
contamination. 
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6.2.8 Recombinant transporter expression in pVL1392/S-ABCG2-
infected Sf9 cells 
6.2.8.1 Immunological detection of ABCG2 expression  
To ensure an optimal accumulation of the desired ABCG2 protein, an ideal Sf9 infection time has to 
be determined. Cells were seeded at a density of 0.75 x 106 cells/mL, infected with high-titer 
baculovirus stock (1:500) and cultured. Cell aliquots were harvested at different times after infection 
(24-96 h) followed by three washing  and centrifugation steps  with PBS at 4 °C for 10 min (3,000 g) 
using a Minifuge 1.0R (Heraeus Instruments GmbH; Hanau, Germany). To monitor the expression of 
ABCG2 in pVL1392/S-ABCG2-infected Sf9 cells, total cell lysates were analyzed by immunoblotting.  
6.2.8.1.1 Sf9 cell lysis 
Cell lysis of ABCG2-infected Sf9 cells was performed by homogenizing the harvested cells in RIPA 
buffer. After incubation for 20 min on ice in an Eppendorf reaction vessel, the cell suspension was 
centrifuged (10 min, 4° C, 16,000 g) and the supernatant containing the proteins was frozen at -80 °C 
after addition of 10% (v/v) glycerol. 
6.2.8.1.2 SDS-Page and Western Blotting 
SDS-PAGE and WB analysis as well as the determination of the protein content of all cell lysates were 
performed as described in section 5.2.9. The primary rat monoclonal antibody ABCG2 (BXP-53) was 
used in a 1:1,000 dilution, the secondary AB (goat anti-rat IgG-HRP) in a 1:10,000 dilution. 
For molecular weight control, the prestained protein marker peqGOLD Protein Marker III 
(20-122 kDa; Peqlab, Erlangen, Germany) or the Biotinylated Protein Ladder (9-200 kDa) from Cell 
Signaling Technology (Danvers, MA, USA) were used (secondary Anti-biotin, HRP-linked AB 1:1,000), 
respectively. 
Western Blot analysis was similarly performed for ABCG2 membrane preparations. 
6.2.8.2 Membrane preparation 
For membrane preparation, 200 mL cultures with 3.0 x 106 cells/mL were infected 1:500 with 
S-ABCG2 high-titer virus stock, cultured and harvested 48 hours after infection by centrifugation at 
4 °C (170 g, 10 min). The cell pellet was resuspended in 100 mL Tris-mannitol buffer (50 mM Tris, 
300 mM mannitol, 0.5 mM phenylmethylsulfonyl fluoride (PMSF); pH 7) and again centrifuged.  
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For membrane preparation the cell pellet was lysed and homogenized (25 strokes) in TMEP (50 mM 
Tris, 50 mM mannitol, 1 mM EDTA, 10 µg/mL leupeptin, 10 µg/mL benzamidine, 0.5 mM PMSF, 2 mM 
DTT; pH 7) by means of a glass-Teflon tissue homogenizer. Buffers were used as described elsewhere 
[Sarkadi et al., 1992] with slight modifications. The use of protease inhibitors is recommended 
especially in insect cells, as the yields of recombinant proteins can significantly decrease due to high 
proteolytic activity [Gotoh et al., 2001]. 
After centrifugation for 10 min at 500 g to get rid of nuclei and unbroken cells, the supernatant, 
containing the membranes, was carefully removed and centrifuged at 100,000 g for 1 h in a Kontron 
TGA-45 ultracentrifuge (Kontron Instruments, Munich, Germany). The spun down membranes were 
resuspended in TMEP and homogenized by a 20 mL syringe in 15 strokes. Protein quantification was 
performed by the method of Bradford in a Bio-Rad Protein Assay (Bio-Rad Laboratories, Munich, 
Germany) according to the manual. Membrane aliquots at a protein concentration of 1.5-2.0 mg/mL 
were stored at -80 °C until use. All steps during membrane preparation were performed at 4 °C. 
Please confer to section 6.3.3.3.2 for a second modified membrane preparation protocol.  
6.2.9 ATPase assay for the human BCRP 
6.2.9.1 Principle  
Determining the ATPase activity in membranes of Sf9 insect cells expressing the ABCG2 transporter 
may provide insight into the mechanism of action of modulators. The ATPase activity correlates with 
the liberation of inorganic phosphate (Pi), resulting from ATP hydrolysis when a substrate is 
transported. Inorganic Pi reacts with ammonium molybdate to form a complex, in the presence of 
the reducing agent ascorbic acid producing an intensively blue colored heteropoly complex 
(molybdenum blue), which can then be determined spectrophotometrically (Figure 6.8). The 
obtained absorbance is proportional to ATPase activity. 
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Figure 6.8: Principle of an ATPase assay: Substrate binding and subsequent ATP hydrolysis results in the release of ADP and 
inorganic phosphate. Pi forms a complex with ammonium molybdate (gray sickles) which results in an intensive blue color 
after reduction; TMD = transmembrane domain, NBD = nucleotide-binding domain, S = substrate; ATP = adenosine 
triphosphate; ADP = adenosine diphosphate; Pi = inorganic phosphate. 
6.2.9.2 ATPase assay protocol 
The ATPase assay protocol was established in the 96-well plate format according to the manual 
provided by GenoMembrane (http://www.genomembrane.com/ATPase_assay_Ver.6.5.n.pdf; 
Yokohama, Japan) based on the work of Sarkadi [Sarkadi et al., 1992].  
6.2.9.2.1 Reagents and buffers 
 MOPS-Tris buffer [100 mM] contained 20.93 g/L 3-morpholinopropane-1-sulfonic acid. The 
pH of 7.0 was adjusted with 1.7 M Tris (37 °C).  
 Reaction buffer was made of 50 mM MOPS-Tris, 50 mM KCl, 5 mM sodium azide, 2 mM DTT 
(AppliChem; Darmstadt, Germany), 1 mM ouabain and 2 mM EGTA. Aliquots were stored at 
-20 °C. 
 For a 100 mM orthovanadate solution, 0.368 g of sodium orthovanadate were dissolved in 
16 mL millipore water, the pH was adjusted to 10 with 1 N HCl or 1 N NaOH and the solution 
was heated (100 °C) for 10 min. When cooled down, the solution was filled up to 20 mL. 
Reaction buffer was used to prepare a 12 mM working solution (also cf. section 6.3.3.1). 
 200 mM MgATP solution was made by dissolving 2.21 g of Na2ATP (Boehringer; Mannheim, 
Germany) in 10 mL MgCl2 solution [400 mM]. The pH was adjusted to 7.0 with 
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1.7 M Tris (37 °C) and the solution was filled up to 20 mL with millipore water. Aliquots of 
1 mL were stored at -20 °C. A 12 mM working solution was made in reaction buffer. 
 For the indicator solution (always freshly prepared), one part of a solution containing 15 mM 
zinc acetate and 35 mM ammonium molybdate were mixed with 4 parts of a 5% (m/v) 
ascorbic acid solution (pH 5.0 with 10 N NaOH) 
 Phosphate standards (0, 0.05, 0.1, 0.25, 0.5, 1.0, 1.5 and 2.0 mM) were obtained by diluting a 
1 M NaH2PO4 stock solution with reaction buffer. Small portions were stored at -20 °C.   
 Reactions were stopped with a 10% (m/v) SDS solution (Sigma).  
 Test compounds (in DMSO) were dissolved in reaction buffer to 3-fold concentrated stock 
solutions. 
 
MgATP (instead of Na2ATP) is essential for the assay system as ABCG2 drug transport requires the 
presence of magnesium ions [Litman et al., 2000; Özvegy et al., 2001]. It is furthermore linked to a 
drug-stimulated, vanadate-sensitive ATPase activity [Sarkadi et al., 1992; Telbisz et al., 2007]. 
Vanadate, an analog of inorganic phosphate, is a known inhibitor of many ATPases, including ATPase 
activities of ABC transporter [Senior et al., 1995; Chen et al., 2001]. Vanadate-sensitive ATPase 
activity (resulting from ABC transporter activity) can thereby be calculated by subtracting vanadate-
insensitive from total ATPase activity.  
6.2.9.2.2 Instrumental set-up 
The ATPase assay for the human ABCG2 transporter was established in the 96-well plate format with 
absorbance detection at the GENios Pro microplate reader (TECAN Deutschland GmbH; Crailsheim, 
Germany). The optimal detection wavelength of the formed phosphomolybdate complex had to be 
determined. Therefore, 5 mL of indicator solution were mixed with 50 mg NaH2PO4. After 20 min the 
absorbance spectrum of the obtained colored complex was detected at a Cary 100 UV-Vis 
spectrophotometer (Varian; Darmstadt, Germany).  
Additionally, the linearity of the absorbance of the phosphate standards after complexation and 
reduction was tested prior to any experiments at the above determined optimal wavelength. 60 µL 
per standard were incubated with 30 µL of 10% SDS and 200 µL coloring solution for 20 min under 
shaking (400 rpm) at 37 °C at a Grant-bio PHMP Thermoshaker for microplates (Grant Instruments; 
Cambrigdeshire, UK) and absorbance was measured at the microplate reader. 
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6.2.9.2.3 Assay procedure 
The activity of the ABCG2 transporter is measured as vanadate-sensitive ATPase activity in the 
presence of inhibitors or stimulating agents (substrates) in membranes of ABCG2 expressing Sf9 cells 
as described earlier [Sarkadi et al., 1992; Glavinas et al., 2007]. 
 
The assay was performed on ice in the 96-well plate format on the basis of the manual provided by 
Geno Membrane: 
Membranes were thawed on ice and carefully homogenized with a pipette. Phosphate standards are 
part of every plate to calculate a calibration plot for phosphate (60 µL/well of each phosphate 
standard performed in doublet). In the remaining wells, membranes (10 µL/well) were loaded with 
either 20 µL of the 3-fold concentrated test compound solutions or 3% (v/v) DMSO (in reaction 
buffer) for the negative and background control (8 wells each), respectively. The background control, 
measures the inorganic phosphate derived from the reaction buffer and was immediately stopped 
with a 10% (m/v) SDS solution (30 µL/well) prior to ATPase reaction. The negative control indicates 
the basal ATPase activity of the ABCG2 transporter in the absence of a substrate.  
Four wells of each compound concentration and each negative control were overlaid with 10 µL of 
the 12 mM o-vanadate solution, the remaining wells with the corresponding volume of reaction 
buffer. The plate was shaken to mix the solutions and incubated for 3 min at 37 °C. 
Subsequently, the reaction was started by the addition of 20 µL of 12 mM MgATP (except for 
phosphate standards). After an incubation time of 1 h (37 °C) under shaking the reaction was 
stopped by adding 30 µL/well of 10% SDS (except for thebackground control). Indicator solution was 
added (200 µL/well) and after further 30 min of incubation at 37 °C, absorbance of the obtained 
phosphomolybdate complex was determined in each well at 830 nm at the GENios Pro microplate 
reader when the temperature of the microplate had cooled down. 
Instrument settings were as follows: Measurement mode: absorbance; number of reads: 10; plate 
definition file GRE96ft.pdf; time between move and flash: 100 ms. All values were corrected to the 
background control and the amount of inorganic phosphate generated in each well was calculated 
from the correlation equation obtained from phosphate standards on each plate. Data obtained 
under the treatment with orthovanadate were subtracted from the data gained in the absence of 
vanadate to obtain phosphate liberation resulting from ABCG2 activity. This amount of phosphate 
was divided by the incubation time and the protein content per well (corresponding to the used 
membrane preparation) to give the desired vanadate-sensitive ATPase activity 
[nmol Pi/min/mg protein]. 
For the investigation of ABCG2 inhibitors, the assay was performed as described with the exception 
that ATPase activity was stimulated with topotecan [100 µM]. Furthermore, topotecan served as 
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positive control on each plate and was used to determine the degree of inhibition caused by the 
highest compound concentration tested. The final DMSO content did not exceed 1% (v/v). 
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6.3 Results and discussion 
The presentation of the results is focused on the ABCG2 protein. 
6.3.1 Results of DNA sequencing 
Plasmid DNA was sequenced using the standard primers pVL1392for and pVL1392rev. For the 
plasmid containing the S-ABCG2 construct with nearly 2000 bp, corresponding to about half of the 
length of the ABCB1 transporter, a complete Primer Walking DNA Sequencing was performed by 
Entelechon (Bad Abbach, Germany). The result confirmed an error-free ABCG2 sequence when 
compared to the NCBI database (Figures 6.9-6.10; data not completely displayed). 
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Seq_1  57    GCCGGCTCCCATCGTGACCTCCAGCCGCAGCGCCTCCCACGCCGGCCGCCGCGCGAGGGG  116 
               |||   |      || || |||| || ||        ||     ||||  | |      
Seq_2  59    ATCGGGCGCGGATCAGATCTGCAGCGGCCGCATGAAGA-CGATCATCGCCCTGAGCTAC-  116 
 
 
Seq_1  117   AGCGCTCGGGCGCGCCGGGTGTGGTTGGGGGAAGGGGTTGTGCCGCGCGCGGGCTGCGTG  176 
                 ||   ||  |      |                                        
Seq_2  117   --ATCTTCTGCCTGGTATTCGCC-------------------------------------  137 
 
     * * * 
 
Seq_1  477   AGATAAAAACTCTCCAGATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAG  536 
                              ||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  138   -----------------ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAG  180 
 
  
Seq_1  537   GAAACACCAATGGCTTCCCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAG  596 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   GAAACACCAATGGCTTCCCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAG  240 
 
 
Seq_1  597   CTGTGTTAAGTTTTCATAACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTT  656 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CTGTGTTAAGTTTTCATAACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTT  300 
 
 
Seq_1  657   GTCGAAAACCAGTTGAGAAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTC  716 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   GTCGAAAACCAGTTGAGAAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTC  360 
 
 
Seq_1  717   TCAACGCCATCCTGGGACCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTG  776 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   TCAACGCCATCCTGGGACCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTG  420 
   
 
Seq_1  777   CAAGGAAAGATCCAAGTGGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTG  836 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CAAGGAAAGATCCAAGTGGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTG  480 
 
 
Seq_1  837   CCAATTTCAAATGTAATTCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGA  896 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   CCAATTTCAAATGTAATTCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGA  540 
   
 
Seq_1  897   CGGTGAGAGAAAACTTACAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATC  956 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   CGGTGAGAGAAAACTTACAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATC  600 
 
 
Seq_1  957   ATGAAAAAAACGAACGGATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAG  1016 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   ATGAAAAAAACGAACGGATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAG  660 
 
 
Seq_1  1017  ACTCCAAGGTTGGAACTCAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTA  1076 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   ACTCCAAGGTTGGAACTCAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTA  720 
 
 
Seq_1  1077  GTATAGGAATGGAGCTTATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTG  1136 
             |||||||||||||||||||||                                        
Seq_2  721   GTATAGGAATGGAGCTTATCA---------------------------------------  741 
 
 
Seq_1  1137  GCTTAGACTCAAGCACAGCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGG  1196 
                                                                          
Seq_2  742   ------------------------------------------------------------  741 
 
 
Figure 6.9: Annealing of the N-terminal domain of the ABCG2 transporter (1965 base pairs) from NCBI database with the 
nucleotide sequence, obtained by sequencing (blue; 604 base pairs) using primer pVL1392for. The encoding region of the 
ABCG2 transporter from NCBI database is shown in red (start codon is underlined). The signal peptide sequence, obtained 
in sequencing is shown in green. 
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Seq_1  1981  GTTAGGATTGAAGCCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGT  2040 
                                                            ||||||||||||| 
Seq_2  530   -----------------------------------------------CCCTTATGATGGT  518 
 
 
Seq_1  2041  GGCTTATTCAGCCAGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGT  2100 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  517   GGCTTATTCAGCCAGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGT  458 
 
 
Seq_1  2101  AGCAACACTTCTCATGACCATCTGTTTTGTGTTTATGATGATTTTTTCAGGTCTGTTGGT  2160 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  457   AGCAACACTTCTCATGACCATCTGTTTTGTGTTTATGATGATTTTTTCAGGTCTGTTGGT  398 
 
 
Seq_1  2161  CAATCTCACAACCATTGCATCTTGGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATA  2220 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  397   CAATCTCACAACCATTGCATCTTGGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATA  338 
 
 
Seq_1  2221  TGGATTTACGGCTTTGCAGCATAATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAA  2280 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  337   TGGATTTACGGCTTTGCAGCATAATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAA  278 
 
 
Seq_1  2281  TGCAACAGGAAACAATCCTTGTAACTATGCAACATGTACTGGCGAAGAATATTTGGTAAA  2340 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  277   TGCAACAGGAAACAATCCTTGTAACTATGCAACATGTACTGGCGAAGAATATTTGGTAAA  218 
 
 
Seq_1  2341  GCAGGGCATCGATCTCTCACCCTGGGGCTTGTGGAAGAATCACGTGGCCTTGGCTTGTAT  2400 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  217   GCAGGGCATCGATCTCTCACCCTGGGGCTTGTGGAAGAATCACGTGGCCTTGGCTTGTAT  158 
 
 
Seq_1  2401  GATTGTTATTTTCCTCACAATTGCCTACCTGAAATTGTTATTTCTTAAAAAATATTCTTA  2460 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  157   GATTGTTATTTTCCTCACAATTGCCTACCTGAAATTGTTATTTCTTAAAAAATATTCTTA  98 
 
 
Seq_1  2461  AATTTCCCCTTAATTCAGTATGATTTATCCTCACATAAAAAAGAAGCACTTTGATTGAAG  2520 
             |                                                            
Seq_2  97    A-----------------------------------------------------------  97 
 
 
Figure 6.10: Annealing of the C-terminal domain of the ABCG2 transporter from NCBI database with the nucleotide 
sequence, obtained by sequencing (blue; anti-parallel; 434 base pairs) using primer pVL1392rev. The encoding region of the 
ABCG2 transporter from NCBI database is shown in red (stop codon is underlined).  
6.3.2 ABCG2 expression in Sf9 cells 
6.3.2.1 Infection time 
The timing of harvesting the Sf9 cells after ABCG2-baculovirus infection seems to be critical. As 
shown in a recently published work, size and morphology of Sf9 cells change dramatically during 
infection: The membrane integrity was disrupted at later stages (>72 h) as numerous pores were 
observed by means of scanning electron microscopy [Saito et al., 2006; Saito et al., 2009]. Membrane 
vesicles prepared from such porous cells are useless. Western blot analysis (total cell lysate) of 
pVL1392/S-ABCG2-infected Sf9 cells revealed an optimal transporter expression after 48 h 
(Figure 6.11). 
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Figure 6.11: Expression of the ABCG2 gene product in Sf9 cells. Western blot analysis of total cell lysates prepared from Sf9 
wt cells (a) and pVL1392/S-ABCG2-infected Sf9 cells at different times after infection: 24 h (b), 48 h (c), 72 h (d), 96 h (e); 
10 µg protein were loaded on lanes a-e; lanes f-h correspond to lanes b-d except for loading with 20 µg protein; i) 
Biotinylated Protein Ladder (9-200 kDa; Cell Signaling); the sizes of molecular weight standards are indicated in kDa. 
 
Closer examination of the Western blot with the Quantity One (Bio-Rad) software unfortunately 
revealed a main band (presumably a doublet) at 63-67 kDa (expected molecular weight of the 
glycosylated ABCG2 transporter monomer: 72 kDa). Additionally, some diffuse bands were visible 
probably resulting from proteolytic cleavage of the target ABCG2 protein into lower molecular 
weight products when expressed in Sf9 cells. 
To confirm this lower molecular mass of the ABCG2 transporter in insect cells, the expression of BCRP 
in membrane preparations was compared to that in MCF-7/Topo cells (ABCG2 overexpressing 
subclone of human MCF-7 cells). Immunoblot analysis (Figure 6.12) showed that ABCG2 expressed in 
Sf9 cells migrates as a double band of lower apparent molecular mass (63 kDa and 66 kDa) than the 
ABCG2 protein of MCF-7/Topo cells (a wide band at 74 kDa). This phenomenon was previously 
reported by other groups [Özvegy et al., 2001; Pozza et al., 2006; Pozza et al., 2009].  
 
 
Figure 6.12: Immunoblot detection of the ABCG2 transporter 
expressed in Sf9 membrane preparations and MCF-7/Topo cells, 
respectively (10 µg of protein); a) Sf9 wt membrane, b) Sf9 
ABCG2-membrane, c) Biotinylated Protein Ladder (9-200 kDa; 
Cell Signaling), d) MCF-7/Topo cells. Red arrow indicates the 
ABCG2 transporter (72 kDa) expressed in human MCF-7/Topo 
cells. Immunoblot analysis revealed an approximately 5-fold 
higher expression level of the lower ABCG2 homolog (doublet 
protein bands) compared to the ABCG2 monomer in 
MCF-7/Topo cells. BXP-53 (1:1,000) was used as primary AB. 
140
80
50
40
20
a       b       c       d        e       f        g        h       i 
a              b           c     d    
80
140
50
40
a              b           c     d    
 
146 Chapter 6 
 
The high extent of proteolysis of the ABCG2 transporter in Sf9 cells is remarkable. To check whether 
the formation of the ABCG2 homolog at lower molecular mass and the proteolytic effect in Sf9 cells 
depends on the time of infection and the dilution of the virus stocks, Sf9 membane preparations 
were made 24, 48 and 72 h after infection, each charged 1:100 and 1:500 with S-ABCG2 high titer 
virus stock, respectively (Figure 6.13).  
 
The ratio of proteolytic degradation products (bands around 50 kDa) compared to the target ABCG2 
protein at 63 kDa is nearly constant in the Sf9 membrane preparations, virtually irrespective of the 
infection time and the used dilution of the virus stock. However, membranes prepared 24 h after 
infection of the cell showed the lowest extent of proteolysis. Despite a lower expression level of the 
ABCG2 homolog in comparison to 48 h- and 72 h-preparations, these short-term infected 
membranes were preferred for the first ATPase experiments. 
6.3.2.2 Glycosylation of the ABCG2 transporter 
The ABCG2 transporter is a glycoprotein consisting of 655 amino acids with a predicted molecular 
weight of 72 kDa. As a ‘half-transporter’ it contains only one TMD forming a homodimer in the 
plasma membrane in order to function.  The topology of human ABCG2 is displayed in Figure 6.14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13: A) Immunoblot analysis of ABCG2 
protein expression in Sf9 membrane preparations 
and MCF-7/Topo cells, respectively; B) corresponding 
Coomassie blue-stained gel.  
Cells were harvested at various times after infection 
(lanes d-i) with different dilutions of ABCG2 high titer 
virus stock (stated in brackets):  a) peqGold protein 
marker I (14-116 kDa; Peqlab); b)  MCF-7/Topo cells; 
c)  Sf9 wt membrane; Sf9 ABCG2 membrane: d) 24 h 
(1:500), e) 24 h (1:100), f) 48 h (1:500), g) 48 h 
(1:100), h) 72 h (1:500), i) 72 h (1:100); j) Biotinylated 
Protein Ladder (9-200 kDa; Cell Signaling). All 
samples (10 µg of total protein) were subjected to 
SDS-PAGE on 12% polyacrylamide gels followed by 
immunoblotting with the rat monoclonal ABCG2 
antibody BXP-53 (1:1,000). 
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Figure 6.14: Topology model of the human ABCG2 half-size transporter consisting of 6 transmembrane domains and one 
nucleotide binding domain (NBD). Potential N-linked glycosylation sites at amino acid positions 418, 557 and 596 are 
displayed in blue (modified from [Ejendal and Hrycyna, 2002; Diop and Hrycyna, 2005]). 
Diop and Hrycyna [Diop and Hrycyna, 2005] showed that stably expressed ABCG2 in membranes 
from human cells was only glycosylated at the N596 site, and treatment with endoglycosidase 
PNGase F (peptide-N-glycosidase F) reduced the molecular mass on SDS-PAGE gels to approximately 
60 kDa. The phenomenon of a modified molecular weight due to deglycosylation has also been 
observed for ABCG2 expressed in MCF-7 cells upon treatment with PNGase F or the nucleoside 
antibiotic tunicamycin [Litman et al., 2002] as well as in Sf9 insect cells [Özvegy et al., 2001; Pozza et 
al., 2009; Jacobs, 2010] and yeast systems [Mao et al., 2004]. In mammalian systems, the ABCG2 
transport protein is N-glycosylated. Yeasts and insect cells show a reduced glycosylation potential 
[Harrison and Jarvis, 2006] and the original human protein is therefore ‘underglycosylated’. 
It was reported that the disparity in the extent of glycosylation did not affect ATPase activity [Diop 
and Hrycyna, 2005; Pal et al., 2007] and the ABCG2 transporter was  functionally active in ATPase 
assays using membrane preparations from Sf9 cells [Özvegy et al., 2001; Glavinas et al., 2007; Pozza 
et al., 2009]. 
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6.3.3 Optimization, validation and application of the ABCG2 
ATPase assay 
6.3.3.1 Set-up of the ATPase assay for the human BCRP 
Prior to any experiments, the instrumental set-up of the planned ATPase assay in the 96-well format 
had to be elucidated. Therefore, the optimal detection wavelength of the obtained blue colored 
phosphomolybdate complex (after reduction with ascorbic acid) was identified (Figure 6.15). 
Considering the spectral intensity of the arc-discharge xenon lamp of the plate reader, the detection 
wavelength was set to 830 nm. 
In the concentration range from 0.05 to 2 mM the used NaH2PO4 standards show excellent linearity 
regarding absorbance at 830 nm (Interference filter 830-15/75; Eureca Messtechnik GmbH, Köln, 
Germany) after complexing and were therefore appropriate for the assay. 
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Figure 6.15: A) Absorbance spectrum of the reduced phosphomolybdate complex recorded with a Cary 100 UV-Vis 
spectrophotometer; B) Absorbance of the phosphate standards after complexation and reduction measured at the GENios 
Pro microplate reader at 830 nm. 
Membrane preparations from Sf9 cells after an infection time of 24 h showed an ATPase activity of 
about 25 nmol Pi/min/mg protein when treated with 100 µM topotecan and prazosin, respectively. 
As shown in Figure 6.16, sodium orthovanadate at a concentration of 5 mM nearly completely 
inhibited vanadate-sensitive ATPase activity. The final concentration in the assay was set to 2 mM 
due to an unspecific color reaction of vanadate with the indicator solution at higher concentrations.  
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Figure 6.16: ATPase activity of ABCG2-membranes 
(Infection: 24 h, 1:500) in the presence of different 
concentrations of sodium orthovanadate was reduced 
from 25 to 7 nmol Pi/min/mg protein (corresponding to 
vanadate-insensitive ATPase activity) when stimulated 
with topotecan [100 µM]. Data were obtained from two 
independent experiments. 
 
 
First experiments on the ABCG2 ATPase activity, performed in the presence of the transporter 
substrates topotecan, mitoxantrone (Figure 6.17) or prazosin, using membrane preparations from 
Sf9 cells infected for 24 h, revealed a very high basal membrane ATPase activity. Under these 
conditions the sensitivity of 
the ATPase assay was 
substantially reduced, as the 
effects of the stimulatory 
drug relative to the negative 
control (2% (v/v) DMSO) 
were quite low. By reducing 
the final DMSO amount to a 
maximum of 1%, the 
difference between the negative (DMSO) control and topotecan could, indeed, be increased but was 
still insufficient (data not shown).  
The molecular background of this high basal activity was extensively studied but is not known till 
now. It is speculated that the ABCG2 transporter is constitutively active, that is, the high basal activity 
may result from uncoupled (transport-independent) ATPase activity. The presence of unknown 
substrates in the membrane compartment [Sarkadi and Telbisz, 2013] and ineffective 
homodimerization of ABCG2 to a ‘full transporter’ have to be taken into account as well.  
The problem of low sensitivity and a high basal activity of ATPase assays for the ABCG2 transporter 
has been described in literature [Özvegy et al., 2001; Özvegy et al., 2002; Mao et al., 2004] and 
different experiments have been conducted to solve the problem by preparing ABCG2 membranes 
with a fully active transporter protein to guarantee a high-sensitivity screening assay [Pal et al., 2007; 
Telbisz et al., 2007]. 
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Figure 6.17: 
Absorbance spectrum 
of the ABCG2 substrate 
mitoxantrone with 
maxima at 612 and 
664 nm. Mitoxantrone 
gives a dark-blue color 
which does not 
interfere with the 
detection of the 
molybdate complex in 
the ATPase assay at 
830 nm. 
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To exclude that the insensitivity of the assay has to be attributed to an insufficient expression level of 
the ABCG2 protein after 24 h of infection, additional experiments with membranes of cells with a 
longer infection time were performed in the presence of the ABCG2 substrates topotecan, prazosin 
and mitoxantrone and potent BCRP inhibitors including fumitremorgin C (FTC), Ko143 and different 
synthesized modulators (cf. Chapter 3). In fact, with ABCG2 overexpressing membranes of Sf9 cells 
with an infection time of 48 h, the difference between basal and substrate stimulated activity could 
be improved, but was still inadequate (Figure 6.18, bars 1-4).  
 
6.3.3.2 Mode of ATPase inhibition  
There was a significant difference in vanadate-sensitive ATPase activity between substrate-treated 
and inhibitor-treated ABCG2 membranes (Figure 6.18). Topotecan-, mitoxantrone- and prazosin-
stimulated ATPase activities (bars 2-4) were reduced by about 30-40% from approximately 30 to 
20 nmol Pi/min/mg protein with the addition of 5 µM fumtremorgin C (bars 6-8). Compound 51 
reduced the basal activity to the same extent, indicating that both FTC and 51 act as real ABCG2 
inhibitors, not as substrates.  
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Figure 6.18: Vanadate-sensitive ATPase 
activity of ABCG2 membranes (48 h; 1:500) 
when treated with ABCG2 substrates, 
ABCG2 inhibitors or a combination of both:  
1) Basal activity (DMSO 1%);  
2) Topotecan [100 µM];  
3) Mitoxantrone [5 µM];  
4) Prazosin [5 µM];  
5) FTC  [5 µM];  
6) Topotecan [100 µM] + FTC [5 µM];  
7) Mitoxantrone [5 µM] + FTC [5 µM];  
8) Prazosin [5 µM] + FTC [5 µM];  
9) UR-MB108-4 (51) [10 µM]. 
Activity was calculated from 2-3 
independent experiments. 
A selection of synthesized modulators was investigated for concentration-dependent inhibition.  
Data are summarized in Table 6.1. The inhibitory effects obtained in the ATPase assay were not 
directly comparable to those in the Hoechst assay: The percental inhibition caused at the highest 
concentration tested in the ATPase assay refers to the drug-stimulated activity caused by 100 µM of 
topotecan, whereas the maximal inhibition in the Hoechst assay is referred to the inhibition caused 
by fumitremorgin C at 10 µM (100% inhibition). Nevertheless, data obtained in the two assay systems 
correlate quite well. IC50 values from the two assays are in a good correlation especially for highly 
potent compounds such as 3, 32, 51 and the standard compounds FTC and Ko143. Compounds with 
low efficiency in the Hoechst assay, for example 22, also show reduced maximal effects in the ATPase 
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assay and vice versa (see compound 32). As an example, the inhibitory effect of FTC and 51 in the 
ATPase assay is displayed in Figure 6.19 in a concentration-dependent manner, giving reproducible 
sigmoidal concentration response curves. In general, the ATPase assay gave lower IC50 values than 
the Hoechst 33342 assay. This was particularly obvious for compounds 22 and 42. Apperently, the 
(partial) proteolytic cleavage of the ABCG2 transporter when expressed in Sf9 cells (cf. section 
6.3.2.1) does not affect the function of the membranes in the ATPase inhibition mode. 
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Figure 6.19: Vanadate-sensitive ATPase activity of ABCG2 membranes under the treatment of the potent BCRP inhibitors 
fumitremorgin C (A) and compound 51 (B). 
 
Table 6.1: ABCG2 inhibition by selected compounds in the ATPase and the Hoechst 33342 assay.   
 ATPase assaya Hoechst 33342 assayb 
Compound IC50 [nM]
c 
Max. Inhibition 
(%)d 
IC50 [nM] 
Max. Inhibition 
(%)e 
FTC 603 ± 161 62 ± 10 731 ± 92 100 
Ko143 73 ± 14 71 ± 8 117 ± 5f 103 ± 7f 
3 (UR-COP77) 65 ± 18 60 ± 8 183 ± 32g 83 ± 5g 
7 (UR-COP145) 143 ± 40 57 ± 7 943 ± 79 87 ± 5 
12 (UR-COP228) 178 ± 28 63 ± 5 591 ± 87 109 ± 8 
22 (UR-COP238) 692 ± 74 35 ± 2 2,238 ± 202 22 ± 0 
32 (UR-COP269) 37 ± 14 69 ± 5 59 ± 11 101 ± 5 
42 (UR-QQS-2) 176 ± 59 59 ± 6 1,043 ± 53 107 ± 7 
51 (UR-MB108-4) 23 ± 11 59 ± 4 64 ± 3 95 ± 3 
a 
Data from inhibition of topotecan-stimulated [100 µM] ATPase activity on membranes of Sf9 cell infected for 48 h and 
72 h, respectively (cholesterol-free); mean values ± SEM from two to three independent experiments performed in 
quadruplicate; 
b 
Hoechst 33342 microplate assay (ABCG2 overexpressing MCF-7/Topo cells); mean values ± SEM from two 
to three independent experiments performed in sextuplicate; 
c
 Respective concentration of the inhibitor required for half-
maximal inhibition; 
d
 expressed as percental inhibition caused by the highest concentration of the test compound (reduced 
ATPase activity) relative to 100 µM topotecan (providing full ATPase activity); 
e
 Maximal inhibitory effects expressed as 
percental inhibition caused by the highest concentration of the compound tested relative to the reference compound FTC 
[10 µM] (100% inhibition); 
f
 [Kühnle, 2010]; 
g
 [Ochoa-Puentes et al., 2011] 
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The results revealed that the synthesized modulators inhibited the topotecan-stimulated ATPase 
activity, indicating that these compounds are not substrate of the ABCG2 transporters, but inhibitors. 
To confirm the mechanism of inhibition and the reliability of the assay, drugs working as inhibitors 
and poorly transported substrates should be included in the test series. With regard to investigations 
on competitive substrates/inhibitors in the ATPase assay, caution should be taken that an inhibitor of 
ABCG2 and its potency is dependent on the used substrate and the respective concentrations.  
Although competitive substrates have been identified for the ABCB1 transporter in drug 
accumulation studies [Scala et al. 1997], only few information is available about competitive ABCG2 
substrates/inhibitors. Lately, imatinib mesylate, was shown to reverse BCRP-mediated resistance to 
topotecan and SN-38 (active metabolite of irinotecan) in vitro suggesting that it directly inhibits 
BCRP-mediated transport not being a competitive substrate [Houghton et al., 2004]. In contrast to 
that, Burger et. al. considered imatinib mesylate as a substrate of ABCG2 [Burger et al., 2004]. 
Furthermore, the inhibitory effect of the ABCG2 substrate flavopiridol on mitoxantrone efflux in 
ABCG2-overexpressing cells in high concentrations was attributed to competitive inhibition 
[Robey et al., 2001]. 
 
Despite low water solubility, the synthesized compounds worked well in this protein-free buffer 
system, although the ABCG2-ATPase activity was not completely inhibited. As the Hoechst 33342 
assay was performed in the presence of FCS, the question arose whether albumin supplementation 
might increase the maximum effects of the compounds in the ATPase assay. The concentration-
response curves of the ABCG2 inhibitor 12 on the ATPase activity in the presence and absence of 
5% (m/v) BSA is shown in Figure 6.20. The addition of serum albumin did obviously not affect the 
ATPase inhibitory effect of 12 in this type of assay.  
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Figure 6.20: Effect of 5% (m/v) BSA (triangles) on the 
inhibition of ABCG2-ATPase activity by compound 12 in Sf9 
membrane preparations; percental inhibition is determined 
as ratio of ATPase activity at the respective concentration 
referred to the topotecan-stimulated [100 µM] activity in 
absence of an inhibitor. 
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6.3.3.3 Cholesterol-loaded ABCG2 Sf9 membranes 
It has been known for a long time that insects are unable to synthesize sterols de novo and require an 
exogenous supply of sterols [Clayton, 1964]. Cholesterol is the precursor of steroid hormones, for 
example cortisol in mammals and ecdysone in insects, and an essential constituent of membranes in 
animals [Ikekawa et al., 1993]. Cholesterol plays a crucial role in the function of membrane proteins. 
Previously, it was demonstrated that the cholesterol levels in insect cells are a limiting factor in the 
expression of the oxytocin receptor in the baculovirus/Sf9 system [Gimpl et al., 1995]. With the 
addition of cholesterol either to the insect cell culture medium or to membrane preparations, the 
specific binding of oxytocin to the oxytocin receptor was significantly increased in a concentration-
dependent manner. Cholesterol-supplementation, however, produced controversial results 
regarding growth and morphology of insect cells, although lipids were shown to be essential for 
baculovirus infection and subsequent protein expression [Gimpl et al., 1995; Gilbert et al., 1996; Lua 
and Reid, 2005]. 
6.3.3.3.1 Effect of cholesterol on ATPase activity of ABCG2-Sf9 membrane preparations  
By analogy with the above described results, Pal et al. observed a lack of ABCG2-ATPase activity 
stimulation by the BCRP substrates prazosin (Figure 6.22) and topotecan referred to the basal activity 
when expressed in Sf9 cell membranes, whereas ABCG2 overexpressing human cell membranes and 
cholesterol-loaded Sf9 membranes could be activated. The authors showed that the low cholesterol 
content of insect cells decisively influences ABCG2 stimulation, as cholesterol loading of membrane 
preparations significantly potentiates the stimulation of basal ABCG2 activity [Pal et al., 2007; Telbisz 
et al., 2007]. Therefore, membranes of Sf9 cells (48 h of infection) were thawed and incubated on ice 
for 20 min with a complex of randomly methylated-β-cyclodextrin (RAMEB) and cholesterol (final 
content: 5.4%) purchased from Cyclolab (Cyclodextrin Research and Development Laboratory; 
Budapest, Hungary) at a final concentration of 2.5 mg/mL. The membranes were centrifuged at 
16,000 to remove residual cholesterol and, subsequently, resuspended in TMEP buffer (cf. 6.2.8.2). 
Wildtype ABCG2 membranes and cholesterol-loaded membranes were treated with ABCG2 
substrates topotecan and prazosin, respectively, and the ATPase stimulation was compared. As 
shown in Figure 6.21 the subsequent incubation with the RAMEB-cholesterol complex led to a 
1.5-fold stimulation of basal activity for topotecan and prazosin, respectively, compared to 1.1 for wt 
membranes without cholesterol. The final ATPase stimulation in these membrane preparations is 
summarized in Table 6.2. 
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Figure 6.21: Vanadate-sensitive ATPase activity of ABCG2 Sf9 wt 
membranes (1) and cholesterol-loaded membranes (2) when 
incubated (1 h) with topotecan [100 µM] (black bars), prazosin 
[100 µM] (grey bars) and DMSO (=basal activity; white bars); 
results were obtained from 3 independent experiments each 
performed in quadruplicate. 
 
Addition of cholesterol to ABCG2-Sf9 membranes significantly increased ATPase activity, suggesting 
that the low cholesterol content in Sf9 cells severely affected the activation of the ABCG2 
transporter. It is difficult to decide whether cholesterol directly increases ABCG2-ATPase activity or 
has an indirect effect by altering the architecture and the fluidity of the phospholipid bilayer in the 
plasma membrane. Only a few studies addressing the effect of cholesterol on ABC transporters have 
been published so far, especially for the ABCB1 transporter [Garrigues et al., 2002; Arima et al., 
2004]. Recently, it has been suggested that cholesterol is a substrate of ABCB1 [Le Goff et al., 2006]. 
This may also be taken into consideration in case of ABCG2 as other members of the ABCG subfamily 
were reported to be involved in cholesterol transport [Pal et al., 2007], e.g. ABCG5 and ABCG8 half 
transporters forming heterodimers for intestinal absorption and biliary excretion of cholesterol 
[Graf et al., 2003]. 
6.3.3.3.2 Modified membrane preparation protocol 
Based on these encouraging results, the original membrane preparation protocol described in section 
6.2.8.2 was slightly modified:  
Prior to the last centrifugation step at 100,000 g, membranes were incubated with the RAMEB-
cholesterol complex at a final concentration of 2.5 mg/mL for 20 min at 4 °C. After resuspension and 
protein quantification, membranes were subsequently aliquoted and stored at -80 °C until use. 
6.3.3.4 Effect of CHAPS on basal and drug-stimulated ABCG2-ATPase activity 
In a recently published patent by Sarkadi and Telbisz [Sarkadi and Telbisz, 2013], the difference 
between drug-stimulated and basal activity could be increased in the presence of CHAPS 
(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate), a non-denaturing zwitterionic 
sulfobetaine detergent which is commonly used for protein solubilization and disruption of protein-
protein interactions (Figure 6.22).  
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Figure 6.22: Chemical structures of the sulfobetaine-type zwitterionic detergent CHAPS (a) and the ABCG2 substrate 
prazosin (b). The flavonoid quercetin (c) was recently shown to be transported by ABCG2 [Sesink et al., 2005]. 
 
Cholesterol-loaded membranes (prepared as described in 6.3.3.3.2) were used for the ATPase assay 
in the presence and absence of prazosin [100 µM] under simultaneous treatment with different 
concentrations of CHAPS [0.1-2.0 mM] (Figure 6.23).  
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Figure 6.23: Effect of of CHAPS on the basal (circles) and 
prazosin-stimulated (squares) ABCG2-ATPase activity in 
cholesterol-loaded Sf9 membranes. 
With the addition of CHAPS to the cholesterol-loaded membrane preparation the basal ATPase 
activity was significantly reduced about 25% whereas the drug-stimulated activity remained nearly 
unchanged. Accordingly, the protocol of the ATPase assay was modified: a final concentration of 
1 mM CHAPS was added to the membrane preparations immediately prior to the experimental 
procedure. 
The differences in topotecan-, quercetin- and prazosin-stimulated and FTC-inhibited ABCG2-ATPase 
activity using ‘ABCG2 wildtype’ and cholesterol-loaded membranes in the presence or absence of 
CHAPS become obvious from Figure 6.24.  
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Figure 6.24:  
Vanadate-sensitive ATPase activity of 
ABCG2 Sf9 wt (1), cholesterol-loaded (2) 
and cholesterol-loaded membranes 
modulated with CHAPS [1 mM] (3) when 
incubated with topotecan [100 µM] 
(black), prazosin [100 µM] (red), 
quercetin [10 µM] (blue), 
fumitremorgin C [10 µM] (gray) and 
DMSO (=basal activity; white), 
respectively; n = 3. 
 
Table 6.2: Effect of cholesterol and CHAPS on the stimulation or inhibition of the ABCG2-ATPase in 
ABCG2 Sf9 membranes in presence of various ABCG2 modulating agents. Stimulation is expressed as 
the ratio of the drug-stimulated and the basal ATPase activity, inhibition is given as the percental 
reduction of the basal activity. 
  
wt ABCG2 
membranes 
cholesterol-
loaded ABCG2 
membranes 
cholesterol-loaded 
ABCG2 membranes + 
CHAPS [1 mM] 
Compound 
concentration 
[µM] 
fold stimulation fold stimulation fold stimulation 
Topotecan 100 1.32 1.51 1.77 
Prazosin 100 1.25 1.43 1.90 
Quercetin 10 2.47 2.36 2.94 
  Inhibition Inhibition Inhibition 
Fumitremorgin C 10 25.4% 35.7% 7.2% 
 
In summary, with the addition of cholesterol to the membrane preparation the ratio of stimulated 
and basal ATPase activity was significantly improved. The treatment with the modulation agent 
CHAPS led to an additional enhancement of sensitivity in the stimulation mode of the assay by 
reducing the basal ATPase activity. FTC was not able to further lower the reduced basal activity in 
presence of CHAPS suggesting that the minimum of basal activity is reached with the addition of the 
detergent. 
Figure 6.25 shows the activation of basal ATPase activity by ABCG2 substrates topotecan, prazosin 
and quercetin in cholesterol-loaded (+ 1 mM CHAPS) and wt ABCG2 membranes in a concentration-
dependent manner. 
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Figure 6.25: ABCG2-ATPase activation of ABCG2 wt 
(circles) and cholesterol-CHAPS-loaded Sf9 membranes 
(squares) upon topotecan (A), prazosin (B) and 
quercetin (C) treatment.  
The comparison of ABCG2 wt and cholesterol-loaded membranes (without CHAPS) in the inhibition 
mode is exemplarily shown for compounds 32 and 52 in Figure 6.26. The use of cholesterol generally 
resulted in higher ATPase activities upon stimulation by topotecan, but did not influence potency and 
efficacy parameters to a noteworthy extent (Table 6.3).  
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Figure 6.26: Inhibition of ABCG2-ATPase by compound 32 (A) and 52 (B) after stimulation with topotecan [100 µM] in 
ABCG2 wt (circles) and cholesterol-loaded Sf9 membranes (squares). 
 
In general, cholesterol-loaded membranes allowed for the construction of better reproducible 
sigmoidal concentration-response curves with higher amplitude, resulting in lower errors of the IC50 
values.  
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Table 6.3: Inhibitory activities of selected ABCG2 modulators, determined in the ATPase assay on 
ABCG2 wt and cholesterol-loaded membranes a 
 wt ABCG2 membranes cholesterol-loaded ABCG2 membranes 
Compound IC50 [nM] Imax (%) IC50 [nM] Imax (%) 
32 32 ± 11 60 ± 8 22 ± 3 65 ± 5 
34 75 ± 13 79 ± 7 46 ± 12 75 ± 7 
52 47 ± 25 79 ± 10 45 ± 11 85 ± 5 
a 
Mean values ± SEM calculated from two independent experiments performed in quadruplicate. 
6.4 Summary and conclusions 
The ABCG2 template in combination with the signal peptide sequence for expression in Sf9 insect 
cells was successfully and error-free cloned into the pVL1392 vector. Recombinant baculoviruses 
encoding the ABCG2 transporter were generated and used for Sf9 cell infection. To achieve ABCG2 
overexpression in Sf9 cell membranes, cells were infected for 48 h with high titer virus stocks despite 
a higher extent of proteolysis of the target ABCG2 protein when compared to cells infected for a 
period of 24 h.  
In insect cells, the ABCG2 monomer was expressed at a lower molecular weight due to 
deglycosylation. However, the difference in the extent of glycosylation did not affect the ATPase 
activity of the transporter. 
Very high basal activity severely compromised assay analysis. The low sensitivity caused high errors 
and an inacceptable signal-to-noise ratio. The narrow margin between basal and drug-stimulated 
ATPase activity of ABCG2 Sf9 membranes was significantly improved by incubating ABCG2-
membranes with a cyclodextrin-cholesterol complex. The concomitant addition of CHAPS to 
cholesterol-loaded membrane preparations decreased the basal activity and led to a sufficient 
difference between basal and stimulated ABCG2-ATPase activity to establish an assay protocol. The 
ATPase inhibition mode produced slightly higher maximal effects when cholesterol was added to the 
membranes, but worked likewise with wildtype ABCG2 Sf9 membranes.  
 
The results obtained from the ATPase assay demonstrated that the synthesized ABCG2 modulators 
described in Chapter 3 are inhibitors and not substrates. The established ATPase assay for the human 
ABCG2 transporter on Sf9 membrane preparations proved to be well-suited system to discriminate 
between ABCG2 substrates and inhibitors. In combination with other assays, the determination of 
ATPase activity harbors the potential of being used for the profiling of ABCG2 modulators to detect 
different mechanisms of drug-transporter interaction. 
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 Chapter 7 
7 Summary 
Multidrug transporter proteins such as ABCB1, ABCC1 and ABCG2 are known to contribute the 
chemoresistance of malignant tumors. Expression of these transporters by cancer cells leads to an 
efflux of anticancer drugs. The inhibition of efflux pumps, namely ABCB1 (p-glycoprotein), has been 
explored in clinical trials as an approach to overcome ABC transporter mediated drug resistance in 
cancer patients, but did not lead to a drug approval. The limitations of this approach can be 
explained by multiple resistance mechanisms including the contribution of ABC transporters other 
than ABCB1. The relevance of ABCG2 inhibition has not been adequately explored.  
Apart from chemoresistance in cancer, ABC transporters play a major role as efflux pumps expressed 
in epithelia and endothelial cells, influencing the bioavailability, tissue distribution, access to the 
brain, and the excretion of drugs. In particular, modulation of ABC transporters at the blood brain 
barrier (BBB) may considerably increase the entry of drugs into the central nervous system (CNS) and 
enhance the effectiveness of pharmacotherapy, including the chemotherapy of malignancies in the 
CNS, as demonstrated in a proof-of-concept study in mice with paclitaxel in combination with the 
ABCB1 modulator valspodar. This strategy should even be more effective in case of inhibition of 
ABCG2, as this transporter is considered to be the most important efflux transporter at the BBB. To 
prove this hypothesis, potent and selective ABCG2 modulators are required.  
This doctoral project was pursued in collaboration with Prof. Dr. B. König (Institute of Organic 
Chemistry, University of Regensburg), aiming at the development of selective ABCG2 modulators. 
Previously reported quinoline carboxamide-type compounds from our laboratory such as UR-ME22-1 
were highly potent and selective ABCG2 modulators, but revealed unfavourable physico-chemical 
properties, mainly due to poor solubility and rapid enzymatic cleavage of a central benzamide bond. 
Next generation inhibitors, synthesized in the Institute of Organic Chemistry, were characterized in 
various functional cellular assays (Hoechst 33342, calcein-AM, pheophorbide a, flow cytometric 
mitoxantrone assay, kinetic cytotoxicity assay) available in our laboratory. Additional in vitro models 
for the characterization of the transporter inhibitors were established (mitoxantrone microplate 
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assay for ABCG2, calcein ABCC1 assay, ATPase assay for ABCG2 using Sf9 membranes), the selectivity 
for ABCG2 compared to ABCB1 and ABCC1 was determined, and (bio)analytical studies (plasma 
protein binding by ultrafiltration, equilibrium dialysis, isothermal titration calorimetry and HPLC; 
stability in buffer and against enzymatic cleavage) were performed. Preliminary preclinical studies in 
nude mice bearing orthotopically implanted genetically modified human glioblastoma enabling 
optical in vivo imaging, proved that U-87MG xenografts grow rapidly in the brain. However, these 
tumors were too aggressive to perform therapeutic studies. Therefore, in search for a more 
appropriate tumor entity, three malignant human brain tumor cell lines (Daoy, LN-18 and SW 1783) 
were characterized in vitro regarding growth kinetics, chemosensitivity against several anti-cancer 
drugs, and ABC transporter expression as well as in vivo for tumorigenicity in a subcutaneous tumor 
model in nude mice.  
 
Bioisosteric replacement of the central amide core of the first and second generation of ABCG2 
inhibitors by a biphenyl, quinoline, indol or a triazole moiety resulted in chemically more stable 
compounds, and the introduction of triethyleneglcyol residues increased solubility. In the new 
compound libraries dual ABCB1/ABCG2 and ABCG2-selective modulators were identified which are 
among the most potent BCRP inhibitors reported so far. 
 
Selected ABCG2 modulators were additionally investigated in an in vitro model of the BBB (porcine 
brain capillary endothelial cell layers, expressing ABCG2; cooperation with Prof. H. J. Galla, University 
of Münster) to get closer to the physiological situation and to predict the influence of the compounds 
on the penetration of co-administered drugs into the brain of nude mice bearing orthotopically 
growing xenografts. Surprisingly, in the BBB model the investigated inhibitors were much more 
potent than in the fluorescence based cellular assays. 
 
The reduced transport of a substrate used to determine ABCG2 activity in the presence of a 
modulator may result from different modes of action: competition of the test compound with the 
indicator as a substrate or inhibition of the transport mechanism. To discriminate between the 
mechanisms of modulation, a colorimetric ATPase assay in the microplate format was established 
using membrane preparations from baculovirus-infected Sf9 cells expressing the human ABCG2 
protein. All tested compounds turned out to be ‘true’ ABCG2 inhibitors, capable of inhibiting 
substrate-induced ATPase activity.  
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In summary, the new ABCG2 modulators were highly potent and selective inhibitors, but showed 
poor water solubility and very high plasma protein binding (almost 100%). The drug-like properties of 
these compounds have to be further improved in view of in vivo studies.
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 Appendix 
A Expression of ABCG2 at the 
murine blood-brain barrier - 
immunohistochemical 
investigations 
A.1 Introduction 
Immunohistochemical (IHC) investigations were performed to study the expression of the Abcg2 
protein (murine ortholog of the human ABCG2 transporter) at the blood-brain barrier of nude NMRI 
(nu/nu) mice using paraffin embedded brain tissue sections. According to an indirect method for the 
detection of the transporter protein, an unlabeled primary antibody and a horseradish peroxidase 
(HRP)-conjugated secondary antibody were used. 
Principle of peroxidase immunohistochemical staining:  
The protein of interest is targeted by an antibody that is conjugated with a peroxidase enzyme (e.g. 
HRP). The antibody or target protein is visualized via a peroxidase-catalyzed reaction in the presence 
of hydrogen peroxide. The substrate 3,3’-diaminobenzidine (DAB) is thereby oxidized giving a brown 
precipitate:  
Peroxidase + 2 H2O2   O2 + 2 H2O 
      O2 + DAB  insoluble, black-brown precipitate. 
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A.2 Materials and methods 
A.2.1 Drugs and chemicals 
Antibodies were obtained from Santa Cruz Biotechnology (Heidelberg, Germany) unless otherwise 
stated. 0.1% PBS-T buffer was made by diluting 1000 µL Triton X-100 (Sigma, Munich, Germany) in 
1000 mL of PBS.  
Nuclear fast red solution (0.1% (m/v); also known as ‘Kernechtrot’) was prepared by dissolving 
nuclear fast red (Sigma, Munich, Germany) in a 5% (m/v) aluminum sulfate solution. The solution was 
heated (80 °C) and filtrated through a paper filter when cooled down. 
All other chemicals were purchased from Merck (Darmstadt, Germany) in p.a. quality if not otherwise 
stated. Millipore water was used. 
A.2.2 Paraffin embedding and sectioning 
In order to investigate the extent of Abcg2 transporter expression at the BBB after tumor 
implantation, a nude NMRI (nu/nu) mouse bearing intracerebral U-87 MG Luc2/Katushka_Clone 15 
xenografts was killed by cervical dislocation (U-87 MG Luc2/Katushka co-transfectants were obtained 
as described elsewhere [Kühnle, 2010]) . 
The brain was excised, fixed in Bouin´s solution (saturated picric acid/ formaldehyde/ glacial acetic 
acid 15:5:1) for one day and embedded in paraffin according to a standard procedure described 
elsewhere [Müller, 2007]. Serial coronal sections (6 μm) were cut every 200 μm using a Leica 
RM2255 microtome (Leica; Bensheim, Germany) and mounted on microscope slides. 
A.2.3 Immunoperoxidase staining 
For IHC investigations, paraffin tissue sections were deparaffinized with xylene (2 x 10 min) and 
rehydrated in graded isopropyl alcohol (iPrOH) followed by two washing steps (10 min) with PBS-T 
buffer. Unspecific binding of the primary antibody was blocked by incubation of the tissue sections in 
3% nonfat dry milk in PBS-T (blocking solution) for one hour. Thereafter, the sections were incubated 
with different concentrations of the primary AB in blocking solution over night at 4 °C in Quadriperm 
lux-multiplates (Greiner, Frickenhausen, Germany). Wet filter paper was added to the Quadriperm 
chambers to create a humid atmosphere. To avoid wasting of the antibodies, the area around the 
tissue samples was encircled with a wax pen (PAP PEN; Kisker Biotech, Steinfurt, Germany) giving a 
water-repellent circle. In controls, the respective solution was added without primary AB to test the 
protocol and the specificity of the antibody used.
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The next day, the secondary AB was added after three washing steps (10 min) with PBS-T, and 
samples were stored for 1-2 hours in the dark. After additional three washing steps with PBS-T, the 
tissue sections were stained via the peroxidase-diaminobenzidine reaction using a DAB Substrate Kit 
for Peroxidase (Vector Laboratories; Burlingame, CA) according to the instructions for IHC staining. In 
brief: immediately before use, the substrate solution was prepared by adding 2 drops of buffer stock 
solution to 5 mL of distilled water. Afterwards, 4 drops of DAB stock solution and 2 drops of the 
hydrogen peroxide solution were added and mixed. To obtain a gray-black stain 2 drops of nickel 
solution were added to the mixture and the tissue sections were incubated with the substrate 
solution at room temperature for 7-10 min. After washing in water for 5 min, nuclei were 
counterstained by mounting the samples for 8 min in a 0.1% nuclear fast red solution and washed 
thoroughly another three times with Millipore water. The wax pen marker was carefully removed 
using xylene. After dehydration in an ascending iPrOH series and xylene, sections were mounted with 
DePeX (EMS; Hatfield, PA). Stained tissue samples were analyzed with a BH-2 microscope (Olympus, 
Hamburg, Germany). 
Two different antibody-combinations were used for IHC: 
1. primary AB:   ABCG2 (BXP-53); 1:50 and 1:100 
 secondary AB:    HRP-conjugated goat anti-rat IgG, 1:750  
2. primary AB:   rabbit polyclonal BCRP/ABCG2 antibody (orb10178), Biorbyt Ltd. 
   (Cambridge,  UK), 1:100 and 1:500 
 secondary AB:    HRP-conjugated donkey anti-rabbit IgG, 1:1,000  
A.3 Results  
The visualization of Abcg2 at the BBB of a nude mouse, bearing an intracerebral U-87 MG 
Luc2/Katushka_Clone 15 tumor, using the ABCG2 (BXP-53) antibody from Santa Cruz Biotechnology 
(recommended for the detection of ABCG2 of mouse and human origin) was not successful. After 
immunoperoxidase staining with the DAB Substrate Kit from Vector Laboratories, only erythrocytes 
and blood constituents were positive, whereas Abcg2 expression was not detected at the murine 
brain capillaries (Figure A.1). 
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Figure A.1: Immunohistochemical peroxidase staining of brain tissue section of nude NMRI (nu/nu) mice bearing 
intracerebral U-87 MG Luc2/Katushka_Clone 15 xenografts using ABCG2 (BXP-53) antibody from Santa Cruz Biotechnology. 
A: Brain capillary with a clearly visible monocyte; B, C: Logitudinal section through a brain capillary; D: Unspecific staining of 
constituents in the tumor brain area; E: Blood vessel; F: Transverse section through a murine brain capillary. 
To exclude that the failure of Abcg2 detection is antibody-dependent, the same experiment was 
performed with a rabbit polyclonal anti-BCRP primary antibody from Biorbyt Ltd. (Cambridge, UK), 
suitable for the detection of ABCG2 of human, mouse and rat origin, in combination with a secondary 
HRP-conjugated donkey anti-rabbit AB from Santa Cruz. 
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Unfortunately, the detection of Abcg2 transporter expression in brain capillaries of nude NMRI 
(nu/nu) also failed. In accordance to the immunohistochemical staining performed with the AB from 
Santa Cruz, only unspecifically stained erythrocytes became visible (results not shown).  
A.4 Summary and conclusions  
Although the presence of Abcg2 at the BBB of CF-1 mice was demonstrated previously by Real-Time 
quantitative RT-PCR [Cisternino et al., 2004], the Abcg2 transporter was not detectable at the mouse 
BBB of nude NMRI (nu/nu) mice by immunohistochemistry using two different antibodies, suggesting 
that either Abcg2 is not expressed in the brain of nude mice or the used antibodies do not react with 
the murine ABCG2 ortholog.  
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